Compositions And Methods To Immunize Against Hepatitis C Virus

Abstract

Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application Ser. No. 61/467,840, filed Mar. 25, 2011, and U.S. Provisional Application Ser. No. 61/529,700, filed Aug. 31, 2011, the entire contents of each of which are incorporated herein by reference.

TECHNICAL FIELD OF THE INVENTION

[0002] The present invention relates in general to the field of immunology, and more particularly, to hepatitis C virus (HCV) immunization, vaccines, and targeting of the HCV peptides to human dendritic cells. The application also describes a bi-functional antibody fused to a HCV target antigen(s) that is directed against a dendritic cell (DC)-specific receptor.

STATEMENT OF FEDERALLY FUNDED RESEARCH

[0003] None.

REFERENCE TO A SEQUENCE LISTING

[0004] The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 15, 2012, is named BHCS1118.txt and is 388,419 bytes in size.

BACKGROUND OF THE INVENTION

[0005] Without limiting the scope of the application, its background is described in connection with immunostimulatory methods and compositions, including vaccines, and increased effectiveness in antigen presentation of HCV peptides in relation to HCV immunization and vaccines.

[0006] U.S. Patent Application Publication No. 2009/0238822 (Rajan et al. 2009) relates to chimeric antigens for targeting and activating antigen presenting cells to elicit cellular and humoral immune responses. The Rajan invention describes compositions and methods that contain or use one or more chimeric antigens that contain one or more pre-selected HCV antigen(s), and an immunoglobulin fragment. The invention further discloses chimeric antigens, comprising an HCV antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is said to be enhanced upon presenting the host immune system with an immune response domain (HCV antigen from HCV core, envelope, or non-structural protein fragments) and a target-binding domain (an Fc fragment).

[0007] U.S. Patent Application Publication No. 2008/0241170 (Zurawski et al. 2008) discloses compositions and methods for making and using vaccine that specifically target (deliver) antigens to antigen-presenting cells for the purpose of eliciting potent and broad immune responses directed against the antigen. The purpose is primarily to evoke protective or therapeutic immune responses against the agent (pathogen or cancer) from which the antigen was derived.

[0008] U.S. Patent Application Publication 2010/0239575 (Banchereau et al. 2010) refers to compositions and methods for the expression, secretion, and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

SUMMARY OF THE INVENTION

[0009] The present invention describes immunostimulatory compositions, vaccines, HCV vaccines, HCV antigen presenting dendritic cells, methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, methods for increasing effectiveness of antigen presentation by an antigen presenting cell, methods for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C in a subject, and methods for generating a HCV presenting dendritic cell. The present invention further describes virus antigens, e.g., proteins and peptides corresponding to HCV proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs). The vaccine composition as described herein delivers HCV antigen specifically to DCs for the purpose of invoking an immune response. The vaccine composition may also promote efficient recall memory in hepatitis C patients.

[0010] In one embodiment the instant invention discloses an immunostimulatory composition for generating an immune response for a prophylaxis, a therapy, or any combination thereof against a Hepatitis C infection in a human or animal subject comprising: one or more antibodies or fragments thereof specific for a dendritic cell (DC) and one or more HCV antigens attached to the one or more antibodies or fragments thereof. In one aspect the composition disclosed hereinabove further comprises at least one Toll-Like Receptor (TLR) agonist selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists. In another aspect the composition further comprises an optional pharmaceutically acceptable carrier that is effective, in combination, to produce the immune response for prophylaxis, for therapy, or any combination thereof in the human or animal subject in need of immunostimulation. In yet another aspect the DC-specific antibody or fragment is specific for a DC specific receptor, wherein the DC-specific antibody or fragment is selected from an antibody that specifically binds to MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN-.gamma. receptor and IL-2 receptor, ICAM-1, Fc.gamma. receptor, LOX-1, and ASPGR.

[0011] In the composition of the instant invention the HCV antigens comprises a peptide sequence derived from a HCV 1a genotype protein or a fragment thereof and the HCV antigens are selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, and a fragment thereof. The one or more HCV antigens are selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and a fragment thereof and from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, E1b, and a fragment thereof. In one aspect of the composition of the instant invention the composition comprises a recombinant antibody that comprises a fusion protein and the one or more HCV antigen are at a C-terminal position relative to the one or more antibody or fragment thereof within a fusion protein. In another aspect the composition comprises a recombinant antibody, and the one or more HCV antigens are fused to a C-terminus of a heavy chain of the antibody. In yet another aspect the composition comprises a recombinant antibody, and the one or more HCV antigens are fused to a C-terminus of a light chain of the one or more antibody or fragment thereof specific for a DC.

[0012] The one or more HCV antigens are selected from the group consisting of SEQ ID NO: 12-linker A-SEQ ID NO: 13, SEQ ID NO: 12-linker A-SEQ ID NO: 11, SEQ ID NO: 12-linker B-SEQ ID NO: 14, SEQ ID NO: 14-linker B-SEQ ID NO: 12, SEQ ID NO: 12-linker B-SEQ ID NO: 10, SEQ ID NO: 10-linker B-SEQ ID NO: 12, SEQ ID NO: 9-linker

[0013] B-SEQ ID NO: 10, SEQ ID NO: 10-linker B-SEQ ID NO: 9, SEQ ID NO: 10-linker B-SEQ ID NO: 14, SEQ ID NO: 14-linker B-SEQ ID NO: 10, SEQ ID NO: 9-linker B-SEQ ID NO: 12, SEQ ID NO: 12-linker B-SEQ ID NO: 9, SEQ ID NO: 8-linker B-E1b. SEQ ID NO: 12-linkerB-SEQ ID NO: 10-linker C-SEQ ID NO: 14, SEQ ID NO: 12-linker B-SEQ ID NO: 14-linker C-SEQ ID NO: 10, SEQ ID NO: 10-linker B-SEQ ID NO: 12-linker C-SEQ ID NO: 14, SEQ ID NO: 10-linker B-SEQ ID NO: 14-linker C-SEQ ID NO: 12, SEQ ID NO: 14-linker B-SEQ ID NO: 12-linker C-SEQ ID NO: 10, SEQ ID NO: 14-linker B-SEQ ID NO: 10-linker C-SEQ ID NO: 12, and SEQ ID NO: 12-linker B-SEQ ID NO: 10-linker C-SEQ ID NO: 14-linker D-SEQ ID NO: 8. In another aspect the one or more HCV antigens are attached to a C-terminus of a light chain of the recombinant antibody and selected from a group consisting of: SEQ ID NO: 9; SEQ ID NO: 11, and E1b. In yet another aspect the one or more HCV antigens are selected from the group consisting of SEQ ID NO: 9 fused to the C-terminus of a light chain and SEQ ID NO: 10-linker B-SEQ ID NO: 12-linker C-SEQ ID NO: 14 fused to the C-terminus of the heavy chain of the antibody. In a related aspect the one or more HCV antigen are chemically coupled to the one or more antibodies or fragments thereof or are attached to the one or more antibodies or fragments thereof via an affinity association. In a specific aspect the DC-specific antibody is humanized. In another aspect the composition is optimized to be administered to the human or animal subject by an oral route, a nasal route, topically, or as an injection.

[0014] Another embodiment of the present invention discloses a vaccine comprising: one or more antibodies or fragments thereof specific for a dendritic cell (DC); and one or more HCV antigens attached to the one or more antibodies or fragments thereof. The vaccine described herein further comprises at least one Toll-Like Receptor (TLR) agonist selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists and an optional pharmaceutically acceptable carrier or an adjuvant that is effective, in combination, to produce an immune response for prophylaxis, for therapy, or any combination thereof in the human or animal subject in need of immunostimulation. In one aspect of the vaccine the DC-specific antibody or fragment is specific for a dendritic cell specific receptor. In another aspect the HCV antigen comprises a peptide sequence derived from a HCV 1a genotype protein or a fragment thereof, wherein the HCV antigen is selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, and a fragment thereof. In other related aspects the DC-specific antibody is humanized and the composition is optimized to be administered to the human or animal subject by an oral route, a nasal route, topically, or as an injection.

[0015] In yet another embodiment the instant invention discloses a Hepatitis C vaccine (HCV) comprising a fusion protein comprising: (i) one or more antibodies or fragments thereof specific for a dendritic cell (DC), (ii) one or more HCV antigens located C-terminal of the antibodies or fragments thereof, (iii) at least one Toll-Like Receptor (TLR) agonist which is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists, and (iv) one or more optional pharmaceutically acceptable carriers and adjuvants, wherein the vaccine is effective to produce an immune response, for a prophylaxis, a therapy, or any combination thereof against hepatitis C in a human or an animal subject in need thereof. In one aspect the vaccine comprises one or more optional agents selected from the group consisting of an agonistic anti-CD40 antibody, an agonistic anti-CD40 antibody fragment, a CD40 ligand (CD40L) polypeptide, a CD40L polypeptide fragment, anti-4-1BB antibody, an anti-4-1BB antibody fragment, 4-1BB ligand polypeptide, a 4-1BB ligand polypeptide fragment, IFN-.gamma., TNF-.alpha., type 1 cytokines, type 2 cytokines or combinations and modifications thereof.

[0016] The instant invention in one embodiment discloses a method for increasing effectiveness of Hepatitis C virus (HCV) antigen presentation by an antigen presenting cell (APC) comprising the steps of: (i) providing an antibody conjugate comprising a dendritic cell (DC) specific antibody or a fragment thereof and one or more native or engineered HCV antigenic peptides, (ii) providing one or more APCs; and (iii) contacting the APC with the conjugate, wherein the antibody-antigen complex is processed and presented for T cell recognition. In a specific aspect of the method the antigen presenting cell comprises a dendritic cell (DC).

[0017] In another embodiment the instant invention provides a method for increasing effectiveness of antigen presentation by an antigen presenting cell (APC) comprising the steps of: i) isolating and purifying one or more dendritic cell (DC)-specific antibody or a fragment thereof, ii) providing one or more HCV antigens or antigenic peptides, iii) loading or chemically coupling the one or more HCV antigens or antigenic peptides to the DC-specific antibody to form an antibody-antigen conjugate, and iv) contacting the antigen presenting cell with the conjugate, wherein the antibody-antigen complex is processed and presented for T cell recognition.

[0018] The method as described hereinabove further comprises adding at least one Toll-Like Receptor (TLR) agonist which is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists and one or more optional steps comprising i) adding one or more optional agents selected from the group consisting of an agonistic anti-CD40 antibody, an agonistic anti-CD40 antibody fragment, a CD40 ligand (CD40L) polypeptide, a CD40L polypeptide fragment, anti-4-1BB antibody, an anti-4-1BB antibody fragment, 4-1BB ligand polypeptide, a 4-1BB ligand polypeptide fragment, IFN-.gamma., TNF-.alpha., type 1 cytokines, type 2 cytokines or combinations and modifications thereof to the antibody-antigen conjugate and the TLR agonist prior to contacting the antigen presenting cells, ii) measuring a level of one or more agents selected from the group consisting of IFN-.gamma., TNF-.alpha., IL-12p40, IL-4, IL-5, and IL-13, wherein a change in the level of the one or more agents is indicative of the increase in the effectiveness antigen presentation by the antigen presenting cell, and iii) adding one or more optional agents selected from the group consisting of an agonistic anti-CD40 antibody, an agonistic anti-CD40 antibody fragment, a CD40 ligand (CD40L) polypeptide, a CD40L polypeptide fragment, anti-4-1BB antibody, an anti-4-1BB antibody fragment, 4-1BB ligand polypeptide, a 4-1BB ligand polypeptide fragment, IFN-.gamma., TNF-.alpha., type 1 cytokines, type 2 cytokines or combinations and modifications thereof.

[0019] In yet another embodiment the instant invention provides method for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject comprising the steps of: identifying the human subject in need of the treatment, the prophylaxis, or a combination thereof against the hepatisti and administering a vaccine composition comprising one or more antibodies or fragments thereof specific for a dendritic cell (DC) and one or more HCV antigens attached to the one or more antibodies or fragments thereof. In one aspect of the method the vaccine composition further comprises at least one Toll-Like Receptor (TLR) agonist which is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists, and one or more optional pharmaceutically acceptable carriers and adjuvants, wherein the conjugate and agonist are each comprised in an amount such that, in combination with the other, are effective to produce an immune response, for the prophylaxis, the therapy or any combination thereof against the influenza in the human subject. In another aspect the vaccine composition further comprises one or more optional agents selected from the group consisting of an agonistic anti-CD40 antibody, an agonistic anti-CD40 antibody fragment, a CD40 ligand (CD40L) polypeptide, a CD40L polypeptide fragment, anti-4-1BB antibody, an anti-4-1BB antibody fragment, 4-1BB ligand polypeptide, a 4-1BB ligand polypeptide fragment, IFN-.gamma., TNF-.alpha., type 1 cytokines, type 2 cytokines or combinations and modifications thereof. In yet another aspect the vaccine is administered to the human subject by an oral route, a nasal route, topically or as an injection.

[0020] In another aspect the one or more antibodies or fragments thereof specific for a dendritic cell comprises antibodies specifically binds to MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN-.gamma. receptor and IL-2 receptor, ICAM-1, Fc.gamma. receptor, LOX-1, or ASPGR. In yet another aspect the HCV antigen is selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, and a fragment thereof, from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and a fragment thereof, or from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, E1b, and a fragment thereof.

[0021] A method of providing immunostimulation by activation of one or more dendritic cells (DCs) to a human subject for a prophylaxis, a therapy or a combination thereof against HCV is described in one embodiment of the present invention. The method comprises the steps of: a) identifying the human subject in need of immunostimulation for the prophylaxis, the therapy or a combination thereof against HCV, b) isolating one or more DCs from the human subject, c) exposing the isolated DCs to activating amounts of a composition or a vaccine comprising an anti-dendritic cell immunoreceptor (DCIR) monoclonal antibody or fragments thereof attached to one or more HCV antigens, and d) reintroducing the activated DC complex into the human subject.

[0022] The method described above further comprises the steps of contacting the one or more DCs with at least one Toll-Like Receptor (TLR) agonist which is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists and a pharmaceutically acceptable carrier to form an activated DC complex and the step of adding one or more optional agents selected from the group consisting of an agonistic anti-CD40 antibody, an agonistic anti-CD40 antibody fragment, a CD40 ligand (CD40L) polypeptide, a CD40L polypeptide fragment, anti-4-1BB antibody, an anti-4-1BB antibody fragment, 4-1BB ligand polypeptide, a 4-1BB ligand polypeptide fragment, IFN-.gamma., TNF-.alpha., type 1 cytokines, type 2 cytokines or combinations and modifications thereof to the conjugate and the TLR agonist prior to exposing the DCs. The method disclosed hereinabove further comprises the optional step of measuring a level of one or more agents selected from the group consisting of IFN-.gamma., TNF-.alpha., IL-12p40, IL-4, IL-5, and IL-13, wherein a change in the level of the one or more agents is indicative of the immunostimulation.

[0023] The present invention also discloses a method to treat or prevent Hepatitis C in a subject comprising the step of administering to the subject a fusion protein comprising an antibody or fragment thereof specific for a dendritic cell (DC) and a Hepatitis C virus antigen or antigenic peptide fused to the antibody or fragment thereof. A Hepatitis C virus antigen presenting dendritic cell (DC) is also disclosed in one embodiment of the present invention. The HCV antigen presenting DC further comprises one or more isolated dendritic cells (DCs) in contact with a fusion protein comprising an antibody or fragment thereof specific for the DC, the fusion protein further comprising a HCV peptide.

[0024] The present invention describes one or more vaccines against HCV comprising one or more antibodies or fragments thereof specific for a dendritic cell (DC) and one or more HCV antigens or antigenic domains attached to the one or more antibodies or fragments thereof. The vaccine has a general structure given by: H-w, H-w-x, H-w-x-y, or H-w-x-y-z, wherein H represents a heavy chain of an antibody or a fragment thereof specific for a DC, w, x, y, and z represent one or more HCV antigens or domains selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, or any combinations thereof. In one aspect w comprises the HCV antigenic domains selected from the group consisting of ProtA, ProtB, HelB, Palm, E1b, and E2. In another aspect x comprises the HCV antigenic domains selected from the group consisting of HelC, HelA, Palm, ProtA, ProtB, and E1b. In yet another aspect comprises the HCV antigenic domains selected from the group consisting of Palm, ProtB, and Protb. In another aspect z comprises HCV antigenic domains selected from E2, ProtA, and HelB. In a related aspect the one or more HCV antigens or antigenic domains are linked or attached to one another by one or more flexible linkers.

[0025] Another embodiment disclosed herein relates to a vaccine comprising one or more antibodies or fragments thereof specific for a dendritic cell (DC) and one or more HCV antigens or antigenic domains attached to the one or more antibodies or fragments thereof, wherein the vaccine has a general structure given by L-w-x-y-z, wherein L represents a light chain of an antibody or a fragment thereof specific for a DC, w, x, y, and z represent one or more HCV antigens or domains selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, or any combinations thereof.

[0026] In yet another embodiment the present invention discloses a vaccine comprising one or more antibodies or fragments thereof specific for a dendritic cell (DC) and one or more HCV antigens or antigenic domains attached to the one or more antibodies or fragments thereof, wherein the vaccine has a general structure given by:

##STR00001##

[0027] Wherein H represents a heavy chain of an antibody or a fragment thereof specific for a DC, L represents a light chain of an antibody or a fragment thereof specific for the DC, w, x, y, and z represent one or more HCV antigens or domains selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, or any combinations thereof.

[0028] Finally, the present invention discloses a method for generating a Hepatitis C virus (HCV) presenting dendritic cells (DCs) in a human subject comprising the steps of: providing one or more DCs and incubating the dendritic cells with a fusion protein, wherein the fusion protein comprises an antibody or fragment thereof specific for a dendritic cell and a HCV antigen fused to the antibody or fragment thereof. The method disclosed herein further comprises the step of administering to the subject an effective amount of IFNA, Ribavirin, or a combination thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] For a more complete understanding of the features and advantages of the present invention, reference is now made to the detailed description of the invention along with the accompanying figures and in which:

[0030] FIG. 1 provides a summary of HCV antigen combined constructs expressed at the C-terminus end of antibody heavy chain. Each HCV domains, as defined in FIG. 2, is represented as color rectangle. Flexible linkers are shown as curved lines. Each color represents a different linker. Domains are fused to the carboxyl terminus end of antibody heavy chain. "Expressed" means that domains fused to the carboxyl terminus end of antibody heavy chain are expressed as fusion antibody after co-transfection with antibody light chain in 293F cells. All possible combination of HCV domains have been constructed, and FIG. 3 shows only those that were expressed as soluble fusion proteins in 293F cells and in CHO cells and purified as recombinant antibodies;

[0031] FIG. 2 provides a summary of HCV antigen combined constructs expressed at the C-terminus end of antibody light chain. All possible combinations of HCV domains have been constructed, and the figure shows only those that are expressed as soluble fusion proteins in 293F cells and in CHO cells and purified as recombinant antibodies. The same color code as in FIG. 1 is used;

[0032] FIGS. 3A-3B demonstrate the ability of recombinant anti-DCIR and anti-CD40 antibodies fused to HCV NS3HelB specific antigen to elicit the expansion of antigen-specific CD4+ T cells from a chronic HCV infected patient cured after IFNa-Ribavirin therapy. Delivering NS3HelB to DCs through CD40 and DCIR induces IFN-.gamma.-TNFa-producing HCV NS3HelB-specific CD4+ T cells. PBMC cells from chronic HCV infected patients; either cured after therapy or in treatment failure, were co-cultured with IFNDCs targeted with anti-CD40-NS3HelB or anti-DCIR-NS3HelB for 10 days. Cells were stimulated with peptides clusters (10 peptides of 15-mers in each clusters) covering HCV NS3 HelB (10 .mu.M): FIG. 3A after 2 days, culture supernatants were analyzed for measuring IFN.gamma. and FIG. 3B PBMC cells were stained for measuring the frequency of peptide-specific CD4+ T cells intracellular IFN.gamma.+TNF.alpha.+ cells;

[0033] FIG. 4 demonstrates the ability of long HCV antigen bearing vaccine constructs to induce multi epitope CD4+ T cells. HCV antigens from NS3 Helicase HelBC construct were delivered to DCs through CD40 or DCIR. PBMC cells from chronic HCV infected patients; either cured after therapy or in treatment failure, were co-cultured with IFNDCs targeted with anti-CD40-NS3HelB, anti-CD40-NS3HelBC or anti-DCIR-NS3HelB, anti-DCIR-NS3HelBC for 10 days. Cells were stimulated for 6 h with peptides clusters (10 .mu.M; 10 peptides of 15-mers in each clusters) covering HCV NS3 HelB or HelBC constructs. PBMC cells were stained for measuring the frequency of peptide-specific CD4+ T cells intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS. Number of double positive CD4+ T cells induced after each peptide cluster stimulation were plotted for each vaccine targeting agent;

[0034] FIGS. 5A to 5C demonstrate the ability of recombinant anti-DCIR and anti-CD40 antibodies fused to HCV NS3HelB, HCV NS3ProtB and HCV NS5BPalm specific antigens to elicit the expansion of antigen-specific CD4+ T cells from a chronic HCV infected patient cured after IFNa-Ribavirin therapy. Delivering HCV antigen to DCs through CD40 and DCIR induces IFN.gamma.-TNFa-producing HCV-specific CD4+ T cells, with multi epitopes, specific CD4 T cells. PBMC cells from chronic HCV infected patients cured after therapy were co-cultured with autologous IFN.alpha.DCs targeted with anti-CD40-NS3HelB-NS3ProtB-NS5BPalm or anti-DCIR-NS3HelB-NS3ProtB-NS5BPalm for 10 days. Cells were stimulated with peptides clusters (10 peptides of 15-mers in each clusters) covering HCV NS3HelB, NS3ProtB or NS5BPalm (2 .mu.M). PBMC cells were stained for measuring the frequency of peptide-specific CD4+ T cells intracellular IFN.gamma.+TNF.alpha.+ cells;

[0035] FIGS. 6A to 6C demonstrate the ability of recombinant anti-DCIR and anti-CD40 antibodies fused to HCV NS3HelB, HCV NS3ProtB and HCV NS5BPalm specific antigens to elicit the expansion of antigen-specific CD8+ T cells from a chronic HCV infected patient cured after IFNa-Ribavirin therapy. Delivering HCV antigen to DCs through CD40 and DCIR induces IFN.gamma.-TNFa-producing HCV-specific CD4+ T cells, with multi epitopes, specific CD4 T cells. PBMC cells from chronic HCV infected patients cured after therapy were co-cultured with autologous IFN.alpha.DCs targeted with anti-CD40-NS3HelB-NS3ProtB-NS5BPalm or anti-DCIR-NS3HelB-NS3ProtB-NS5BPalm for 10 days. Cells were stimulated with peptides clusters (10 peptides of 15-mers in each clusters) covering HCV NS3HelB, NS3ProtB or NS5BPalm (2 .mu.M). PBMC cells were stained for measuring the frequency of peptide-specific CD8+ T cells intracellular IFN.gamma.+TNF.alpha.+ cells;

[0036] FIGS. 7A to 7D demonstrate the ability of recombinant anti-DCIR and anti-CD40 antibodies fused to HCV NS3HelB, HCV NS3ProtB or HCV NS5BPalm specific antigens to elicit the expansion of antigen-specific CD4+ T cells from chronic HCV infected patients cured after IFNa-Ribavirin therapy. HCV antigens from were delivered to DCs through CD40 or DCIR. IFN.alpha.DCs were targeted with anti-CD40-NS3HelB; anti-CD40-NS3ProtB; anti-CD40NS5bPalm or anti-DCIR-NS3HelB; anti-DCIR-NS3ProtB; anti-DCIRNS5bPalm and co-cultured for 10 days with PBMC cells from 3 chronic HCV infected patients cured after therapy. Cells were stimulated for 6 h with peptide clusters C7 and C9 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB constructs; with peptide clusters C2 and C3 covering HCV NS3 ProtB constructs or peptide cluster C2 C4 C5 C6 C7 covering NS5bPalm construct. PBMC cells were stained for measuring the frequency of peptide-specific CD4+ intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS. The left panel represent IFN-.gamma. amount secreted after 10 days culture of PBMCs with peptide cluster covering HCVNS3 and HCVNS5b entire proteins;

[0037] FIGS. 8A to 8D demonstrates the ability of recombinant anti-DCIR and anti-CD40 antibodies fused to HCV NS3HelB, HCV NS3ProtB or HCV NS5BPalm specific antigens to elicit the expansion of antigen-specific CD4+ T cells from chronic HCV infected patients in treatment failure. HCV antigens from were delivered to DCs through CD40 or DCIR. IFN.alpha.DCs were targeted with anti-CD40-NS3HelB; anti-CD40-NS3ProtB or anti-DCIR-NS3HelB; anti-CD40NS5bPalm or anti-DCIR-NS3HelB; anti-DCIR-NS3ProtB; anti-DCIRNS5bPalm and co-cultured for 10 days with PBMC cells from 3 chronic HCV infected patients in treatment failure (HCV+). Cells were stimulated for 6 h with peptide clusters C7 and C9 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB constructs; with peptide clusters C2 and C3 covering HCV NS3 ProtB constructs or peptide cluster C2 C4 C5 C6 C7 covering NS5bPalm construct. PBMC cells were stained for measuring the frequency of peptide-specific CD4+ intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS. The left panel represent IFN-.gamma. amount secreted after 10 days culture of PBMCs with peptide cluster covering HCVNS3 and HCVNS5b entire proteins;

[0038] FIGS. 9A and 9B demonstrate the ability of combination of TLR agonist and anti-DCIR HCV-NS3HelB can induced multi epitopes CD8+ T cells. HCV antigens from NS3 Helicase HelB construct were delivered to DCs through CD40 or DCIR. IFNDCs were targeted with anti-CD40-NS3HelB, or anti-DCIR-NS3HelB in presence of PAM3 (TLR2 agonist; 200 ng/ml), CL097 (TLR7/8 agonist; 5 .mu.g/ml) or polyIC (TLR3 agonist; 25 .mu.g/ml) before co-culture for 10 days with PBMC cells from chronic HCV infected patients; either cured after therapy or in treatment failure. Cells were stimulated for 6 h with peptide clusters C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB constructs: (FIG. 9A) PBMC cells were stained for measuring the frequency of peptide-specific CD4+ and CD8+ intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS, (FIG. 9B) Number of double positive CD4+ and CD8+ intracellular IFN.gamma.+TNF.alpha.+T cells induced after each TLR agonist stimulation were plotted;

[0039] FIGS. 10A-10D demonstrate the ability of combination of TLR agonist and anti-DCIR HCV-construct to increase CD4+ and induce CD8+ T cells responses in chronic HCV infected patients cured after therapy. HCV antigens from NS3 Helicase HelB or from NS3 Protease ProtB constructs were delivered to DCs through CD40 or DCIR. IFN.alpha.DCs were targeted with anti-CD40-NS3HelB, anti-DCIR-NS3HelB, anti-CD40-NS3ProtB, anti-DCIR-NS3ProtB, in presence of PAM3 (TLR2 agonist; 200 ng/ml), CL095 (TLR7/8 agonist; 5 .mu.g/ml) or polyIC (TLR3 agonist; 25 .mu.g/ml) or cyclic glucan (TLR4 agonist, 10 .mu.g/ml) before co-culture for 10 days with PBMC cells from chronic HCV infected patients cured after therapy. Cells were stimulated for 6 h with peptide clusters C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB constructs or with peptide clusters C3 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 ProtB constructs: FIGS. 10A and 10B PBMC cells were stained for measuring the frequency of peptide-specific CD4+ intracellular IFN.gamma.+TNF.alpha.+ cells, and analyzed by FACS and FIGS. 10C and 10D PBMC cells were stained for measuring the frequency of peptide-specific CD8+ intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS;

[0040] FIG. 11 demonstrates the ability of combination of TLR agonists and anti-CD40 HCV-constructs to increase CD4+ T cells responses in chronic HCV infected patients in treatment failure. HCV antigens from NS3 Helicase HelB or from NS3 Protease ProtB constructs were delivered to DCs through CD40 or DCIR. IFN.alpha.DCs were targeted with anti-CD40-NS3HelB, anti-DCIR-NS3HelB, anti-CD40-NS3ProtB, anti-DCIR-NS3ProtB, in presence of PAM3 (TLR2 agonist; 200 ng/ml), CL095 (TLR7/8 agonist; 5 .mu.g/ml) or polyIC (TLR3 agonist; 25 .mu.g/ml) or cyclic glucan (TLR4 agonist, 10 .mu.g/ml) before co-culture for 10 days with PBMC cells from chronic HCV infected patients cured after therapy. Cells were stimulated for 6 h with peptide clusters C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB constructs or with peptide clusters C3 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 ProtB constructs. PBMC cells were stained for measuring the frequency of peptide-specific CD4+ intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS;

[0041] FIGS. 12A-12C demonstrate the ability of HCV vaccine candidates to recall CD4+ T cells responses in all chronic HCV infected patients (cured or in treatment failure). HCV antigens from NS3 Helicase HelB, NS5b polymerase Palm or from NS3 Protease ProtB constructs were delivered to DCs through CD40 or DCIR. IFN.gamma.DCs were targeted with anti-CD40-[NS3HelB.about.NS3ProtB.about.NS5bPalm on heavy chain], anti-DCIR-[NS3HelB.about.NS3ProtB.about.NS5bPalm on heavy chain] before co-culture for 10 days with PBMC cells from chronic HCV infected patients cured after therapy. Cells were stimulated for 6 h with peptide clusters C7, C9 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB domain, with peptide clusters C2-C3-C4 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 ProtB domain or with peptide clusters C2-C4-C5-C6-C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS5b Palm domain. PBMC cells were stained for measuring the frequency of peptide-specific CD4+ and CD8+ intracellular IFN.gamma.+TNF.alpha.+ cells, and analyzed by FACS. The number of CD4+IFN.gamma.+TNF.alpha.+ cells induced vaccine candidate is shown;

[0042] FIGS. 13A-13E demonstrate of the ability of different HCV antigen combination on vaccine candidate for recall CD4+ T cells responses in chronic HCV infected cured patients. HCV antigens from NS3 Helicase HelB, NS5b polymerase Palm or from NS3 Protease ProtB combination constructs were delivered to DCs through CD40 or DCIR. IFNaDCs were targeted with second-generation vaccines anti-CD40-[NS3HelB on light chain and NS3ProtB.about.NS5bPalm on heavy chain], anti-DCIR-[NS3HelB on light chain and NS3ProtB.about.NS5bPalm on heavy chain], or first-generation vaccines anti-CD40-[NS3HelB.about.NS3ProtB.about.NS5bPalm on heavy chain], anti-DCIR-[NS3HelB.about.NS3ProtB.about.NS5bPalm on heavy chain] before co-culture for 10 days with PBMC cells from chronic HCV infected patients cured after therapy. Cells were stimulated for 6 h with peptide clusters C7 and C9 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB domain (shown in green on the figure), with peptide clusters C2-C3-C4 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 ProtB domain (shown in pink on the figure) or with peptide clusters C2-C4-C5-C6-C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS5b Palm domain (shown in orange in the figure). PBMC cells were stained for measuring the frequency of peptide-specific CD4+ intracellular IFN.gamma.+TNFa+ cells, an analyzed by FACS. The number of CD4+IFN.gamma.+TNF.alpha.+ cells induced by first-generation vaccine or second-generation vaccine is compared in the last panel; and

[0043] FIGS. 14A to 14H demonstrate the ability of vaccine candidate to recall CD4+ T cells responses in HCV patients infected with non 1 genotype and HCV-exposed but non-infected individual. HCV antigens from NS3 Helicase HelB, NS5b polymerase Palm or from NS3 Protease ProtB combination constructs were delivered to DCs through CD40 or DCIR and DC loaded were co-culture for 10 days with PBMC cells from HCV patients infected with non 1 genotype HCV-infected patients (HCV-015, 2b) and HCV-exposed but non infected individual (HCV-029). Cells were stimulated for 6 h with peptide clusters C7 and C9 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB domain, with peptide clusters C2-C3-C4 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 ProtB domain or with peptide clusters C2-C4-C5-C6-C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS5b Palm domain. PBMC cells were stained for measuring the frequency of peptide-specific CD4+ intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS.

[0044] FIGS. 15A to 15B shows the results from a 10 day expansion culture whereby a dose range of 1st generation anti-DCIR-HCV vaccine (left panels) is compared to second generation anti-DCIR-HCV vaccine (right panels). Doses were 0.05 nM, 0.5 nM, and 5 nM and antigen-specific responses were ascertained by stimulation with no peptide (control) or ProtA, HelB, or Palm peptide pools in the presence of Brefeldin, followed by staining for CD3+, CD4+ and intracellular IFNg and TNFa. Samples were analyzed by FACS. Shown are comparable CD4+ HCV antigen-specific responses to the two generations of vaccines.

[0045] FIGS. 16A to 16B shows the results from a 10 day expansion culture whereby a dose range of 1st generation anti-CD40-HCV vaccine (left panels) is compared to second generation anti-CD40-HCV vaccine (right panels). Doses were 0.05 nM, 0.5 nM, and 5 nM and antigen-specific responses were ascertained by stimulation with no peptide (control) or ProtA, HelB, or Palm peptide pools in the presence of Brefeldin, followed by staining for CD3+, CD4+ and intracellular IFNg and TNFa. Samples were analyzed by FACS. Shown are comparable CD4+ HCV antigen-specific responses to the two generations of vaccines.

DETAILED DESCRIPTION OF THE INVENTION

[0046] While the making and using of various embodiments of the present invention are discussed in detail below, it should be appreciated that the present invention provides many applicable inventive concepts that can be embodied in a wide variety of specific contexts. The specific embodiments discussed herein are merely illustrative of specific ways to make and use the invention and do not delimit the scope of the invention.

[0047] To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as "a", "an" and "the" are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.

[0048] The invention includes also variants and other modification of an antibody (or "Ab") of fragments thereof, e.g., anti-CD40 fusion protein (antibody is used interchangeably with the term "immunoglobulin"). As used herein, the term "antibodies or fragments thereof," includes whole antibodies or fragments of an antibody, e.g., Fv, Fab, Fab', F(ab')2, Fc, and single chain Fv fragments (ScFv) or any biologically effective fragments of an immunoglobulins that binds specifically to, e.g., CD40. Antibodies from human origin or humanized antibodies have lowered or no immunogenicity in humans and have a lower number or no immunogenic epitopes compared to non-human antibodies. Antibodies and their fragments will generally be selected to have a reduced level or no antigenicity in humans.

[0049] As used herein, the terms "Ag" or "antigen" refer to a substance capable of either binding to an antigen binding region of an immunoglobulin molecule or of eliciting an immune response, e.g., a T cell-mediated immune response by the presentation of the antigen on Major Histocompatibility Antigen (MHC) cellular proteins. As used herein, "antigen" includes, but is not limited to, antigenic determinants, haptens, and immunogens, which may be peptides, small molecules, carbohydrates, lipids, nucleic acids or combinations thereof. The skilled immunologist will recognize that when discussing antigens that are processed for presentation to T cells, the term "antigen" refers to those portions of the antigen (e.g., a peptide fragment) that is a T cell epitope presented by MHC to the T cell receptor. When used in the context of a B cell mediated immune response in the form of an antibody that is specific for an "antigen", the portion of the antigen that binds to the complementarity determining regions of the variable domains of the antibody (light and heavy) the bound portion may be a linear or three-dimensional epitope. In the context of the present invention, the term antigen is used on both contexts, that is, the antibody is specific for a protein antigen (CD40), but also carries one or more peptide epitopes for presentation by MHC to T cells. In certain cases, the antigens delivered by the vaccine or fusion protein of the present invention are internalized and processed by antigen presenting cells prior to presentation, e.g., by cleavage of one or more portions of the antibody or fusion protein.

[0050] As used herein, the term "conjugate" refers to a protein having one or more targeting domains, e.g., an antibody, and at least one antigen, e.g., a small peptide or a protein. These conjugates include those produced by chemical methods, such as by chemical coupling, for example, coupling to sulfhydryl groups, and those produced by any other method whereby one or more antibody targeting domains and at least one antigen, are linked, directly or indirectly via linker(s) to a targeting agent. An example of a linker is a cohesin-dockerin (coh-doc) pair, a biotin-avidin pair, histidine tags bound by Zn, and the like.

[0051] As used herein, the term "Antigen Presenting Cells" (APC) refers to cells that are capable of activating T cells, and include, but are not limited to, certain macrophages, B cells and dendritic cells. "Dendritic cells" (DCs) refers to any member of a diverse population of morphologically similar cell types found in lymphoid or non-lymphoid tissues. These cells are characterized by their distinctive morphology, high levels of surface MHC-class II expression (Steinman, et al., Ann. Rev. Immunol 9:271 (1991); incorporated herein by reference for its description of such cells). These cells can be isolated from a number of tissue sources, and conveniently, from peripheral blood, as described herein. Dendritic cell binding proteins refers to any protein for which receptors are expressed on a dendritic cell. Examples include GM-CSF, IL-1, TNF, IL-4, CD40L, CTLA4, CD28, and FLT-3 ligand.

[0052] For the purpose of the present invention, the term "vaccine composition" is intended to mean a composition that can be administered to humans or to animals in order to induce an immune system response; this immune system response can result in a production of antibodies or simply in the activation of certain cells, in particular antigen-presenting cells, T lymphocytes and B lymphocytes. The vaccine composition can be a composition for prophylactic purposes or for therapeutic purposes, or both. As used herein, the term "antigen" refers to any antigen which can be used in a vaccine, whether it involves a whole microorganism or a subunit, and whatever its nature: peptide, protein, glycoprotein, polysaccharide, glycolipid, lipopeptide, etc. They may be viral antigens, bacterial antigens, or the like; the term "antigen" also comprises the polynucleotides, the sequences of which are chosen so as to encode the antigens whose expression by the individuals to which the polynucleotides are administered is desired, in the case of the immunization technique referred to as DNA immunization. They may also be a set of antigens, in particular in the case of a multivalent vaccine composition which comprises antigens capable of protecting against several diseases, and which is then generally referred to as a vaccine combination, or in the case of a composition which comprises several different antigens in order to protect against a single disease, as is the case for certain vaccines against whooping cough or the flu, for example. The term "antibodies" refers to immunoglobulins, whether natural or partially or wholly produced artificially, e.g. recombinant. An antibody may be monoclonal or polyclonal. The antibody may, in some cases, be a member of one, or a combination immunoglobulin classes, including: IgG, IgM, IgA, IgD, and IgE.

[0053] The term "adjuvant" refers to a substance that enhances, augments or potentiates the host's immune response to a vaccine antigen.

[0054] The term "gene" is used to refer to a functional protein, polypeptide or peptide-encoding unit. As will be understood by those in the art, this functional term includes both genomic sequences, cDNA sequences, and fragments or combinations thereof, as well as gene products, including those that may have been altered by the hand of man. Purified genes, nucleic acids, protein and the like are used to refer to these entities when identified and separated from at least one contaminating nucleic acid or protein with which it is ordinarily associated.

[0055] As used herein, the term "nucleic acid" or "nucleic acid molecule" refers to polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., .alpha.-enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like. The term "nucleic acid molecule" also includes so-called "peptide nucleic acids," which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded.

[0056] As used herein, "polynucleotide" or "nucleic acid" refers to a strand of deoxyribonucleotides or ribonucleotides in either a single- or a double-stranded form (including known analogs of natural nucleotides). A double-stranded nucleic acid sequence will include the complementary sequence. The polynucleotide sequence may encode variable and/or constant region domains of immunoglobulin that are formed into a fusion protein with one or more linkers. For use with the present invention, multiple cloning sites (MCS) may be engineered into the locations at the carboxy-terminal end of the heavy and/or light chains of the antibodies to allow for in-frame insertion of peptide for expression between the linkers. As used herein, the term "isolated polynucleotide" refers to a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof. By virtue of its origin the "isolated polynucleotide" (1) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotides" are found in nature, (2) is operably linked to a polynucleotide which it is not linked to in nature, or (3) does not occur in nature as part of a larger sequence. The skilled artisan will recognize that to design and implement a vector can be manipulated at the nucleic acid level by using techniques known in the art, such as those taught in Current Protocols in Molecular Biology, 2007 by John Wiley and Sons, relevant portions incorporated herein by reference. Briefly, the encoding nucleic acid sequences can be inserted using polymerase chain reaction, enzymatic insertion of oligonucleotides or polymerase chain reaction fragments in a vector, which may be an expression vector. To facilitate the insertion of inserts at the carboxy terminus of the antibody light chain, the heavy chain, or both, a multiple cloning site (MCS) may be engineered in sequence with the antibody sequences.

[0057] As used herein, the term "polypeptide" refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. The term "domain," or "polypeptide domain" refers to that sequence of a polypeptide that folds into a single globular region in its native conformation, and that may exhibit discrete binding or functional properties.

[0058] As used in this application, the term "amino acid" means one of the naturally occurring amino carboxylic acids of which proteins are comprised. The term "polypeptide" as described herein refers to a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides." A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

[0059] A polypeptide or amino acid sequence "derived from" a designated nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 3-5 amino acids, preferably at least 4-7 amino acids, more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence. This terminology also includes a polypeptide expressed from a designated nucleic acid sequence.

[0060] As used herein, the terms "stable," "soluble," or "unstable" when referring to proteins is used to describe a peptide or protein that maintains its three-dimensional structure and/or activity (stable) or that loses immediately or over time its three-dimensional structure and/or activity (unstable). As used herein, the term "insoluble" refers to those proteins that when produced in a cell (e.g., a recombinant protein expressed in a eukaryotic or prokaryotic cell or in vitro) are not soluble in solution absent the use of denaturing conditions or agents (e.g., heat or chemical denaturants, respectively). The antibody or fragment thereof and the linkers taught herein have been found to convert antibody fusion proteins with the peptides from insoluble and/or unstable into proteins that are stable and/or soluble. Another example of stability versus instability is when the domain of the protein with a stable conformation has a higher melting temperature (Tm) than the unstable domain of the protein when measured in the same solution. A domain is stable compared to another domain when the difference in the Tm is at least about 2.degree. C., more preferably about 4.degree. C., still more preferably about 7.degree. C., yet more preferably about 10.degree. C., even more preferably about 15.degree. C., still more preferably about 20.degree. C., even still more preferably about 25.degree. C., and most preferably about 30.degree. C., when measured in the same solution.

[0061] As used herein, the term "in vivo" refers to being inside the body. The term "in vitro" used as used in the present application is to be understood as indicating an operation carried out in a non-living system.

[0062] As used herein, the term "treatment" or "treating" means any administration of a compound of the present invention and includes (1) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or (2) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology).

[0063] As used herein, "pharmaceutically acceptable carrier" refers to any material that when combined with an immunoglobulin (Ig) fusion protein of the present invention allows the Ig to retain biological activity and is generally non-reactive with the subject's immune system. Examples include, but are not limited to, standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as an oil/water emulsion, and various types of wetting agents. Certain diluents may be used with the present invention, e.g., for aerosol or parenteral administration, that may be phosphate buffered saline or normal (0.85%) saline.

[0064] Substantial similarity of a peptide refers to similarity of a peptide as reflected in the amino acid sequence of the peptide. Identity of a continuous stretch of least 8 amino acids in an antigenic epitope of the peptide may be sufficient to establish substantial identity that enables cross reactivity. A first peptide and a second peptide are substantially similar in this regard if they have substantial similar antigenic epitopes so that immunization with the first peptide causes an immune response against the second peptide.

[0065] A fragment of an antibody, as used in the present application, refers to a portion of an antibody, created by protein engineering including proteolysis, or genetic engineering including recombination of nucleic acids; the fragment of an antibody retains specificity for the antigen.

[0066] A fragment of a peptide used as antigen refers to a portion of the peptide that retains its immunogenicity. A person of ordinary skill in the art will recognize that a continuous stretch of least 8 amino acids in an antigenic epitope of the peptide may be sufficient I order for a peptide to retain its immunogenicity.

[0067] Recombinant protein or antibody is generated by genetic engineering of nucleic acid encoding the protein or antibody and subsequent translation of the coding sequence by a cell or in a cell-free translation system.

[0068] The present invention describes a vaccine composition for delivering a HCV antigen specifically to DCs for the purpose of invoking an immune response In one embodiment, due to the high polymorphism of HCV, a sequence that is representative of most of circulating HCV sequence was selected. Based on sequence variation HCV can be classified into 6 genotypes that differs one to the other on the basis of sequence identity. World wide, 1 genotype is the most represented and also the most difficult to treat with the current IFNa-Ribavirin double therapy. More precisely, 1a genotype is the most represented subsequence in industrial country, and especially in US.

[0069] In one embodiment, 1a genotype was used as target sequence to derive a vaccine. It was observed that sequence alignment with all available 1a sequences found in data bases (euHCVdb and Los Alamos National Laboratory) showed less than 70% of sequence identity and the sequence of the HCV antigen would have to be adjusted accordingly.

[0070] A mosaic sequence was derived using the mosaic vaccine tools at www.hiv.lanl.gov/content/sequence/MOSAIC/ interface choosing mosaic sequence cocktail, 1 as cocktail size and 9 as epitope size. We used 249 sequences for E1 mosaic, 656 sequences for E2 mosaic, 213 sequences for NS3 mosaic and 310 sequences for NS5b mosaic. All sequences correspond to complete genes of 576, 1089, 1893, 1773 nucleotides respectively and found in euHCVdb (euhcvdb.ibcp.fr/euHCVdb/).

[0071] HCV antigen choice: HCV is an RNA enveloped virus. Virions are consisted by 4 structural proteins Core, E1, E2 and p7. As an RNA virus replication is based on viral proteins that need to be expressed after infection. Six non-structural proteins (NS2, NS3, NS4a, NS4b, NS5a, NS5b) are necessary to establish and maintain replication and virus production. HCV targets the liver and can infect barely all the liver with 90% of hepatocytes infected. However, the virus is able to replicate only in 30% of hepatocytes. Infected cells presented at their surface epitopes coming from structural proteins, while infected virus-producing cells presented all HCV antigens, structural and non structural.

[0072] Because HCV targets a vital organ such as the liver, therapeutic vaccine need to be very specific in order to avoid complete liver destruction and death of the patients. Indeed, we choose for our therapeutic vaccine antigens that are only found in infected virus producing hepatocytes, and then target antigen will be non-structural proteins. Moreover, NS3 and NS4b are highly immunogenic in chronic infected patients, as efficient as structural core or E1 E2 structural proteins. Therefore the present inventors included NS5b as an antigen too.

[0073] In one embodiment, NS3 and NS5b were chosen because of their possible expression as recombinant protein and the availability of their 3D structure.

[0074] Description of an embodiment of a vaccine: A particular embodiment of a vaccine consisted of bifunctional antibodies, which were directed against Dendritic Cells specific receptors and have target antigens fused at C terminus part of heavy chain. This allows unique targeting of DC and more precisely different DC subset that expressed different receptors, DC activation through the targeted receptor, and direct delivery of antigen to DC. In turn antigens are presented more efficiently and APC function is associated to cytokine secretion that orient T cells activation towards different functions.

[0075] Design of domains: It is not readily predictable whether any particular non-structural viral protein will be efficiently expressed as a direct antibody-antigen fusion protein. Commonly, fusion proteins may not be soluble and not be secreted. The present application describes that by using flexible linker modules, fragmenting the antigen coding sequence, and varying the fragment order, efficient secretion of recombinant antibody-antigen vaccines bearing extensive stretches of non-structural proteins can be achieved. The current application describes a first testing of constructs by expression of antibody fused to individual HCV non-structural proteins, then linking those that are expressible as soluble protein to each other to maximize the antigen load. Domains were first designed based on the 3D structure of the corresponding full-length proteins. Domains were design as the minimal structured regions in between unfolded loops. Length of the loops was varied in order to increase expression of corresponding domains. Pymol software was used to visualize 3d structures. The domains that expressed at the C-terminal of the antibody heavy chain are represented by SEQ ID NOs: 7-14.

[0076] Multiple combinations of individual domains have been made in order to provide as much HCV antigen as possible. In some embodiments, each single domain is separated from the next by flexible linkers, which can be as small as two amino acids (e.g., AS) but can also be longer, e.g., 3, 4, 5, 6, 7 8, 9, 10, 12, 15, 18, 20, 25 or 30 amino acids long. FIG. 1 shows the summary of all combine constructs. The linkers are found in the assembled sequences, can also be SSVSPTTSVHPTPTSVPPTPTKSSP (SEQ ID NO.: 166); PTSTPADSSTITPTATPTATPTIKG (SEQ ID NO.: 167); TVTPTATATPSAIVTTITPTATTKP (SEQ ID NO.: 168); TNGSITVAATAPTVTPTVNATPSAA (SEQ ID NO.: 169).

[0077] In another embodiment, domains were also expressed at the C-terminus part of the light chain, and used in combination with heavy chain fused to multiple HCV domains. This allows the formation of a combine antibody with 3HCV domains fused to the heavy chain and one fused to the light chain. FIG. 2 summarizes the construct obtain after fusion of HCV domains at the C-terminus end of light chain.

[0078] Preparation of targeting constructs: Anti human DCIR and CD40 V region form H and L chain were cloned in a IgG4 backbone. Spe I cloning site was introduced at the end of the carboxy terminus to clone in frame antigen sequences. HCV antigens from NS3 and NS5b viral proteins represented as subdomains of these proteins were subcloned as a Spe-Not fragment in Nhe-Not linearized pIRES vector.

[0079] HCV-domains were designed based on the 3D-structure of the corresponding full-length proteins (PDB code IJXP for NS3protease, 1HEI for NS3Helicase and 1GX5 for NS5b). 3D-structures were visualized using PyMol software. Domains were designed as the minimal structured regions in between unfolded loops. Length of the loops was varied in order to increase expression of corresponding domains fused to the recombinant antibody. For multiple domains cloning, linkers were introduced between domains using Spe-Not/Nhe-Not strategy. Mosaic sequences, used in this study, corresponding to the maximum HCV-domains expressed as antibody-antigen recombinant fusion proteins are shown below. They included amino acids 95 to 180 from NS3Protease, amino acids 132 to 254 from NS3Helicase and a recombinant fusion of amino acids 55 to 80; 172 to 261 and 276 to 362 from NS5bPolymerase. Spe, Nhe and Not introduced cloning sites are underlined.

[0080] SEQ ID NOS: 1-6 show the amino acid sequence of the HCV proteins E1, E2, NS3, and NS5b mosaic sequences. Membrane domains are underlined. The full-length protein NS3 contains 631 amino acids and is also presented as being cut in its two enzymatic activities proteins: NS3Protease and NS3Helicase. These may also be produced as recombinant proteins N-terminal fused to either histidine tag or Cohesin tag.

TABLE-US-00001 Envelop protein E1 (192 amino acids) (SEQ ID NO: 1): YQVRNSSGLYHVTNDCPNSSIVYEAADAILHTPGCVPCVREGNASRCWVAVTPTVATRDGKLPTTQ LRRHIDLLVGSATLCSALYVGDLCGSVFLVGQLFTFSPRRHWTTQDCNCSIYPGHITGHRMAWDMM MNWSPTTAVVAQLLRIPQAILDMIAGAHWGVLAGIAYFSMVGNWAKVLVVLLLFAGVDA Envelop protein E2 (363 amino acids) (SEQ ID NO: 2): ETHVTGGSAARTTAGLAGLFTPGAKQNIQLINTNGSWHINRTALNCNDSLNTGWVAGLFYYHKFNS SGCPERLASCRPLTDFDQGWGPISYANGSGPDQRPYCWHYPPKPCGIVPAKSVCGPVYCFTPSPVVV GTTDRSGAPTYNWGENDTDVFVLNNTRPPLGNWFGCTWMNSTGFTKVCGAPPCVIGGVGNNTLH CPTDCFRKHPEATYSRCGSGPWITPRCLVDYPYRLWHYPCTINYTIFKIRMYVGGVEHRLEAACNW TRGERCDLEDRDRSELSPLLLSTTQWQVLPCSFTTLPALSTGLIHLHQNIVDVQYLYGVGSSIASWAI KWEYVVLLFLLLADARVCSCLWMMLLISQAEA Non structural protein 3 NS3 (FL 631 amino acids) (SEQ ID NO: 3): APITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPK GPVIQMYTNVDQDLVGWPAPQGARSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYL KGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPAVPQSFQVAHL HAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTGSPITYST YGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTVPHPNIE EVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVIPTSGV VVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFSLDPTFTIETTTLPQDAVSRTQRRGRTGRGKPGI YRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFWEGVFT GLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPLLYRLG AVQNEVTLTHPITKYIMTCMSADLEVVT NS3 (prot 189 amino acids) (SEQ ID NO: 4): APITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATCINGVCWTVYHGAGTRTIASPK GPVIQMYTNVDQDLVGWPAPQGARSLTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYL KGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPAVPQS NS3 (hel 442 amino acids) (SEQ ID NO: 5): FQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGIDPNIRTGVRTITTG SPITYSTYGKFLADGGCSGGAYDIIICDECHSTDATSILGIGTVLDQAETAGARLVVLATATPPGSVTV PHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVALGINAVAYYRGLDVSVI PTSGVVVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFSLDPTFTIETTTLPQDAVSRTQRRGRTGR GKPGIYRFVAPGERPSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHLEFW EGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWDQMWKCLIRLKPTLHGPTPL LYRLGAVQNEVTLTHPITKYIMTCMSADLEVVT Non structural NS5b (591 amino acids) (SEQ ID NO: 6): SMSYSWTGALVTPCAAEEQKLPINALSNSLLRHHNLVYSTTSRSACQRQKKVTFDRLQVLDSHYQD VLKEVKAAASKVKANLLSVEEACSLTPPHSAKSKFGYGAKDVRCHARKAVNHINSVWKDLLEDSV TPIDTTIMAKNEVFCVQPEKGGRKPARLIVFPDLGVRVCEKMALYDVVSKLPLAVMGSSYGFQYSP GQRVEFLVQAWKSKKTPMGFSYDTRCFDSTVTESDIRTEEAIYQCCDLDPQARVAIKSLTERLYVGG PLTNSRGENCGYRRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCTMLVCGDDLVVICESAGVQ EDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITSCSSNVSVAHDGAGKRVYYLTRDPTTPLARAA WETARHTPVNSWLGNIIMFAPTLWARMILMTHFFSVLIARDQLEQALDCEIYGACYSIEPLDLPPIIQ RLHGLSAFSLHSYSPGEINRVAACLRKLGVPPLRAWRHRARSVRARLLSRGGRAAICGKYLFNWAV RTKLKLTPIAAAGQLDLSGWFTAGYSGGDIYHSVSHARPRWFWFCLLLLAAGVGIYLLPNR

[0081] The nucleotide sequences are presented herein below.

TABLE-US-00002 NS3Protease domain B (SEQ ID NO: 145) ACTAGTACTCCTTGTACCTGCGGCTCATCCGACCTGTACCTGGTCACCCGGCACGCAGACGTCA TTCCTGTACGCCGACGCGGGGATAGTAGGGGGAGCCTGCTCTCTCCAAGACCCATATCCTACCT CAAGGGCAGCAGCGGTGGACCACTGCTGTGTCCCGCTGGTCATGCTGTGGGAATATTTAGGGCC GCAGTGTGTACCAGAGGCGTGGCCAAAGCTGTTGATTTTATTCCCGTCGAAAATCTTGAAACAA CCATGAGAAGCCCAGTGTTCACAGACAACTCATCTCCCCCAGCAGTGCCGCAGAGTGCTAGCT GAGAATTCGCGGCCGC NS3Helicase domain B (SEQ ID NO: 146): ACTAGTGTGACTGTGCCCCACCCCAATATCGAAGAGGTGGCCCTTAGTACTACCGGGGAAATTC CTTTCTACGGGAAGGCCATCCCTCTCGAGGTTATTAAAGGAGGGCGACATCTGATTTTTTGCCA CTCCAAGAAGAAGTGTGACGAGCTGGCCGCGAAACTGGTTGCCTTGGGCATCAACGCTGTCGC ATACTATCGGGGACTGGATGTATCAGTGATACCCACCAGCGGAGTGGTAGTTGTCGTCGCTACA GACGCATTGATGACCGGCTTTACAGGAGATTTCGACTCCGTCATCGACTGTAACACATGCGTGA CTCAGACAGTGGATTTCAGCCTTGACCCGACGTTTACGATTGAGACCACCACTCTCCCTCAGGA TGCTGTGTCTAGGACCCAAAGACGCGGTCGCACAGGCCGGGGCAAACCAGGCATCTATAGGTT CGTGGCACCAGGGGAAAGAGCTAGCTGAgaattcGCGGCCGC NS5bPalm (SEQ ID NO: 147): ACTAGTGTGCTGGACTCTCACTACCAGGATGTCCTGAAGGAAGTAAAAGCAGCCGCTTCTAAA GTCAAAGCGAACGCTCTGTACGATGTCGTTTCCAAACTGCCGCTGGCTGTCATGGGCTCTTCCTA CGGCTTTCAGTATTCCCCGGGTCAGCGCGTTGAGTTCCTGGTCCAGGCGTGGAAATCCAAAAAG ACTCCGATGGGTTTTTCCTATGACACTCGCTGCTTCGACAGCACCGTTACCGAAAGCGACATTC GCACCGAGGAAGCAATCTACCAGTGCTGCGACCTGGACCCACAGGCCCGCGTGGCGATCAAAT CTCTGACCGAACGCCTGTACGTTGGCCGCTGTCGCGCTTCCGGTGTTCTGACGACCTCCTGCGGT AATACGCTGACCTGCTACATCAAAGCACGCGCTGCCTGTCGCGCAGCCGGTCTGCAGGACTGCA CCATGCTGGTGTGTGGCGATGACCTGGTGGTGATCTGCGAAAGCGCTGGCGTGCAGGAAGACG CAGCAAGCCTGCGCGCTTTCACCGAAGCTATGACTCGCTACTCTGCGCCGCCGGGTGACCCGCC GCAGCCAGAATACGATCTGGAGCTGATCACCGCTAGCTAAGAATTCGCGGCCGC

[0082] SEQ ID NOS: 7-14 show the HCV antigen domains E1a, E2, ProtA, Prot B, Hel A, Hel B, HelC, and NS5 bpalm. These were expressed as antibody fusion proteins. For all constructs, amino acids TS and AS (shown in red) have been added for cloning purpose to the mosaic HCV sequence. NS5b palm has been constructed based on NS5b 3D structure (1C2P). It is based on structural domain corresponding of the palm domain of NS5b polymerase and do not correspond to the linear amino acid sequence;

TABLE-US-00003 Envelop protein E1a construct (63 amino acids) (SEQ ID NO: 7): TSVGQLFTFSPRRHWTTQDCNCSIYPGHITGHRMAWDMMMNWSPTTAVVA QLLRIPQAILDMIAGAS

[0083] In SEQ ID NO: 7 membrane domain and predicted unfolded regions have been removed from E1 mosaic 192 aa sequence to increase expression of the Ab fusion protein.

TABLE-US-00004 Envelop protein E2 mosaic sequence (342 amino acids) (SEQ ID NO: 8): TSETHVTGGSAARTTAGLAGLFTPGAKQNIQLINTNGSWHINRTALNCND SLNTGWVAGLFYYHKFNSSGCPERLASCRPLTDFDQGWGPISYANGSGP DQRPYCWHYPPKPCGIVPAKSVCGPVYCFTPSPVVVGTTDRSGAPTYNW GENDTDVFVLNNTRPPLGNWFGCTWMNSTGFTKVCGAPPCVIGGVGNNT LHCPTDCFRKHPEATYSRCGSGPWITPRCLVDYPYRLWHYPCTINYTI FKIRMYVGGVEHRLEAACNWTRGERCDLEDRDRSELSPLLLSTTQWQVLP CSFTTLPALSTGLIHLHQNIVDVQYLYGVGSSIASWAIKWEYVVLLFLL AS

[0084] In SEQ ID NO: 8 the membrane domain has been removed for E2 mosaic sequence.

[0085] NS3Protease has been cut in 2 structural domains based on its 3D structure (IJXP).

TABLE-US-00005 ProtA (SEQ ID NO: 9) TSAPITAYAQQTRGLLGCIITSLTGRDKNQVEGEVQIVSTAAQTFLATC INGVCWTVYHGAGTRTIAS Prot B (SEQ ID NO: 10) TSTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSG GPLLCPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNS SPPAVPQSAS

[0086] NS3 Helicase enzymatic protein has been cut in 3 structural domains based on NS3 Helicase 3D structure. (1HEI)

TABLE-US-00006 Hel A (SEQ ID NO: 11) FQVAHLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSK AHGIDPNIRTGVRTITTGSPITYSTYGKFLADGGCSGGAYDIIICDECHS TDATSILGIGTVLDQAETAGARLVVLATATPPGSAS Hel B (SEQ ID NO: 12) VTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDE LAAKLVALGINAVAYYRGLDVSVIPTSGVVVVVATDALMTGFTGDFDSVI DCNTCVTQTVDFSLDPTFTIETTTLPQDAVSRTQRRGRTGRGKPGIYRFV APGERAS Hel C (SEQ ID NO: 13) PSGMFDSSVLCECYDAGCAWYELTPAETTVRLRAYMNTPGLPVCQDHL EFWEGVFTGLTHIDAHFLSQTKQSGENLPYLVAYQATVCARAQAPPPSWD QMWKCLIRLKPTLHGPTPLLYRLGAVQNEVTLTHPITKYIMTCMSADLEV VTAS NS5bpalm (SEQ ID NO: 14) TSVLDSHYQDVLKEVKAAASKVKANALYDVVSKLPLAVMGSSYGFQYSPG QRVEFLVQAWKSKKTPMGFSYDTRCFDSTVTESDIRTEEAIYQCCDLDPQ ARVAIKSLTERLYVGRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCT MLVCGDDLVVICESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLEL ITAS

[0087] HCV sequence and HCV domains constructions: Due to the high polymorphism of HCV, a sequence that is representative of most of circulating HCV sequence was selected.

[0088] A mosaic sequence was derived using the mosaic vaccine tools at http://www.hiv.lanl.gov/content/sequence/MOSAIC/ interface choosing mosaic sequence cocktail, 1 as cocktail size and 9 as epitope size. We used 213 sequences for NS3 mosaic and 310 sequences for NS5b mosaic. All sequences correspond to complete genes of 1893, 1773 nucleotides respectively and found in euHCVdb (available on the internet at: euhcvdb.ibcp.fr/euHCVdb/).

[0089] Synthetic corresponding genes were purchased from Bio Basic Inc. (Ontario Canada). For cloning purposes, Spe cloning site was introduced at 5' end and Nhe, EcoRI and Not I at the 3' end. HCV domains were then constructed by PCR. NS3Protease domain B was construct using the synthetic gene cloned in pUC57 as template and the following primers: NS3Protease domain B forward: 5'-GAGCTCGGATCCACTAGTACTCCTTGTACCTGCGGCTCATCC-3' (SEQ ID NO: 148) NS3Protease domain B reverse: 5'-GCCCGCGGCCGCGAATTCTCAGCTAGCACTCTGCGGCACTGCTGGGGG-3' (SEQ ID NO: 149). NS3Helicase domain B was ordered directly as a synthetic gene. For NS5bPolymerase Palm domain construction, regions coding for amino acids 172 to 261 and 276 to 362 were amplified using NS5b synthetic gene and the respective following primers: Ns5b Palm (aa 172-261) forward: 5'-TCTAAAGTCAAAGCGAACGCTCTGTACGATGTCGTTTCC-3' (SEQ ID NO: 150), Ns5b Palm (aa 172-261) reverse: 5'-ACCGGAAGCGCGACAGCGGCCAACGTACAGGCGTTCGGT-3' (SEQ ID NO: 151), NS5b Palm (aa 276-362) forward: 5'-ACCGAACGCCTGTACGTTGGCCGCTGTCGCGCTTCCGGT-3' (SEQ ID NO: 152), NS5b Palm (aa 276-362) reverse: 5'-GCGGCCGCGAATTCttAGCTAGCGGTGATCAGCTCCAG-3' (SEQ ID NO: 153). Amplified products were then used as templates together with annealed primers 5'-CAAGCCCAACCCCACTAGTGTGCTGGACTCTCACTACCAGGATGTCCTGAAGGAAGTAAAAG CAGCCGCTTCTAAAGTCAAAGCGAACGCTCTGTACGAT-3' (SEQ ID NO: 154) and 5'-ATCGTACAGAGCGTTCGCTTTGACTTTAGAAGCGGCTGCTTTTACTTCCTTCAGGACATCCTG GTAGTGAGAGTCCAGCACACTAGTGGGGTTGGGCTTG-3' (SEQ ID NO: 155) in a final PCR using primers 5'-CAAGCCCAACCCC-3' (SEQ ID NO: 156) and 5'-GCGGCCGCGAATTCTTAGCTAGCGGTGATCAGCTCCAG-3' (SEQ ID NO: 157). The amplified NS5bPolymerase Palm domain was then cloned in TA vector and sub-cloned in XX vector using Nhe/Not strategy.

[0090] Chimeric Recombinant Antibodies Purification: For construct selection, chimeric DC-specific antibodies were transiently expressed in HEK293 cells and purified from the supernatant using Protein A sepharose chromatograhy. DNA from chimeric constructs expressed in HEK293 was then sub-cloned in cetHSpuro vector as AgeI/NotI fragment for expression in CHO cells after stable transfection. Antibodies were purified from supernatants using ProteinA sepharose.

[0091] Patients were recruited at the Baylor Hospital Liver Transplant Clinic (BHLTC, Dallas, Tex.) after obtaining informed consent. The study was approved by the Institutional Review Board of the Baylor Health Care System (Dallas, Tex.). Peripheral blood (100 ml) was collected at the BHLTC from 29 chronic HCV-infected adult patients and one healthy donor in contact with chronic HCV-infected patient. Leukapheresis were collected at Baylor University Medical Center Apharesis Collection Center (Dallas, Tex.) from all the enrolled individuals within 30 days after the first visit. Patient information is summarized in Table I.

[0092] Preparation of dendritic cells and PBMCs: PBMCs were isolated from heparinized blood on Ficoll density gradients. Monocytes were enriched from the leukapheresis according to cellular density and size by elutriation (Elutra.TM., CaridianBCT, Lakewood, Colo.) as per the manufacturer's recommendations. Elutriation Fraction 5 consisted mainly on monocytes (85% on average). Cells were cryopreserved in 10% DMSO 50% FCS 10% culture medium before use. For dendritic cell generation, monocytes were resuspended in serum-free CellGro DC culture medium (CellGenix Technologie Transfer Gmbh, Germany) at a concentration of 1 10.sup.6 cells/ml. Media were supplemented with 100 ng/ml granulocyte-macrophage colony-stimulated factor (GMCSF, Leukine, Berlex, Wayne, N.J.) and 500 UI/ml alpha-interferon (IFN-.alpha., Intro A, IFN-.alpha.-2b, Merck/Schering-Plough, Kenilworth, N.J.). After 24 h of culture at 37 degree Celsius, 5% CO.sub.2, fresh cytokines were added. On day 3, recombinant antibody vaccines were added at various concentration (5 nM, 0.5 nM or 0.05 nM) or peptide cluster controls (2 mM each peptide) as indicated. Alternatively, TLR agonists (polylC, 25 .mu.g/ml; CL075 1 .mu.g/ml; or PAM3, 200 ng/ml; all from Invivogen) were added in the culture at the same time as vaccine candidates or peptide controls. DC were pulsed for 16 h before harvest and used in PBMCs co-culture.

TABLE-US-00007 TABLE I Demographics of patients used in the study. HCV Viral HLA HLA HLA Patient ID Genotype Sex Ethnicity Race status Age Load HLA A* HLA B* Cw* DRB1 DQB1 HCV-VAC-001 1a M Hispanic White non 39 5 877033 0201; 1302; 0202; 0701; 0202; responder (H) 0205 5101 0602 1301 0603 HCV-VAC-002 1a F Non White cured 57 UnDectable 0101; 0818; 0701G; 1101; 0301; Hispanic after (UD) 0301 5108 1502 1301 0603 therapy HCV-VAC-003 1a M Non White cured 59 UD 0301; 0702; 0401; 0101; 0501; Hispanic after 3004 3501 0702 0402 0302 therapy HCV-VAC-004 1a M Non White cured 55 UD 0201; 0702; 0202; 0401; 0302; Hispanic after 3201 1002 0702 0901 0303 therapy HCV-VAC-005 1a M Non White cured 58 UD 0101; 1801; 0501; 0301; 0503; Hispanic after 1101 5101 1402 1407 0201 therapy HCV-VAC-006 3a M Non White cured 57 UD 0101; 0702; 0602; 0701; 0303; Hispanic after 2902 5701 0702 therapy HCV-VAC-007 3a M Non White cured 48 UD no no no no no Hispanic after apheresis apheresis apheresis apheresis apheresis therapy HCV-VAC-008 1b M Non White non 63 0101; 0801; 0701; 0301; 0201; Hispanic responder 6901 3508 1203 HCV-VAC-009 1a M Non White non 51 0101; 0801; 0701G; 0301; 0201; Hispanic responder 3004 0701 0303 HCV-VAC-010 1a M Non White cured 48 UD 0201; 0801; 0202; 0301; 0201; Hispanic after 2402 4002 0701G 0701 0202 therapy HCV-VAC-011 1a F Non White non 52 ? 0205; 1530; 0102; 0301; 0201; Hispanic responder 3101 4901 0707G 0802 0402 HCV-VAC-012 1a M Non White cured 43 UD 0101; 4101; 1502; 0301; 0201; Hispanic after 1101 5101 1710G 1305 0301 therapy HCV-VAC-013 1a M Non White non 55 0101; 0801; 0401; 0301; 0502; Hispanic responder 0201 3502 0701G 1601 0201 HCV-VAC-014 1b F Non White non 56 3101; 0702; 0401; 0403; 0302; Hispanic responder 6801 3503 0702 1501 0602 HCV-VAC-015 2b M Non White positive 50 0101; 0801; 0401; 0301; 0201; Hispanic untreated 0301 3501 0701G 0701 0303 HCV-VAC-016 1a M Non White non 55 0101; 5001; 0303; 0701; 0503; Hispanic responder 5501 0602 1401 0202 HCV-VAC-017 1a M Non White positive 52 2402; 3901; 0602; 0701; 0202; Hispanic untreated 2501 5701 1203 0303 HCV-VAC-018 1a M Non White non 53 no no no no no Hispanic responder apheresis apheresis apheresis apheresis apheresis HCV-VAC-019 1a M Non White cured 62 UD 2402; 3901; 0102; 0701; 0202; Hispanic after 2501 4402 1203 1501 0602 therapy HCV-VAC-020 1a F Non White cured 46 UD 0201; 1501; 0202; 0401; 0301; Hispanic after 0301 2705 0304 1101 0302 therapy HCV-VAC-021 1a M Non White non 64 0101; 0801; 0304; 0101; 0501; Hispanic responder 3002 4001 0701G 0301 0201 HCV-VAC-022 1b F Non White non 58 0301; 1801; 0304; 0301; 0201; Hispanic responder 6801 4001 0501 1302 0604 HCV-VAC-023 2 F Non White positive 45 no no no no no Hispanic untreated apheresis apheresis apheresis apheresis apheresis HCV-VAC-024 2b M Non White positive 43 0301; 1402; 0202; Hispanic untreated 4701 0602 HCV-VAC-025 3a F Non White positive 31 ? no no no no no Hispanic untreated apheresis apheresis apheresis apheresis apheresis HCV-VAC-026 3a M Non White positive 29 ? no no no no no Hispanic untreated apheresis apheresis apheresis apheresis apheresis HCV-VAC-027 1a F Non White positive 26 02; 26 15(62); 03(7); Hispanic untreated 51 05 HCV-VAC-028 1a F Hispanic other positive 47 03; 25 07; 18 06; untreated HCV-VAC-029 Non F Non White uninfected 63 01; 11 44; 55 02; 05 infected Hispanic HCV-VAC-030 1 M Non White positive 57 ? 03; 24 07; 27 03(7); Hispanic untreated 06

[0093] Expansion of Antigen-specific T cells in DC/PBMCs coculture. Frozen PBMCs from leukapharesis were thawed, washed by centrifugation and resuspended at 2.times.10.sup.6 cells/ml in cRPMI medium. Autologous DC loaded with vaccine candidates or peptides cluster controls were co-cultured with PBMCs in a 24 well tissue plate at a ratio of 1/20 and incubated for a total of 10 days. IL2 (20 IU/ml, Aldesleukine, ProleukineR; Bayer Healthcare and Novartis, Emeryville, Calif.) was added every two days. At day 9, PBMCs from a 24-well plate were washed, distributed in 2 wells in a 96-well plates and rested for 24 h. The specificity of the T-cell response elicited by vaccine candidate loaded-DC was assessed by restimulation of PBMCs with peptide clusters (2 .mu.M each peptide). For each condition, a negative background control was included as a restimulation without peptides.

[0094] Flow cytometry: After 1 hour of peptide clusters restimulation, BFA (Sigma) was added for the last 5-6 h to block cytokine secretion. The cells were stained for surface markers with a combination of fluorochrome antibodies (perCP-CD3, PE-CD8, APCH7-CD4), fixed, permeabilized and intracellular-stained with a mixture of APC-IFN.gamma., FITC-IL2 and PEc.gamma.7-TNF.alpha. antibodies. For CTL marker function analysis, FITC-CD107a antibody was added with BFA in the culture medium and the following antibodies combination was used for the surface staining. PerCP-CD3, pacific blue-CD8, APCH7-CD4 and for the intracellular staining: PE-IFN.gamma., APC-GranzB, APCcy7-TNF.alpha.. All antibodies were purchased from BD sciences except APC-GranzB (Invitrogen). Cells were analyzed on a FACS-Canto collecting 500,000 events, and results analyzed using FlowJo software. Most of the data were displayed as two colors plot to measure IFN-.gamma. and TNF-.alpha. production in CD3.sup.+CD8.sup.+ or CD3.sup.+CD4.sup.+ cells.

[0095] Luminex: Supernatants of DC-PBMCs co-culture were harvested 48 h after PBMCs restimulation with peptide clusters. Cytokine multiplex assays were employed to analyzed IFN-.gamma., IL-10, and IL-13.

[0096] Evaluation of embodiments of vaccines: Vaccine candidate were tested in targeting experiment by co-culture of vaccine with PBMCs from chronic HCV infected patients or chronic HCV infected patients cured after IFNa-Ribavirin therapy. The data show that anti-CD40 or anti-DCIR vaccines bearing a HCV NS3HelB antigen can recall a potent memory antigen-specific anti-CD4+ T cell response in vitro using immune cells from HCV infected patients. In this in vitro culture system anti-CD40 and anti-DCIR are equally potent vaccines--these DCs express both receptors. Anti-DCIR vaccine construct bearing longer HCV antigen coverage induced multifunctional CD4+ antigen specific T cells against multiple HCV epitopes.

[0097] The data further show that anti-DCIR vaccines bearing a HCV NS3HelBC antigen can recall a potent memory antigen-specific anti-CD4+ T cell response in vitro using immune cells from HCV infected patients. This response is directed against multiples HCV epitopes. In this in vitro culture system, both concentration used for anti-DCIR HCV-NS3HelBC targeting are equally potent in contrast to anti-DCIR HCV-NS3HelB vaccine.

[0098] FIGS. 3A-3B demonstrate the ability of recombinant anti-DCIR and anti-CD40 antibodies fused to HCV NS3HelB specific antigen to elicit the expansion of antigen-specific CD4+ T cells from a chronic HCV infected patient cured after IFNa-Ribavirin therapy. Delivering NS3HelB to DCs through CD40 and DCIR induces IFN-.gamma.-TNFa-producing HCV NS3HelB-specific CD4+ T cells. PBMC cells from chronic HCV infected patients; either cured after therapy or in treatment failure, were co-cultured with IFNDCs targeted with anti-CD40-NS3HelB or anti-DCIR-NS3HelB for 10 days. Cells were stimulated with peptides clusters (10 peptides of 15-mers in each clusters) covering HCV NS3 HelB (10 .mu.M): FIG. 3A after 2 days, culture supernatants were analyzed for measuring IFN.gamma. and FIG. 3B PBMC cells were stained for measuring the frequency of peptide-specific CD4+ T cells intracellular IFN.gamma.+TNF.alpha.+ cells.

[0099] Longer construct are equally potent to recall multi epitopes HCV specific T cells. The data in e.g., FIG. 4, show that both anti-CD40 and anti-DCIR vaccines bearing HCV NS3HelB NS3ProtB and NS5BPalm antigens can recall a potent memory antigen-specific anti-CD4+ T cell response in vitro using immune cells from HCV infected patients cured after IFN-Ribavirin therapy. This response is directed against multiples HCV epitopes. In this in vitro culture system, dose effect is observed consistent with clear targeting, with an optimum concentration being at 5 nM for anti-CD40 construct and 0.5 nM for anti-DCIR construct. At these concentrations IgG4 controls induce significantly lower CD4+ T cells responses, consistent with antibody targeting of DC.

[0100] FIGS. 5A to 5C demonstrate the ability of recombinant anti-DCIR and anti-CD40 antibodies fused to HCV NS3HelB, HCV NS3ProtB and HCV NS5BPalm specific antigens to elicit the expansion of antigen-specific CD4+ T cells from a chronic HCV infected patient cured after IFNa-Ribavirin therapy. Delivering HCV antigen to DCs through CD40 and DCIR induces IFN.gamma.-TNFa-producing HCV-specific CD4+ T cells, with multi epitopes, specific CD4 T cells. PBMC cells from chronic HCV infected patients cured after therapy were co-cultured with autologous IFN.alpha.DCs targeted with anti-CD40-NS3HelB-NS3ProtB-NS5BPalm or anti-DCIR-NS3HelB-NS3ProtB-NS5BPalm for 10 days. Cells were stimulated with peptides clusters (10 peptides of 15-mers in each clusters) covering HCV NS3HelB, NS3ProtB or NS5BPalm (2 .mu.M). PBMC cells were stained for measuring the frequency of peptide-specific CD4+ T cells intracellular IFN.gamma.+TNF.alpha.+ cells.

[0101] The data in FIGS. 6A to 6C demonstrate that anti-CD40 vaccines bearing HCV NS3HelB NS3ProtB and NS5BPalm antigens can recall a potent memory antigen-specific anti-CD8+ T cell response in vitro using immune cells from HCV infected patients cured after IFN-Ribavirin therapy. This response is directed against multiples HCV epitopes. In this in vitro culture system, dose effect is observed consistent with clear targeting, of DC with an optimum concentration being at 5 nM for anti-CD40 constructs. At these concentrations IgG4 controls induce significantly no CD8+ T cells responses, consistent with antibody targeting of DC.

[0102] Similar responses are induced in multiple different chronic HCV infected patients either cured or after therapy or in treatment failure.

[0103] The data in FIGS. 7A to 7D show that all chronic HCV infected patients cured after therapy are able to recall CD4+ T cells memory after co-culture of PBMCs with DC targeted with either anti-CD40 or anti-DCIR or both, construct bearing HCV antigens.

[0104] The data in FIGS. 8A to 8D shows that all chronic HCV infected patients in treatment failure are able to recall CD4+ T cells memory after co-culture of PBMCs with DC targeted with either anti-CD40 or anti-DCIR or both, construct bearing HCV antigens. Compare to chronic HCV infected patients cured after therapy, responses are low in chronic HCV infected patients in treatment failure and more antigen dependent since for example HCV-VAC-016 patient has no CD4+ T cells memory cells recalled after DC targeting with NS5bPalm construct.

[0105] CD8+ antigen specific T cells were obtained after TLR agonist introduction in the co-culture of vaccine with PBMC cells from HCV patients.

[0106] The data in FIGS. 9A and 9B show that TLR2 triggering with PAM3 during DC targeting with anti-DCIR vaccines bearing a HCV NS3HelB antigen can recall a potent memory antigen-specific anti-CD4+ and CD8+ T cell response in vitro using immune cells from HCV infected patients. Moderated CD8+ response is also induced by TLR3 triggering and no CD4+or CD8+ response is induced after TLR7/8 triggering by CL097 in this study. Similar responses are induced in multiple different chronic HCV infected patients either cured or after therapy or in treatment failure.

[0107] The data in FIGS. 10A-10D show that TLR2 triggering with PAM3 during DC targeting with anti-CD40 or anti-DCIR vaccines bearing a HCV NS3HelB or HCV NS3ProtB antigen can recall a potent memory antigen-specific anti-CD4+ and CD8+ T cell responses in vitro using immune cells from HCV infected patients. Moderated CD8+ response is also induced by TLR3 triggering in some patients, and cyclic glucan can dramatically increase CD8+ T cells responses in one patient.

[0108] FIG. 11 demonstrates the ability of combination of TLR agonists and anti-CD40 HCV-constructs to increase CD4+ T cells responses in chronic HCV infected patients in treatment failure. HCV antigens from NS3 Helicase HelB or from NS3 Protease ProtB constructs were delivered to DCs through CD40 or DCIR. IFN.alpha.DCs were targeted with anti-CD40-NS3HelB, anti-DCIR-NS3HelB, anti-CD40-NS3ProtB, anti-DCIR-NS3ProtB, in presence of PAM3 (TLR2 agonist; 200 ng/ml), CL095 (TLR7/8 agonist; 5 .mu.g/ml) or polyIC (TLR3 agonist; 25 .mu.g/ml) or cyclic glucan (TLR4 agonist, 10 .mu.g/ml) before co-culture for 10 days with PBMC cells from chronic HCV infected patients cured after therapy. Cells were stimulated for 6 h with peptide clusters C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB constructs or with peptide clusters C3 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 ProtB constructs. PBMC cells were stained for measuring the frequency of peptide-specific CD4+ intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS.

[0109] All tested HCV patients are able to recall CD4+ and CD8+ HCV specific memory after DC-targeting with HCV vaccine candidates.

[0110] FIG. 12A to 12C demonstrate the ability of HCV vaccine candidates to recall CD4+ T cells responses in all chronic HCV infected patients (cured or in treatment failure). HCV antigens from NS3 Helicase HelB, NS5b polymerase Palm or from NS3 Protease ProtB constructs were delivered to DCs through CD40 (FIG. 12B) or DCIR (FIG. 12C). IFNaDCs were targeted with anti-CD40-[NS3HelB.about.NS3ProtB.about.NS5bPalm on heavy chain], anti-DCIR-[NS3HelB.about.NS3ProtB.about.NS5bPalm on heavy chain] before co-culture for 10 days with PBMC cells from chronic HCV infected patients cured after therapy. Cells were stimulated for 6 h with peptide clusters C7-C9 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB domain, with peptide clusters C2-C3-C4 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 ProtB domain or with peptide clusters C2-C4-C5-C6-C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS5b Palm domain. PBMC cells were stained for measuring the frequency of peptide-specific CD4+ and CD8+ intracellular IFN.gamma.+TNFa+ cells, and analyzed by FACS. The number of CD4+ IFNg+TNFa+ cells induced vaccine candidate is shown.

[0111] It was also observed that different combinations of HCV domains on vaccine candidate are equally equivalent to recall CD4+ HCV memory. Moreover, HCV antigen combination where two domains are borne on heavy chain and one on light chain is more efficient than having the 3 borne by heavy chain.

[0112] FIGS. 13A-13E demonstrate the ability of different HCV antigen combination on vaccine candidate for recall CD4+ T cells responses in chronic HCV infected cured patients. HCV antigens from NS3 Helicase HelB, NS5b polymerase Palm or from NS3 Protease ProtB combination constructs were delivered to DCs through CD40 or DCIR. IFN.alpha.DCs were targeted with second-generation vaccines anti-CD40-[NS3HelB on light chain and NS3ProtB.about.NS5bPalm on heavy chain], anti-DCIR-[NS3HelB on light chain and NS3ProtB.about.NS5bPalm on heavy chain], or first-generation vaccines anti-CD40-[NS3HelB.about.NS3ProtB.about.NS5bPalm on heavy chain], anti-DCIR-[NS3HelB.about.NS3ProtB.about.NS5bPalm on heavy chain] before co-culture for 10 days with PBMC cells from chronic HCV infected patients cured after therapy. Cells were stimulated for 6 h with peptide clusters C7 and C9 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB domain (shown in green on the figure), with peptide clusters C2-C3-C4 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 ProtB domain (shown in pink on the figure) or with peptide clusters C2-C4-C5-C6-C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS5b Palm domain (shown in orange in the figure). PBMC cells were stained for measuring the frequency of peptide-specific CD4+ intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS. The number of CD4+IFN.gamma.+TNF.alpha.+ cells induced by first-generation vaccine or second-generation vaccine is compared in the last panel.

[0113] The vaccine candidates described in the present invention also showed the ability induce cross reactivity recall memory responses in patients infected with an HCV genotype different from those used to build the vaccine (FIGS. 14A to 14H). FIGS. 14A to 14H demonstrate ability of vaccine candidate to recall CD4+ T cells responses in HCV patients infected with non 1 genotype and HCV-exposed but non infected individual. HCV antigens from NS3 Helicase HelB, NS5b polymerase Palm or from NS3 Protease ProtB combination constructs were delivered to DCs through CD40 or DCIR and DC loaded were co-culture for 10 days with PBMC cells from HCV patients infected with non 1 genotype HCV-infected patients (HCV-015, 2b) and HCV-exposed but non infected individual (HCV-029). Cells were stimulated for 6 h with peptide clusters C7 and C9 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 HelB domain, with peptide clusters C2-C3-C4 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS3 ProtB domain or with peptide clusters C2-C4-C5-C6-C7 (10 .mu.M; 10 peptides of 15-mers) covering HCV NS5b Palm domain. PBMC cells were stained for measuring the frequency of peptide-specific CD4+ intracellular IFN.gamma.+TNF.alpha.+ cells, an analyzed by FACS.

[0114] FIGS. 15A and 15B show the results from a 10 day expansion culture whereby a dose range of 1st generation anti-DCIR-HCV vaccine (left panels) is compared to second generation anti-DCIR-HCV vaccine (right panels). Doses were 0.05 nM, 0.5 nM, and 5 nM and antigen-specific responses were ascertained by stimulation with no peptide (control) or ProtA, HelB, or Palm peptide pools in the presence of Brefeldin, followed by staining for CD3+, CD4+ and intracellular IFNg and TNFa. Samples were analyzed by FACS. Shown are comparable CD4+ HCV antigen-specific responses to the two generations of vaccines.

[0115] FIGS. 16A and 16B show the results from a 10 day expansion culture whereby a dose range of 1st generation anti-CD40-HCV vaccine (left panels) is compared to second generation anti-CD40-HCV vaccine (right panels). Doses were 0.05 nM, 0.5 nM, and 5 nM and antigen-specific responses were ascertained by stimulation with no peptide (control) or ProtA, HelB, or Palm peptide pools in the presence of Brefeldin, followed by staining for CD3+, CD4+ and intracellular IFNg and TNFa. Samples were analyzed by FACS. Shown are comparable CD4+ HCV antigen-specific responses to the two generations of vaccines.

[0116] Non-limiting examples different DC-specific antibodies or fragments (both nucleotide and protein sequences) that may be used in the preparation of the HCV vaccine of the present invention are shown herein below, the nomenclature corresponding to the target (e.g., Anti_CLEC.sub.--6.sub.--9B9.2G12_Heavy Hv-V-hIgG4H-C--is an anti-CLEC-6 antibody from the mouse hybridoma clone "9B9.2G12" (which is the source of the anti-CLEC-6 antibody sequence); heavy chain "H" variable region "v" (which can be humanized) heavy and is an IgG4 constant region isotype. The same nomenclature applies to light chains (from mouse Kappa light chains), and the antigens.

TABLE-US-00008 Anti_CLEC_6_9B9.2G12_Hv-V-hIgG4H-C (SEQ ID NO: 15): ATGGGCAGGCTTACTTCTTCATTCTTGCTACTGATTGTCCCTGCATATGTCCTGTCCCAGGTTACT CTGAAAGAGTCTGGCCCTGGGATATTGCAGCCCTCCCAGACCCTCAGTCTGACCTGTTCTTTCTC TGGGTTTTCACTGAGCACTTCTGGTATGAGTGTAGGCTGGATTCGTCAGCCTTCAGGGAAGGGT CTGGAGTGGCTGGCTCACATTTGGTGGAATGATGATAAGTACTATAATCCAGTCCTGAAAAGCC GGCTCACAATCTCCAAGGAGACCTCCAACAACCAGGTATTCCTCAAGATCGCCAGTGTGGTCTC TGCAGATACTGCCACATACTACTGTGCTCGATTCTATGGTAACTGTCTTGACTACTGGGGCCAA GGCACCACTCTCACAGTCTCCTCGGCCAAAACAAAGGGCCCATCCGTCTTCCCCCTGGCGCCCT GCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGA ACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTC CTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCA CGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTG AGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGT CTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGC GTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTG GAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTC AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCC AACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAG CCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACC TGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG GAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCA GGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATG AGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGATT AATTAA Anti_CLEC_6_9B9.2G12_Heavy (H)v-V-hIgG4H-C (SEQ ID NO: 80): MGRLTSSFLLLIVPAYVLSQVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMSVGWIRQPSGKGLEWL AHIWWNDDKYYNPVLKSRLTISKETSNNQVFLKIASVVSADTATYYCARFYGNCLDYWGQGTTLT VSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti_CLEC_6_9B9.2G12_Kv-V-hIgGK-C (SEQ ID NO: 16): ATGATGTCCTCTGCTCAGTTCCTTGGTCTCCTGTTGCTCTGTTTTCAAGGTACCAGATGTGATATC CAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCA GGGCAAGTCAGGACATTAGCAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTA AACTCCTGATCTACTACACATCAATATTACAATTAGGAGTCCCATCAAGATTCAGTGGCAGTGG GTCTGAAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTT GCCAACAGGGTGATTCGCTTCCATTCACGTTCGGCTCGGGGACAAAGCTCGAGATCAAACGAAC TGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCT CTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAA CGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTA CAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCTG CGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG Anti_CLEC_6_9B9.2G12_Light (K)v-V-hIgGK-C (SEQ ID NO: 81): MMSSAQFLGLLLLCFQGTRCDIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLL IYYTSILQLGVPSRFSGSGSETDYSLTISNLEQEDIATYFCQQGDSLPFTFGSGTKLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA DYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-ASGPR_49C11_7H-LV-hIgG4H-C (SEQ ID NO: 17): ATGAGAGCGCTGATTCTTTTGTGCCTGTTCACAGCCTTTCCTGGTATCCTGTCTGATGTGCAGCT TCAGGAGTCAGGACCTGACCTGGTGAAACCTTCTCAGTCACTTTCACTCACCTGCACTGTCACTG GCTACTCCATCACCAGTGGTTATAGCTGGCACTGGATCCGGCAGTTTCCAGGAAACAAACTGGA ATGGATGGGCTACATACTCTTCAGTGGTAGCACTAACTACAACCCATCTCTGAAAAGTCGAATC TCTATCACTCGAGACACATCCAAGAACCAGTTCTTCCTGCAGTTGAATTCTGTGACTACTGAGG ACACAGCCACATATTTCTGTGCAAGATCTAACTATGGTTCCTTTGCTTCCTGGGGCCAAGGGACT CTGGTCACTGTCTCTGCAGCCAAAACAACGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCA GGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGT GACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGA CCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCA AATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCT GTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTG GTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTG CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTC CTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA GGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTG GTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAAC AACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAA CCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCT GCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGATTAATTAA Anti-ASGPR_49C11_7H-LV-hIgG4H-C (SEQ ID NO: 82): MRALILLCLFTAFPGILSDVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYSWHWIRQFPGNKLEWM GYILFSGSTNYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYFCARSNYGSFASWGQGTLVTVSA AKTTGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE NNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti-ASGPR_49C11_7K-LV-hIgGK-C (SEQ ID NO: 18): ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATATCCAGAGG ACAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATG ACCTGCAGTGCCAGCTCAAGTGTAAGTCACATGCACTGGTACCAGCAGAAGTCAGGCACTTCCC CCAAAAGATGGATTTATGACACATCCAGACTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAG TGGGTCTGGGACCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTAT TACTGCCAGCAGTGGAGTAGTCACCCATGGTCGTTCGGTGGAGGCACCAAACTCGAGATCAAA CGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAC TGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTG GATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAT GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAG TGTTAG Anti-ASGPR_49C11_7K-LV-hIgGK-C (SEQ ID NO: 83): MDFQVQIFSFLLISASVIISRGQIVLTQSPAIMSASPGEKVTMTCSASSSVSHMHWYQQKSGTSPKRWI YDTSRLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSHPWSFGGGTKLEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLS KADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-ASGPR_4G2.2_Hv-V-hIgG4H-C (SEQ ID NO: 19): ATGGCTTGGGTGTGGACCTTGCTATTCCTGATGGCAGCTGCCCAAAGTGCCCAAGCACAGATCC AGTTGGTGCAGTCTGGACCTGAGCTGAAGAAGCCTGGAGAGACAGTCAAGATCTCCTGCAAGG CTTCTGGGTATACCTTCACAAACTATGGAATGAACTGGGTGAAGCAGGTTCCAGGAAAAGGTTT AAGGTGGATGGGCTGGATGGACACCTTCACTGGAGAGCCAACATATGCTGATGACTTCAAGGG ACGGTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACTGCCTATTTGCAGATCAACAGCCTCAAAA ATGAGGACACGGCTACTTATTTCTGTGCAAGAGGGGGGATTTTACGACTCAACTACTTTGACTA CTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCC CTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACT ACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGC AGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGAC AAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGG GACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGA GGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGT GGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTA CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC AAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAG CCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC TCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCG TGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGC TAGCTGATTAATTAA Anti-ASGPR_4G2.2_Hv-V-hIgG4H-C (SEQ ID NO: 84): MAWVWTLLFLMAAAQSAQAQIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQVPGKGL RWMGWMDTFTGEPTYADDFKGRFAFSLETSASTAYLQINSLKNEDTATYFCARGGILRLNYFDYW GQGTTLTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLS

LSLGKAS Anti-ASGPR_4G2.2_Kv-V-hIgGK-C (SEQ ID NO: 20): ATGAAGTTTCCTTCTCAACTTCTGCTCTTACTGCTGTTTGGAATCCCAGGCATGATATGTGACAT CCAGATGACACAATCTTCATCCTCCTTTTCTGTATCTCTAGGAGACAGAGTCACCATTACTTGCA AGGCAAGTGAGGACATATATAATCGGTTAGGCTGGTATCAGCAGAAACCAGGAAATGCTCCTA GGCTCTTAATATCTGGTGCAACCAGTTTGGAAACTGGGGTTCCTTCAAGATTCAGTGGCAGTGG ATCTGGAAAGGATTACGCTCTCAGCATTACCAGTCTTCAGACTGAAGATCTTGCTACTTATTACT GTCAACAGTGTTGGACTTCTCCGTACACGTTCGGAGGGGGGACCAAGCTCGAGATCAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCC TCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATA ACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCT ACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCT GCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTT AG Anti-ASGPR_4G2.2_Kv-V-hIgGK-C (SEQ ID NO: 85): MKFPSQLLLLLLFGIPGMICDIQMTQSSSSFSVSLGDRVTITCKASEDIYNRLGWYQQKPGNAPRLLIS GATSLETGVPSRFSGSGSGKDYALSITSLQTEDLATYYCQQCWTSPYTFGGGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA DYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-ASGPR_5F10H-LV-hIgG4H-C (SEQ ID NO: 21): ATGGGATGGAGCTGGATCTTTCTCTTTCTCTTGTCAGGAACTGGAGGTGTCCTCTCTGAGGTCCA GCTGCAACAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCT TCTGGATACACCTTCACTGACTACTACATGAAGTGGGTGAAGCAGAGCCATGGAAAGAGCCTTG AGTGGATTGGAGATATTAATCCTAACTATGGTGATACTTTCTACAACCAGAAGTTCGAGGGCAA GGCCACATTGACTGTAGACAAATCCTCCAGGACAGCCTACATGCAGCTCAACAGCCTGACATCT GAGGACTCTGCAGTCTATTATTGTGGAAGAGGGGACTATGGATACTTCGATGTCTGGGGCGCAG GGACCACGGTCACCGTCTCCTCAGCCAAAACAAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTG CTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCAC GAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGA GTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTC TTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCG TGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGG AGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCA GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCA ACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGC CACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCT GCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGG AGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAG GCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGA GGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-ASGPR_5F10H-LV-hIgG4H-C (SEQ ID NO: 86): MGWSWIFLFLLSGTGGVLSEVQLQQSGPELVKPGASVKMSCKASGYTFTDYYMKWVKQSHGKSLE WIGDINPNYGDTFYNQKFEGKATLTVDKSSRTAYMQLNSLTSEDSAVYYCGRGDYGYFDVWGAGT TVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLLSLGKAS Anti-ASGPR_5F10K-LV-hIgGK-C (SEQ ID NO: 22): ATGGAGACACATTCTCAGGTCTTTGTATACATGTTGCTGTGGTTGTCTGGTGTTGAAGGAGACAT TGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGC AAGGCCAGTCAGGATGTGGGTACTGCTGTAGCCTGGTATCAACAGAAACCAGGGCAATCTCCT AAACTACTGATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTG GATCTGGGACAGATTTCACTCTCACCATTAACAATGTGCAGTCTGAAGACTTGGCAGATTATTT CTGTCAGCAATATAGCAGCAATCCGTACATGTTCGGAGGGGGGACCAAGCTCGAGATCAAACG AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTG CCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGA TAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGC CTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTG TTAG Anti-ASGPR_5F10K-LV-hIgGK-C (SEQ ID NO: 87): METHSQVFVYMLLWLSGVEGDIVMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSP KLLIYWASTRHTGVPDRFTGSGSGTDFTLTINNVQSEDLADYFCQQYSSNPYMFGGGTKLEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-ASGPR1H11_H-V-hIgG4H-C (SEQ ID NO: 23): ATGGGATGGAGCTGGATCTTTCTCTTTCTCCTGTCAGGAACTGCAGGTGTCCTCTCTGAGGTCCA GCTGCAACAGTCTGGACCTGAGTTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGACT TCTGGATACACATTCACTGAATACACCATGCACTGGGTGAGGCAGAGCCATGGAAAGAGCCTT GAGTGGATTGGAGGTATTAATCCTATCAATGGTGGTCCTACCTACAACCAGAAGTTCAAGGGCA AGGCCACATTGACTGTTGACAAGTCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATC TGAGGACTCTGCAGTCTATTACTGTGCAAGATGGGACTATGGTAGTCGAGATGTTATGGACTAC TGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCC TGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTA CTTCCCCGAACCGGTACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCAC ACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTC CAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGT GGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAA GGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCC CTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGT ACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCA CGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCA GGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT TCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTC CGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAA GCTAGCTGA Anti-ASGPR1H11_H-V-hIgG4H-C (SEQ ID NO: 88): MGWSWIFLFLLSGTAGVLSEVQLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVRSHGKSLEWI GGINPINGGPTYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCARWDYGSRDVMDYWGQ GTSVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLS LSLGKAS Anti-ASGPR1H11K-LV-var2-hIgGK-C (SEQ ID NO: 24): ATGGAATCACAGACTCTGGTCTTCATATCCATACTGCTCTGGTTATATGGTGCTGATGGGAACAT TGTAATGACTCAATCTCCCAAATCCATGTCCATGTCAGTAGGGGAGAGGGTCACCTTGAGCTGC AAGGCCAGTGAGAATGTGGGAACTTATGTATCCTGGTATCAACAGAGACCAGAACAGTCTCCA AAACTGCTGATATACGGGGCATCCAACCGGTACACTGGGGTCCCCGATCGCTTCACAGGCAGTG GATCTGCAACAGATTTCACTCTGACCATCAGCAGTGTGCAGGCTGAGGACCTTGCAGATTATCA CTGTGGACAGACTTACAGCTATATATTCACGTTCGGCTCGGGGACAAAGCTCGAGATCAAACGA ACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGC CTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGAT AACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACC TACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCC TGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT TAG Anti-ASGPR1H11K-LV-var2-hIgGK-C (SEQ ID NO: 89): METHSQVFVYMLLWLSGVEGNIVMTQSPKSMSMSVGERVTLSCKASENVGTYVSWYQQRPEQSPK LLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQTYSYIFTFGSGTKLEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-CD1d_2B5.3G10_H-V-hIgG4H-C (SEQ ID NO: 25): ATGGGATGGAGCCGGATCTTTCTCTTCCTCCTGTCAATAACTGCAGGTGTCCATTGCCAGGTCCA GGTGCAGCAGTCGGGACCTGAGTTGGTGAAGCCTGGGGCCTCAGTGAAGATTTCCTGCAAAGC CTCTGGCGACGCATTCAGTAGTTCTTGGATGAACTGGGTGAAGCAGAGGCCTGGACAGGGTCTT GAGTGGATTGGACGGATTTATCTTGGAGATGGAGATATTAATTACAATGGGAAGTTCAAGGGC AGGGCCACACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACCT CTGTGGACTCTGCGGTCTATTTCTGCGCGAGGCAGCTCGGGCTATGGTATGTTATGGACTACTG GGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAAAGGGCCCATCCGTCTTCCCCCTG GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACT TCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCC GGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC TTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAG

AGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGAC CATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTC ACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAT GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGT GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAG GTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC GAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCC TGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTA CAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGAT GCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGC TGA Anti-CD1d_2B5.3G10_H-V-hIgG4H-C (SEQ ID NO: 90): MGWSRIFLFLLSITAGVHCQVQVQQSGPELVKPGASVKISCKASGDAFSSSWMNWVKQRPGQGLE WIGRIYLGDGDINYNGKFKGRATLTADKSSSTAYMQLSSLTSVDSAVYFCARQLGLWYVMDYWG QGTSVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS LGKAS Anti-CD1d_2B5.3G10_K-V-hIgGK-C (SEQ ID NO: 26): ATGAGTGTGCCCACTCAGGTCCTGGGGTTGCTGCTGCTGTGGCTTACAGGTGCCAGATGTGACA TCCAGATGGCTCAGTCTCCAGCCTCCCTATCTGCATCTGTGGGAGAAACTGTCACCATCACATGT CGAGCAAGTGAGAATATTTACAGTTATTTAGCATGGTATCAGCAGAAACAGGGAAAATCTCCTC AGCTCCTGGTCTATAATGCAAAAACCTTAGCAGAAGGTGTGCCATCAAGGTTCAGTGGCAGTGG ATCAGGCACACAGTTTTCTCTGAAGATCAACAGCCTGCAGCCTGAAGATTTTGGGAGTTATTAC TGTCAACATCATTATGGTTTTCCGTGGACGTTCGGTGGAGGCACCAAGCTCGAGATCAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCC TCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATA ACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCT ACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCT GCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTT AG Anti-CD1d_2B5.3G10_K-V-hIgGK-C (SEQ ID NO: 91): MSVPTQVLGLLLLWLTGARCDIQMAQSPASLSASVGETVTITCRASENIYSYLAWYQQKQGKSPQL LVYNAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGFPWTFGGGTKLEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-CD1d_2H11.2G5_H-V-hIgG4H-C (SEQ ID NO: 27): ATGAACTTCGGGCTCAGCTTGATTTTCCTTGTCCTCATTTTAAAAGGTGTCCAGTGTGAGGTGCA GCTGGTGGAGTCTGGGGGAGACTTAGTGAAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAGCC TCTGGATTCACTTTCAGTAGCTATGGCATGTCTTGGGTTCGCCAGACTCCAGACAAGAGGCTGG AGTGGGTCGCAGTCATTAGTAGTGGTGGAAGTTCCACCTTCTATCCAGACAGTGTGAAGGGGCG ATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCAGTCTGAAGTCT GAGGACACAGCCGTGTATTACTGTTCAAGAGGAGGTTACTACTTTGACTACTGGGGCCAAGGCA CCACTCTCACAGTCTCCGCAGCCAAAACAAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTC CAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACC GGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTA CAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGA AGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGT CCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTT CCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTG GTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAG GTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGC GTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAAC AAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCA CAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGC CTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAG AACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGC TAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGG CTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-CD1d_2H11.2G5_H-V-hIgG4H-C (SEQ ID NO: 92): MNFGLSLIFLVLILKGVQCEVQLVESGGDLVKPGGSLKLSCAASGFTFSSYGMSWVRQTPDKRLEW VAVISSGGSSTFYPDSVKGRFTISRDNAKNTLYLQMSSLKSEDTAVYYCSRGGYYFDYWGQGTTLT VSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS LSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLM ISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti-CD1d_2H11.2G5_K-V-hIgGK-C (SEQ ID NO: 28): ATGAGGTTCCAGGTTCAGGTTCTGGGGCTCCTTCTGCTCTGGATATCAGGTGCCCAGTGTGATGT CCAGATAACCCAGTCTCCATCTTATCTTGCTGCATCTCCTGGAGAAACCATTACTATTAATTGCA GGGCAAGCAAGACCATTAGCAAATATTTAGCCTGGTATCAAGAGAAACCTGAGAAAACTGATA AGCTTCTTATCTACTCTGGATCCACTTTGCAATCTGGAATTCCATCAAGGTTCAGTGGCAGTGGA TCTGGTACAGATTTCACTCTCACCATCAGTGGCCTGGAGCCTGAAGATTTTGCAATGTATTACTG TCAACAGCATAATGAATACCCGTGGACGTTCGGTGGAGGCACCAAGCTCGAGATCAAACGAAC TGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCT CTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAA CGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTA CAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCTG CGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG Anti-CD1d_2H11.2G5_K-V-hIgGK-C (SEQ ID NO: 93): MRFQVQVLGLLLLWISGAQCDVQITQSPSYLAASPGETITINCRASKTISKYLAWYQEKPEKTDKLLI YSGSTLQSGIPSRFSGSGSGTDFTLTISGLEPEDFAMYYCQQHNEYPWTFGGGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA DYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-CD40_11B6.1C3_H-LV-hIgG4H-C (SEQ ID NO: 29): ATGGGATGGAGCTGGATCTTTCTCTTTCTCCTGTCAGGAACTGCAGGTGTCCTCTCTGAGGTCCA GCTGCAACAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGGCT TCTGGTTACTCATTCACTGGCTACTACATGCACTGGGTGAAGCAAAGCCATGTAAAGAGCCTTG AGTGGATTGGACGTATTAATCCTTACAATGGTGCTACTAGCTACAACCAGAATTTCAAGGACAA GGCCAGCTTGACTGTAGATAAGTCCTCCAGCACAGCCTACATGGAGCTCCACAGCCTGACATCT GAGGACTCTGCAGTCTATTACTGTGCAAGAGAGGACTACGTCTACTGGGGCCAAGGCACCACTC TCACAGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAG CACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACG GTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCT CAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTA CACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATA TGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTC CCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGG ACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATA ATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCA CCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCC TCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGT ACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCA AAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACT ACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGT GGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCA CAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-CD40_11B6.1C3_H-LV-hIgG4H-C (SEQ ID NO: 94): MGWSWIFLFLLSGTAGVLSEVQLQQSGPELVKPGASVKISCKASGYSFTGYYMHWVKQSHVKSLE WIGRINPYNGATSYNQNFKDKASLTVDKSSSTAYMELHSLTSEDSAVYYCAREDYVYWGQGTTLT VSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti-CD40_11B6.1C3_K-LV-hIgGK-C (SEQ ID NO: 30): ATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTGCTTCCAGCAGTGATGTTGT GATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGAT CTAGTCAGAGCCTTGTACACAGTAATGGAAACACCTATTTACATTGGTACCTGCAGAAGCCAGG CCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTC AGTGGCAGTGGATCAGGGACAGATTTCGCACTCAAGATCAGTAGAGTGGAGGCTGAGGATCTG GGAGTTTATTTCTGCTCTCAAAGTACACATGTTCCGTGGACGTTCGGTGGAGGCACCAAGCTCG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA ATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAG TGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC AAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA GGGGAGAGTGTTAG

Anti-CD40_11B6.1C3_K-LV-hIgGK-C (SEQ ID NO: 95): MKLPVRLLVLMFWIPASSSDVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQ SPKLLIYKVSNRFSGVPDRFSGSGSGTDFALKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSS TLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-CD40_12B4.2C10_H-LV-hIgG4H-C (SEQ ID NO: 31): ATGGAATGGAGTTGGATATTTCTCTTTCTTCTGTCAGGAACTGCAGGTGTCCACTCTGAGGTCCA GCTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCT TCTGGATACACATTCACTGACTATGTTTTGCACTGGGTGAAACAGAAGCCTGGGCAGGGCCTTG AGTGGATTGGATATATTAATCCTTACAATGATGGTACTAAGTACAATGAGAAGTTCAAAGGCAA GGCCACACTGACTTCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCAGCAGCCTGACCTCT GAGGACTCTGCGGTCTATTACTGTGCAAGGGGCTATCCGGCCTACTCTGGGTATGCTATGGACT ACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCC CCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGAC TACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCT TCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGC AGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGAC AAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGG GACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGA GGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGT GGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTA CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC AAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAG CCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC TCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCG TGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGC TAGCTGA Anti-CD40_12B4.2C10_H-LV-hIgG4H-C (SEQ ID NO: 96): MEWSWIFLFLLSGTAGVHSEVQLQQSGPELVKPGASVKMSCKASGYTFTDYVLHWVKQKPGQGLE WIGYINPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARGYPAYSGYAMDYW GQGTSVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLS LSLGKAS Anti-CD40_12B4.2C10_K-LV-v2-hIgGK-C (SEQ ID NO: 32): ATGATGTCCTCTGCTCAGTTCCTTGGTCTCCTGTTGCTCTGTTTTCAAGGTACCAGATGTGATATC CAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCA GGGCAAGTCAGGACATTAGCAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTA AACTCCTGATCTACTACACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGG GTCTGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTT GCCATCATGGTAATACGCTTCCGTGGACGTTCGGTGGAGGCACCAAGCTCGAGATCAAACGAA CTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCC TCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATA ACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCT ACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCT GCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTT AG Anti-CD40_12B4.2C10_K-LV-v2-hIgGK-C (SEQ ID NO: 97): MMSSAQFLGLLLLCFQGTRCDIQMTQTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLL IYYTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCHHGNTLPWTFGGGTKLEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-CD40_12E12.3F3_H-V-hIgG4H-C (SEQ ID NO: 33): ATGAACTTGGGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTGTCCAGTGTGAAGTGAA GCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAAACTCTCCTGTGCAACC TCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCCAGACTCCAGAGAAGAGGCTGG AGTGGGTCGCATACATTAATTCTGGTGGTGGTAGCACCTATTATCCAGACACTGTAAAGGGCCG ATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCCGGCTGAAGTCT GAGGACACAGCCATGTATTACTGTGCAAGACGGGGGTTACCGTTCCATGCTATGGACTATTGGG GTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGC GCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTC CCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTG GGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGA GTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCAC GTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGG CGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGT GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGT CTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCG AGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCT GACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC AGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATG CATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCT GA Anti-CD40_12E12.3F3_H-V-hIgG4H-C (SEQ ID NO: 98): MNLGLSLIFLVLVLKGVQCEVKLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQTPEKRLE WVAYINSGGGSTYYPDTVKGRFTISRDNAKNTLYLQMSRLKSEDTAMYYCARRGLPFHAMDYWG QGTSVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS LGKAS Anti-CD40_12E12.3F3_K-LV-hIgGK-C (SEQ ID NO: 34): ATGATGTCCTCTGCTCAGTTCCTTGGTCTCCTGTTGCTCTGTTTTCAAGGTACCAGATGTGATATC CAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTAGGAGACAGAGTCACCATCAGTTGCA GTGCAAGTCAGGGCATTAGCAATTATTTAAACTGGTATCAGCAGAAACCAGATGGAACTGTTAA ACTCCTGATCTATTACACATCAATTTTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGG TCTGGGACAGATTATTCTCTCACCATCGGCAACCTGGAACCTGAAGATATTGCCACTTACTATTG TCAGCAGTTTAATAAGCTTCCTCCGACGTTCGGTGGAGGCACCAAACTCGAGATCAAACGAACT GTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTC TGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAAC GCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTAC AGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCTGC GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG Anti-CD40_12E12.3F3_K-LV-hIgGK-C (SEQ ID NO: 99): MMSSAQFLGLLLLCFQGTRCDIQMTQTTSSLSASLGDRVTISCSASQGISNYLNWYQQKPDGTVKLL IYYTSILHSGVPSRFSGSGSGTDYSLTIGNLEPEDIATYYCQQFNKLPPTFGGGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA DYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR_24A5.4A5_H-V-hIgG4H-C (SEQ ID NO: 35): ATGGATTGGCTGTGGAACTTGCTATTCCTGATGGCAGCTGCCCAAAGTGCCCAAGCACAGATCC AGTTGGTGCAGTCTGGACCTGAGCTGAAGAAGCCTGGAGAGACAGTCAAGATCTCCTGCAAGG CTTCTGGGTATTCCTTCACAAACTATGGAATGAACTGGGTGAAACAGGCTCCAGGAAAGGGTTT AAAGTGGATGGGCTGGATAAACACCTACACTGGAGAGTCAACATATGCTGATGACTTCAAGGG ACGGTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACTGCCTATTTGCAGATCAGTAACCTCAAAA ATGAGGACATGGCTACATATTTCTGTGCTAGAGGGGACTTTAGGTACTACTATTTTGACTACTG GGGCCAAGGCACCACTCTCACAGGCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTG GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACT TCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCC GGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC TTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAG AGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGAC CATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTC ACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAT GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGT GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAG GTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC GAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCC TGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTA CAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGAT GCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGC TGAT

Anti-DCIR_24A5.4A5_H-V-hIgG4H-C (SEQ ID NO: 100): MDWLWNLLFLMAAAQSAQAQIQLVQSGPELKKPGETVKISCKASGYSFTNYGMNWVKQAPGKGL KWMGWINTYTGESTYADDFKGRFAFSLETSASTAYLQISNLKNEDMATYFCARGDFRYYYFDYWG QGTTLTGSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS LGKAS Anti-DCIR_24A5.4A5_K-V-hIgGK-C (SEQ ID NO: 36): ATGAGTGTGCTCACTCAGGTCCTGGCGTTGCTGCTGCTGTGGCTTACAGGTGCCAGATGTGACA TCCAGATGACTCAGTCTCCAGCCTCCCTATCTGCATCTGTGGGAGAAACTGTCACCATCACGTGT CGAGCAAGTGGGAATATTCACAATTATTTAGCATGGTATCAGCAGAAACAGGGAAAATCTCCTC AGCTCCTGGTCTATAATGCAAAAACCTTGGCAGATGGTGTGCCATCAAGGTTCAGTGGCAGTGG ATCAGGAACACAATATTCTCTCAAGATCAACACCCTGCAGCCTGAAGATTTTGGGAGTTATTAC TGTCAACATTTTTGGGATTCTTGGACGTTCGGTGGAGGCACCAAGCTCGAGATCAAACGAACTG TGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCT GTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACG CCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACA GCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCTGCG AAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG Anti-DCIR_24A5.4A5_K-V-hIgGK-C (SEQ ID NO: 101): MSVLTQVLALLLLWLTGARCDIQMTQSPASLSASVGETVTITCRASGNIHNYLAWYQQKQGKSPQL LVYNAKTLADGVPSRFSGSGSGTQYSLKINTLQPEDFGSYYCQHFWDSWTFGGGTKLEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR_24E7.3H9_H-V-hIgG4H-C (SEQ ID NO: 37): ATGGAATGGACCTGGGTCTTTCTCTTCCTCCTGTCAGTAACTGCAGGTGTCCACTCCCAGGTTCA GCTGCAGCAGTCTGGAGCTGAGCTGATGAAGCCTGGGGCCTCAGTGAAGATATCCTGCAAGGC TACTGGCTACACATTCAGTAGCTACTGGATAGAGTGGGTAAAGCAGAGGCCTGGACATGGCCTT GAGTGGATTGGAGAGATTTTACCTGGAAGTGGTAGGACTAACGACAATGAGAAGTTCAAGGGC AAGGCCACATTCACTGCAGATACATCCTCCAAGAAAGCCTACATGCAACTCAGCAGCCTGACAT CTGAGGACTCTGCCGTCTATTATTGTGCAAGAAGGGGTGGTTACTCCTTTGCTTACTGGGGCCA AGGGACTCTGGTCACTGTCTCTGCAGCCAAAACAAAGGGCCCATCCGTCTTCCCCCTGGCGCCC TGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGT CCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGC ACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT GAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAG TCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGC GTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTG GAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTC AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCC AACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAG CCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACC TGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG GAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCA GGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATG AGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-DCIR_24E7.3H9_H-V-hIgG4H-C (SEQ ID NO: 102): MEWTWVFLFLLSVTAGVHSQVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWVKQRPGHGLE WIGEILPGSGRTNDNEKFKGKATFTADTSSKKAYMQLSSLTSEDSAVYYCARRGGYSFAYWGQGTL VTVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti-DCIR_24E7.3H9_K-V-hIgGK-C (SEQ ID NO: 38): ATGACCATGTTCTCACTAGCTCTTCTCCTCAGTCTTCTTCTCCTCTGTGTCTCTGATTCTAGGGCA GAAACAACTGTGACCCAGTCTATGACCATGTTCTCACTAGCTCTTCTCCTCAGTCTTCTTCTCCT CTGTGTCTCTGATTCTAGGGCAGAAACAACTGTGACCCAGTCTCCAGCATCCCTGTCCATGGCT ATAGGGGAAAAAGTCACCATCAGATGCGTAACCAGCACTGATATTGATGATGATGTGAACTGG TACCAGCAGAAGCCAGGGGAACCTCCTAAACTCCTTATTTCAGAAGGCAATACTCTTCGTCCTG GAGTCCCATCCCGATTCTCCAGCAGTGGCTATGGTACAGATTTTGTTTTTACAATTGAGAACATG CTCTCAGAAGATGTTGCAGATTACTACTGTTTGCAAAGTGGTAACTTGCCGTACACGTTCGGAG GGGGGACCAAGCTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATC TGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGA GAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTC ACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA GACTACGAGAAACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTC ACAAAGAGCTTCAACAGGGGAGAGTGTTAGCCAGCATCCCTGTCCATGGCTATAGGGGAAAAA GTCACCATCAGATGCGTAACCAGCACTGATATTGATGATGATGTGAACTGGTACCAGCAGAAGC CAGGGGAACCTCCTAAACTCCTTATTTCAGAAGGCAATACTCTTCGTCCTGGAGTCCCATCCCG ATTCTCCAGCAGTGGCTATGGTACAGATTTTGTTTTTACAATTGAGAACATGCTCTCAGAAGATG TTGCAGATTACTACTGTTTGCAAAGTGGTAACTTGCCGTACACGTTCGGAGGGGGGACCAAGCT CGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTG AAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTAC AGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACA GCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAAC ACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAA CAGGGGAGAGTGTTAG Anti-DCIR_24E7.3H9_K-V-hIgGK-C (SEQ ID NO: 103): MTMFSLALLLSLLLLCVSDSRAETTVTQSPASLSMAIGEKVTIRCVTSTDIDDDVNWYQQKPGEPPK LLISEGNTLRPGVPSRFSSSGYGTDFVFTIENMLSEDVADYYCLQSGNLPYTFGGGTKLEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR_29E9.2E2_H-VhIgG4H-C (SEQ ID NO: 39): ATGGCTTGGGTGTGGACCTTGCTATTCCTGATGGCAGCTGCCCAAAGTGCCCAAGCACAGATCC AGTTGGTGCAGTCTGGACCTGAGCTGAAGAAGCCTGGAGAGACAGTCAAGATCTCCTGCAAGG CTTCTGGGTATACCTTCACAAACTATGGAATGAACTGGGTGAAGCAGGCTCCAGGAAAGGGTTT AAAGTGGGTGGGCTGGATAAACACCTTCACTGGAGAGCCAACATATGTTGATGACTTCAAGGG ACGGTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACTGCCTATTTGCAGATCAACAACCTCAAAA ATGAGGACACGGCTACATATTTCTGTGCAAGAGGGAATTTTAGGTACTACTACTTTGACTACTG GGGCCAAGGCACCACTCTCACAGTCTCCTCAGCCAAAACAAAGGGCCCATCCGTCTTCCCCCTG GCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACT TCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCC GGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGC TTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAG AGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGAC CATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTC ACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGAT GGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGT GTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAG GTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC GAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCC TGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGC AGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTA CAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGAT GCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGC TGA Anti-DCIR_29E9.2E2_H-VhIgG4H-C (SEQ ID NO: 104): MAWVWTLLFLMAAAQSAQAQIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGL KWVGWINTFTGEPTYVDDFKGRFAFSLETSASTAYLQINNLKNEDTATYFCARGNFRYYYFDYWG QGTTLTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS LGKAS Anti-DCIR_29E9.2E2_K-V-hIgGK-C (SEQ ID NO: 40): ATGAGTGTGCTCACTCAGGTCCTGGCGTTGCTGCTGCTGTGGCTTACAGGTGCCAGATGTGACA TCCAGATGACTCAGTCCCCAGCCTCCCTATCTGCATCTGTGGGAGAAACTGTCACCATCACATG TCGAACAAGTGGGAATATTCGCAATTATTTAGCATGGTATCAGCAGAAACAGGGAAAATCTCCT CAACTCCTGGTCTATAATGCAAAAACCTTAGCAGATGGTGTGCCATCAAGGTTCGGTGGCAGTG GATCAGGAACACAATATTCTCTCAAGATCAACAGCCTGCAGCCTGAAGATTTTGGGAATTATTA CTGTCAACATTTTTGGAGTAGTCCGTACACGTTCGGAGGGGGGACCAAGCTCGAGATCAAACGA ACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGC CTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGAT AACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACC TACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCC TGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT

TAG Anti-DCIR_29E9.2E2_K-V-hIgGK-C (SEQ ID NO: 105): MSVLTQVLALLLLWLTGARCDIQMTQSPASLSASVGETVTITCRTSGNIRNYLAWYQQKQGKSPQL LVYNAKTLADGVPSRFGGSGSGTQYSLKINSLQPEDFGNYYCQHFWSSPYTFGGGTKLEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR_29G10.3D9_H-V-hIgG4H-C (SEQ ID NO: 41): ATGATGGGATGGAGCTATATCATCCTCTTTTTGGTAGCAACAGCTACAGATGTCCACTCCCAGG TCCAACTGCAGCAGCCTGGGGCTGAACTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCCTGCAA GGCTTCTGGCTACACCTTCACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGAGAAGG CCTTGAGTGGATTGGAGAGATTAATCCTAGCTACGGTCGTACTGACTACAATGAGAAGTTCAAG AACAAGGCCACACTGACTGTAGCCAAATCCTCCAGCACAGCCTACATGCAACTCAGCAGCCTG ACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGAGGAGATTACTACGGTAGTAGCTCGTTTG CTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACAAAGGGCCCATCCGTCTT CCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAG GACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACA CCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC AGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTG GACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAG GGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTA CGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCAC GTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCA GGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT TCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTC CGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAA GCTAGCGGATGGAGCTATATCATCCTCTTTTTGGTAGCAACAGCTACAGATGTCCACTCCCAGG TCCAACTGCAGCAGCCTGGGGCTGAACTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCCTGCAA GGCTTCTGGCTACACCTTCACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGAGAAGG CCTTGAGTGGATTGGAGAGATTAATCCTAGCTACGGTCGTACTGACTACAATGGGAAGTTCAAG AACAAGGCCACACTGACTGTAGCCAAATCCTCCAGCACAGCCTACATGCAACTCAGCAGCCTG ACATCTGAGGACTCTGCGGTCTATTACTGTGCAAGAGGAGATTACTACGGTAGTAGCTCGTTTG CTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACAAAGGGCCCATCCGTCTT CCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAG GACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACA CCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCC AGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTG GACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAG GGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCC TGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTA CGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCAC GTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAA GTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGG GCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCA GGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGC AATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCT TCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTC CGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAA GCTAGCTGA Anti-DCIR_29G10.3D9_H-V-hIgG4H-C (SEQ ID NO: 106): MMGWSYIILFLVATATDVHSQVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGEG LEWIGEINPSYGRTDYNEKFKNKATLTVAKSSSTAYMQLSSLTSEDSAVYYCARGDYYGSSSFAYW GQGTLVTVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDI AVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLS LSLGKAS Anti-DCIR_29G10.3D9_K-Var1-V-hIgGK-C (SEQ ID NO: 42): ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATGAGTGCCTCAGTCATAATGTCCAGGGG ACAAATTGTTCTCACCCAGTCTCCAGCACTCATGTCTGCATCTCCAGGGGAGAAGGTCACCATG ACCTGCAGTGCCAGCTCAAATATAAGTTACATGTACTGGTACCAGCAGAAGCCAAGATCCTCCC CCAAACCCTGGATTTATCTCACATCCAACCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGT GGGTCTGGGACCTCTTACTCTCTCACAACCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATT GCTGCCAGCAGTGGAGTAGTAACCCACCCACGTTCGGTGCTGGGACCAAGCTCGAGATCAAAC GAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGG ATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCA CCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATG CCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT GTTAG Anti-DCIR_29G10.3D9_K-Var1-V-hIgGK-C (SEQ ID NO: 107): MDFQVQIFSFLLMSASVIMSRGQIVLTQSPALMSASPGEKVTMTCSASSNISYMYWYQQKPRSSPKP WIYLTSNLASGVPARFSGSGSGTSYSLTTSSMEAEDAATYCCQQWSSNPPTFGAGTKLEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR_29G10.3D9_K-Var2-V-hIgGK-C (SEQ ID NO: 43): ATGGATTTTCGAGTGCAGATTTTCAGCTTCCTGCTAATGAGTGCCTCAGTCATAATGTCCAGGGG ACAAATTGTTCTCACCCAGTCTCCAGCACTCATGTCTGCATCTCCAGGGGAGAAGGTCACCATG ACCTGCAGTGCCAGCTCAAATATAAGTTACATGTACTGGTACCAGCAGAAGCCAAGATCCTCCC CCAAACCCTGGATTTATCTCACATCCAACCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGT GGGTCTGGGACCTCTTACTCTCTCACAATCAGCAGCATGGAGGCTGAAGATGCTGCCACTTATT ACTGCCAGCAGTGGAGTAGTAACCCACCCACGTTCGGTGCTGGGACCAAGCTCGAGATCAAAC GAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGG ATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCA CCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATG CCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT GTTAG Anti-DCIR_29G10.3D9_K-Var2-V-hIgGK-C (SEQ ID NO: 108): MDFRVQIFSFLLMSASVIMSRGQIVLTQSPALMSASPGEKVTMTCSASSNISYMYWYQQKPRSSPKP WIYLTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGAGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR_2C9K-V-hIgGK-C (SEQ ID NO: 44): ATGGAGACAGACACACTCCTGCTATGGGTGCTGCTGCTCTGGGTTCCAGGTTCCACAGGTGACA TTGTGCTGATCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATATCCTGC AGAGCCAGTGAAAGTGTTGATAGTTATGTCAATAGTTTTATGCACTGGTACCAGCAGAAACCAG GACAGCCACCCAAACTCCTCATCTATCGTGTATCCAACCTAGAATCTGGGATCCCTGCCAGGTT CAGTGGCAGTGGGTCTAGGACAGACTTCACCCTCACCATTAATCCTGTGGAGGCTGATGATGTT GCAACCTATTACTGTCAGCAAAGTAATGAGGATCCATTCACGTTCGGCTCGGGGACAAAGCTCG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA ATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAG TGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC AAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA GGGGAGAGTGTTAG Anti-DCIR_2C9K-V-hIgGK-C (SEQ ID NO: 109): METDTLLLWVLLLWVPGSTGDIVLIQSPASLAVSLGQRATISCRASESVDSYVNSFMHWYQQKPGQ PPKLLIYRVSNLESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPFTFGSGTKLEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC. Anti-DCIR_31A6.1F5_H-var2-V-hIgG4H-C (SEQ ID NO: 45): ATGGAATGTAACTGGATACTTCCTTTTATTCTGTCGGTAATTTCAGGGGTCTACTCAGAGGTTCA GCTCCAGCAGTCTGGGACTGTGCTGGCAAGGCCTGGGGCTTCCGTGAATATGTCCTGTAAGGCT GCTGGCTACAGCTTTACCAGTTACTGGGTGTACTGGGTCAAACAGAGGCCTGGACAGGGTCTGG AATGGATTGGTGCTATTTACCCTAAAAATAGTAGAACTAGCTACAACCAGAAGTTCCAGGACAA GGCCACACTGACTGCAGTCACATCCGCCAGCACTGCCTACATGGAGCTCAGCAGCCTGACAAAT GAGGACTCTGCGGTCTATTACTGTACAAGACCTCACTATGATTCGTTTGGTTACTGGGGCCAAG GGACTCTGGTCACTGTCTCTGCAGCCAAAACAAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTG CTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCAC GAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGA GTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTC TTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCG TGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGG

AGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCA GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCA ACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGC CACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCT GCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGG AGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAG GCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGA GGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-DCIR_31A6.1F5_H-var2-V-hIgG4H-C (SEQ ID NO: 110): MECNWILPFILSVISGVYSEVQLQQSGTVLARPGASVNMSCKAAGYSFTSYWVYWVKQRPGQGLE WIGAIYPKNSRTSYNQKFQDKATLTAVTSASTAYMELSSLTNEDSAVYYCTRPHYDSFGYWGQGTL VTVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti-DCIR_31A6.1F5_K-var2-V-hIgGK-C (SEQ ID NO: 46): ATGGAGACAGACACACTCCTGCTATGGGTGCTGCTGCTCTGGGTTCCAGGTTCCACAGGTGACA TTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATATCCTGC AGAGCCAGTGAAAGTGTAGATAGTTATGGCATTAGTTTTATGCACTGGTACCAGCAGAAACCAG GACAGCCACCCAAACTCCTCATCTATCGTGCATCCAACCAAGAATCTGGGATCCCTGCCAGGTT CAGTGGCAGTGGGTCTAGGACAGACTTCACCCTCACCATTAATCCTGTGGAGGCTGATGATGTT GCAACCTATTACTGTCAGCAAAGTAATGAGGATCCGCTCACGTTCGGTGCTGGGACCAAGCTCG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA ATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAG TGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC AAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA GGGGAGAGTGTTAG Anti-DCIR_31A6.1F5_K-var2-V-hIgGK-C (SEQ ID NO: 111): METDTLLLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCRASESVDSYGISFMHWYQQKPGQ PPKLLIYRASNQESGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPLTFGAGTKLEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR_3C2.2D9_H-LV-hIgG4H-C (SEQ ID NO: 47): ATGAACAGGCTTACTTCCTCATTGCTGCTGCTGATTGTCCCTGCATATGTCCTGTCCCAGGTTAC TCTGAAAGAGTCTGGCCCTGGGATATTGCAGCCCTCCCAGACCCTCAGTCTGACTTGTTCTTTCT CTGGGTTTTCACTGAGCACTTCTGGTATGGGTGTGAGCTGGATTCGTCAGCCTTCAGGAAAGGG TCTGGAGTGGCTGGCACACATTTACTGGGATGATGACAAGCGCTATAATCCATCCCTGAAGAGC CGGCTCACAATCTTTAAGGATCCCTCCAGCAACCAGGTATTCCTCAGGATCACCAGTGTGGACA CTGCAGATACTGCCACATACTACTGTGCTCGAAACTCCCATTACTACGGTAGTACTTACGGGGG ATACTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCAGCCAAAACAAAGGGCCC ATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGC CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCG GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGAC CGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAA CACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCT GAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCT CCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGT TCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGT TCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAA GGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAA AGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGAC CAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCT TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTC TCTGGGTAAAGCTAGCTGA Anti-DCIR_3C2.2D9_H-LV-hIgG4H-C (SEQ ID NO: 112): NRLTSSLLLLIVPAYVLSQQVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGVSWIRQPSGKGLEWL AHIYWDDDKRYNPSLKSRLTIFKDPSSNQVFLRITSVDTADTATYYCARNSHYYGSTYGGYFDVWG AGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS LGKAS. Anti-DCIR_3C2.2D9_K-LV-hIgGK-C (SEQ ID NO: 48): ATGGAGACAGACACACTCCTGCTATGGGTGCTGCTGCTCGGGGTTCCAGGTTCCACAGGTAACA TTGTGCTGACCCAGTCTCCAACTTCTTTCACTGTGTCTCTTGGGCAGAGGGCCACCATATCCTGC AGAGCCAGTGAAAGTGTTCATAGTTATGGCAATAGTTTTATGCACTGGTACCAGCAGAAACCAG GGCAGCCACCCAAACTCCTCATCTATCTTGCATCCAACGTAGAATCTGGGGTCCCTGCCAGGTT CAGTGGTAGTGGGTCCAGGACAGACTTCACCCTCACCATTGATCCTGTGGAGGCTGATGATGCT GCAACCTATTACTGTCAGCAAAATAGTGAGGATCCGTGGACGTTCGGTGGAGGCACCAAGCTC GAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGA AATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACA CAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAAC AGGGGAGAGTGTTAG Anti-DCIR_3C2.2D9_K-LV-hIgGK-C (SEQ ID NO: 113): METDTLLLWVLLLGVPGSTGNIVLTQSPTSFTVSLGQRATISCRASESVHSYGNSFMHWYQQKPGQP PKLLIYLASNVESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNSEDPWTFGGGTKLEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSS TLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR_6C8.1G9_H-V-hIgG4H-C (SEQ ID NO: 49): ATGGAATGGACCTGGGTCTTTCTCTTCCTCCTGTCAGTAACTGCAGGTGTCCACTCCCAGGTTCA GCTGCAGCAGTCTGGAACTGAGCTGATGAAGCCTGGGGCCTCAGTGAAGATATCCTGCAAGGC TACTGGCTACACATTCAGTACCTACTGGATAGAGTGGGTAAAGCAGAGGCCTGGACATGGCCTT GAGTGGATTGGAGAGATTTTACCTGGAAGTGGTAGGACTAACGACAATGAGAAGTTCAAGGGC AAGGCCACAATCACTGCAGATACATCCTCCAAGAAAGCCTACATGCAACTCAGCAGCCTGACA TCTGAGGACTCTGCCGTCTATTACTGTGCAAGAAGGGGTGGTTACTCCTTTGCTTTCTGGGGCCA AGGGACTCTGGTCTCTGTCTCTGCAGCCAAAACAAAGGGCCCATCCGTCTTCCCCCTGGCGCCC TGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCG AACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGT CCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGC ACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTT GAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAG TCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGC GTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTG GAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTC AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCC AACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAG CCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACC TGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCG GAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCA GGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATG AGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-DCIR_6C8.1G9_H-V-hIgG4H-C (SEQ ID NO: 114): MEWTWVFLFLLSVTAGVHSQVQLQQSGTELMKPGASVKISCKATGYTFSTYWIEWVKQRPGHGLE WIGEILPGSGRTNDNEKFKGKATITADTSSKKAYMQLSSLTSEDSAVYYCARRGGYSFAFWGQGTL VSVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti-DCIR_6C8.1G9_K-V-hIgGK-C (SEQ ID NO: 50): ATGACCATGTTCTCACTAGCTCTTCTCCTCAGTCTTCTTCTCCTCTGTGTCTCTGATTCTAGGGCA GAAACAACTGTGACCCAGTCTCCAGCATCCCTGTCCATGGCTATAGGAGAAAAAGTCACCATCA GATGCGTAACCAGCACTGATATTGATGATGATGTGAACTGGTACCAGCAGAAGCCAGGGGAAC CTCCTAAGCTCCTTATTTCAGAAGGCAATACTCTTCGTGCTGGAGTCCCATCCCGATTCTCCAGC AGTGGCTATGGTACAGATTTTGTTTTTACAATTGAGAACATGCTCTCAGAAGATGTTGCAGATT ACTACTGTTTGCAAAGTGGTAACTTGCCGTACACGTTCGGAGGGGGGACCAAGCTCGAGATCAA ACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGA ACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGG TGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACA GCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCT ATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAG AGTGTTAG Anti-DCIR_6C8.1G9_K-V-hIgGK-C (SEQ ID NO: 115): MTMFSLALLLSLLLLCVSDSRAETTVTQSPASLSMAIGEKVTIRCVTSTDIDDDVNWYQQKPGEPPK

LLISEGNTLRAGVPSRFSSSGYGTDFVFTIENMLSEDVADYYCLQSGNLPYTFGGGTKLEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR_9E8.1E3_H-V-hIgG4H-C (SEQ ID NO: 51): ATGAACAGGCTTACTTCCTCATTGCTGCTGCTGATTGTCCCTGCATATGTCCTGTCCCAGGTTAC TCTGAAAGAGTCTGGCCCTGGGATATTGCAGCCCTCCCAGACCCTCAGTCTGACTTGTTCTTTCT CTGGGTTTTCACTGAGCACTTCTGGTATGGGTCTGAGCTGGATTCGTCAGCCTTCAGGAAAGGG TCTGGAGTGGCTGGCACACATTTACTGGGATGATGACAAGCGCTATAACCCATCCCTGAAGAGC CGGCTCACAATCTCCAAGGATACCTCCAGCAACCAGGTTTTCCTCAAGATCACCATTGTGGACA CTGCAGATGCTGCCACATACTACTGTGCTCGAAGCTCCCATTACTACGGTTATGGCTACGGGGG ATACTTCGATGTCTGGGGCGCAGGGACCACGGTCACCGTCTCCTCAGCCAAAACGAAGGGCCC ATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGC CTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCG GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGAC CGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAA CACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCT GAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCT CCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGT TCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGT TCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAA GGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAA AGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGAC CAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAG TGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGAC GGCTCCTTCTTCCTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCT TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTC TCTGGGTAAAGCTAGCTGA Anti-DCIR_9E8.1E3_H-V-hIgG4H-C (SEQ ID NO: 116): MNRLTSSLLLLIVPAYVLSQVTLKESGPGILQPSQTLSLTCSFSGFSLSTSGMGLSWIRQPSGKGLEWL AHIYWDDDKRYNPSLKSRLTISKDTSSNQVFLKITIVDTADAATYYCARSSHYYGYGYGGYFDVWG AGTTVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ SSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPK PKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIA VEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS LGKAS Anti-DCIR_9E8.1E3_K-LV-hIgGK-C (SEQ ID NO: 52): ATGGAGACAGACACACTCCTGCTATGGGTGCTGCTGCTCTGGGTTCCAGGTTCCACAGGTAACA TTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATATCCTGC AGAGCCAGTGAAAGTATTCATAGTTATGGCAATAGTTTTCTGCACTGGTACCAGCAGAAACCAG GACAGCCACCCAAACTCCTCATCTATCTTGCATCCAACCTAGAATCTGGGGTCCCTGCCAGGTT CAGCGGCAGTGGGTCTAGGACAGACTTCACCCTCACCATTGATCCTGTGGAGGCTGATGATGCT GCAACCTATTACTGTCAGCAAAATAATGAGGATCCGTGGACGTTCGGTGGAGGCACCAAGCTC GAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGA AATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACA CAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAAC AGGGGAGAGTGTTAGGCGGCCGCACTAGCGCGGGCCGCATTCGAAGAGCTCGGTACCCGGGGA TCCTCTAGAGTCGACCTGCAGGCATGCAAGCTGGCCGCGACTCTAGATCATAATCAGC Anti-DCIR_9E8.1E3_K-LV-hIgGK-C (SEQ ID NO: 117): METDTLLLWVLLLWVPGSTGNIVLTQSPASLAVSLGQRATISCRASESIHSYGNSFLHWYQQKPGQP PKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVEADDAATYYCQQNNEDPWTFGGGTKLEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSS TLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-DCIR2C9H-LV-hIgG4H-V-hIgG4H-C (SEQ ID NO: 53): ATGAAATGCAGCTGGGTCATCTTCTTCCTGATGGCAGTGGTTACAGGGGTCAATTCAGAGGTTC AGCTGCAGCAGTCTGGGGCTGAGCTTGTGAGGCCAGGGGCCTTAGTCAAGTTGTCCTGCAAAGC TTCTGGCTTCAACATTAATGACTACTATATCCACTGGGTGAAGCAGCGGCCTGAACAGGGCCTG GAGCGGATTGGATGGATTGATCCTGACAATGGTAATACTATATATGACCCGAAGTTCCAGGGCA AGGCCAGTATAACAGCAGACACATCCCCCAACACAGCCTACCTGCAGCTCAGCAGCCTGACAT CTGAGGACACTGCCGTCTATTACTGTGCTAGAACCCGATCTCCTATGGTTACGACGGGGTTTGTT TACTGGGGCCAAGGGACTGTGGTCACTGTCTCTGCAGCCAAAACGAAGGGCCCATCCGTCTTCC CCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGA CTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACC TTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAG CAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGA CAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGG GGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTG AGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACG TGGATGGCGTGGAGGTGCATAATGCCAAGACRAAGCCGCGGGAGGAGCAGTTCAACAGCACGT ACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGT GCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC AGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGG TCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAA TGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTC CTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCC GTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAT GA Anti-DCIR2C9H-LV-hIgG4H-V-hIgG4H-C (SEQ ID NO: 118): MKCSWVIFFLMAVVTGVNSEVQLQQSGAELVRPGALVKLSCKASGFNINDYYIHWVKQRPEQGLE RIGWIDPDNGNTIYDPKFQGKASITADTSPNTAYLQLSSLTSEDTAVYYCARTRSPMVTTGFVYWGQ GTVVTVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKXKPREEQFNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL GK Anti-DC-SIGNL16E3H (SEQ ID NO: 54): ATGGAAAGGCACTGGATCTTTCTCTTCCTGTTTTCAGTAACTGCAGGTGTCCACTCCCAGGTCCA GCTTCAGCAGTCTGGGGCTGAGCTGGCAAAACCTGGGGCCTCAGTGAAGATGTCCTGCAAGGCT TCTGGCTACACCTTTACTACCTACTGGATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTGG AATGGATTGGATACATTAATCCTATCACTGGTTATACTGAGTACAATCAGAAGTTCAAGGACAA GGCCACCTTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAACTGAGCAGCCTGACATCT GAGGACTCTGCAGTCTATTACTGTGCAAGAGAGGGTTTAAGTGCTATGGACTATTGGGGTCAGG GAACCTCAGTCACCGTCACCTCAGCCAAAACAACAGCCCCATCGGTCTATCCACTGGCCCCTGT GTGTGGAGATACAACTGGCTCCTCGGTAACTCTAGGATGCCTGGTCAAGGGTTATTTCCCTGAG CCAGTGACCTTGACCTGGAACTCTGGATCCCTGTCCAGTGGTGTGCACACCTTCCCAGCTGTCCT GCAGTCTGACCTCTACACCCTCAGCAGCTCAGTGACTGTAACCTCGAGCACCTGGCCCAGCCAG ACCGTCACCTGCAGCGTTGCTCACCCAGCCAGCAGCACCACGGTGGACAAAAAACTTGAGCCC AGCGGGCCCATTTCAACAATCAACCCCTGTCCTCCATGCAAGGAGTGTCACAAATGCCCAGCTC CTAACCTCGAGGGTGGACCATCCGTCTTCATCTTCCCTCCAAATATCAAGGATGTACTCATGATC TCCCTGACACCCAAGGTCACGTGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGACGTCCAG ATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGAT TACAACAGTACTATCCGGGTGGTCAGCACCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCA AGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCATCACCCATCGAGAGAACCATCTCAA AAATTAAAGGGCTAGTCAGAGCTCCACAAGTATACATCTTGCCGCCACCAGCAGAGCAGTTGTC CAGGAAAGATGTCAGTCTCACTTGCCTGGTCGTGGGCTTCAACCCTGGAGACATCAGTGTGGAG TGGACCAGCAATGGGCATACAGAGGAGAACTACAAGGACACCGCACCAGTCCTGGACTCTGAC GGTTCTTACTTCATATATAGCAAGCTCAATATGAAAACAAGCAAGTGGGAGAAAACAGATTCCT TCTCATGCAACGTGAGACACGAGGGTCTGAAAAATTACTACCTGAAGAAGACCATCTCCCGGTC TCCGGGTAAAGCTAGCTGA Anti-DC-SIGNL16E3H (SEQ ID NO: 119): MERHWIFLFLFSVTAGVHSQVQLQQSGAELAKPGASVKMSCKASGYTFTTYWMHWVKQRPGQGL EWIGYINPITGYTEYNQKFKDKATLTADKSSSTAYMQLSSLTSEDSAVYYCAREGLSAMDYWGQGT SVTVTSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDL YTLSSSVTVTSSTWPSQTVTCSVAHPASSTTVDKKLEPSGPISTINPCPPCKECHKCPAPNLEGGPSVFI FPPNIKDVLMISLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTIRVVSTLPIQ HQDWMSGKEFKCKVNNKDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDI SVEWTSNGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYYLKKTISR SPGKAS Anti-DC-SIGNL16E3K (SEQ ID NO: 55): ATGGGCATCAAGATGGAGTCACGGATTCAGGCATTTGTATTCGTGTTTCTCTGGTTGTCTGGTGT TGGCGGAGACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTC AGCGTCACCTGCAAGGCCAGTCAGGATGTGACTTCTGCTGTAGCCTGGTATCAACAAAAACCAG GGCAATCTCCTAAACTACTGATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTGATCGCTT CACAGGCAGTGGATCTGGGACAGATTATACTCTCACCATCAGCAGTGGGCAGGCTGAAGACCT GGCACTTTATTACTGTCACCAATATTATAGCGCTCCTCGGACGTTCGGTGGAGGCACCAAGCTG GAAGTCAAACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGTGAGCAGTTAA CATCTGGAGGTGCCTCAGTCGTGTGCTTCTTGAACAACTTCTACCCCAAAGACATCAATGTCAA

GTGGAAGATTGATGGCAGTGAACGACAAAATGGCGTCCTGAACAGTTGGACTGATCAGGACAG CAAAGACAGCACCTACAGCATGAGCAGCACCCTCACGTTGACCAAGGACGAGTATGAACGACA TAACAGCTATACCTGTGAGGCCACTCACAAGACATCAACTTCACCCATCGTCAAGAGCTTCAAT AGGAATGAGTGTTAG Anti-DC-SIGNL16E3K (SEQ ID NO: 120): MESRIQAFVFVFLWLSGVGGDIVMTQSHKFMSTSVGDRVSVTCKASQDVTSAVAWYQQKPGQSPK LLIYWASTRHTGVPDRFTGSGSGTDYTLTISSGQAEDLALYYCHQYYSAPRTFGGGTKLEVKRADA APTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSST LTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC Anti-DC-SIGNL16E7H-LV-hIgG4H-C (SEQ ID NO: 56): ATGGAAAGGCACTGGATCTTTCTCTTCCTGTTTTCAGTAACTGCAGGTGTCCACTCCCAGGTCCA GCTTCAGCAGTCTGGGGCTGAGCTGGCAAAACCTGGGGCCTCAGTGAAGATGTCCTGCAAGGCT TCTGGCTACACCTTTACTACCTACTGGATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTGG AATGGATTGGATACATTAATCCTATCACTGGTTATACTGAGTACAATCAGAAGTTCAAGGACAA GGCCACCTTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAACTGAGCAGCCTGACATCT GAGGACTCTGCAGTCTATTACTGTGCAAGAGAGGGTTTAAGTGCTATGGACTATTGGGGTCAGG GAACCTCAGTCACCGTCACCTCAGCCAAAACAACGGGCCCATCCGTCTTCCCCCTGGCGCCCTG CTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAA CCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCC TACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCAC GAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGA GTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTC TTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCG TGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGG AGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCA GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCA ACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGC CACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCT GCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGG AGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAG GCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGA GGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-DC-SIGNL16E7H-LV-hIgG4H-C (SEQ ID NO: 121): MERHWIFLFLFSVTAGVHSQVQLQQSGAELAKPGASVKMSCKASGYTFTTYWMHWVKQRPGQGL EWIGYINPITGYTEYNQKFKDKATLTADKSSSTAYMQLSSLTSEDSAVYYCAREGLSAMDYWGQGT SVTVTSAKTTGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKA S. Anti-DC-SIGNL16E7K-LV-hIgGK-C (SEQ ID NO: 57): ATGGGCATCAAGATGGAGTCACAGATTCAGGCATTTGTATTCGTGTTTCTCTGGTTGTCTGGTGT TGGCGGAGACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTC AGCGTCACCTGCAAGGCCAGTCAGGATGTGACTTCTGCTGTAGCCTGGTATCAACAAAAACCAG GGCAATCTCCTAAACTACTGATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTGATCGCTT CACAGGCAGTGGATCTGGGACAGATTATACTCTCACCATCAGCAGTGGGCAGGCTGAAGACCT GGCACTTTATTACTGTCACCAATATTATAGCGCTCCTCGGACGTTCGGTGGAGGCACCAAGCTC GAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGA AATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACA GTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAG CAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACA CAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAAC AGGGGAGAGTGTTAG Anti-DC-SIGNL16E7K-LV-hIgGK-C (SEQ ID NO: 122): MESQIQAFVFVFLWLSGVGGDIVMTQSHKFMSTSVGDRVSVTCKASQDVTSAVAWYQQKPGQSPK LLIYWASTRHTGVPDRFTGSGSGTDYTLTISSGQAEDLALYYCHQYYSAPRTFGGGTKLEIKRTVAA PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-Dectin_1_11B6.4_H-V-hIgG4H-C (SEQ ID NO: 58): ATGGCTGTCCTGGCACTACTCCTCTGCCTGGTGGCTTTCCCAACTTGTACCCTGTCCCAGGTGCA ACTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCATTACCTGCTCTGTC TCTGGGTTCTCATTAAGCAACTATGATATAAGCTGGATTCGCCAGCCACCAGGAAAGGGTCTGG AGTGGCTTGGAGTAATGTGGACTGGTGGAGGCGCAAATTATAATTCAGCTTTCATGTCCAGACT GAGCATCAACAAGGACAACTCCAAGAGCCAAGTTTTTTTAAAAATGAACAATCTGCAAACTGA TGACACAGCCATTTATTACTGTGTCAGAGATGCGGTGAGGTACTGGAACTTCGATGTCTGGGGC GCAGGGACCACGGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGC CCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCC CGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCT GTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGG GCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAG TTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATC AGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACG TGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGC GTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTG GTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTC TCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA GAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTG ACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAG CCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACA GCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGC ATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-Dectin_1_11B6.4_H-V-hIgG4H-C (SEQ ID NO: 123): MAVLALLLCLVAFPTCTLSQVQLKESGPGLVAPSQSLSITCSVSGFSLSNYDISWIRQPPGKGLEWLG VMWTGGGANYNSAFMSRLSINKDNSKSQVFLKMNNLQTDDTAIYYCVRDAVRYWNFDVWGAGT TVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti-Dectin_1_11B6.4_K-LV-hIgGK-C (SEQ ID NO: 59): ATGGATTTTCAAGCGCAGATTTTCAGCTTCCTGCTAATCAGTGCTTCAGTCATAATGTCCAGAGG ACAAATTGTTCTCTCCCAGTCACCAGCAATCCTGTCTGCATCTCCAGGGGAGAAGGTCACAATG ACTTGCAGGGCCAGCTCAAGTGTAAGTTACATACACTGGTACCAGCAGAAGCCAGGATCCTCCC CCAAACCCTGGATTTATGCCACATCCCACCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGT GGGTCTGGGACCTCTTACTCTCTCACAATCAGCAGAGTGGAGGCTGAAGATACTGCCACTTATT ACTGCCAGCAGTGGAGTAGTAACCCATTCACGTTCGGCTCGGGGACAAAGCTCGAGATCAAAC GAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGG ATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCA CCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATG CCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT GTTAG Anti-Dectin_1_11B6.4_K-LV-hIgGK-C (SEQ ID NO: 124): MDFQAQIFSFLLISASVIMSRGQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWYQQKPGSSPKPWI YATSHLASGVPARFSGSGSGTSYSLTISRVEAEDTATYYCQQWSSNPFTFGSGTKLEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-Dectin_1_15E2.5_H-V-hIgG4H-C (SEQ ID NO: 60): ATGGAAAGGCACTGGATCTTTCTACTCCTGTTGTCAGTAACTGCAGGTGTCCACTCCCAGGTCC AGCTGCAGCAGTCTGGGGCTGAACTGGCAAGACCTGGGGCCTCAGTGAAGATGTCCTGCAAGG CTTCTGGCTACACCTTTACTACCTACACTATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCT GGAATGGATTGGATACATTAATCCTAGCAGTGGTTATACTAATTACAATCAGAAGTTCAAGGAC AAGGCCACATTGACTGCAGACAAATCCTCCAGCACAGCCTCCATGCAACTGAGCAGCCTGACAT CTGAGGACTCTGCAGTCTATTACTGTGCAAGAGAGAGGGCGGTATTAGTCCCCTATGCTATGGA CTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAAAGGGCCCATCCGTCTTC CCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGG ACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACAC CTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCA GCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGG ACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGG GGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCT GAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTAC GTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACG TACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGT GCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGC AGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGG TCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAA TGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTC CTCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCC GTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAG

CTAGCTGA Anti-Dectin_1_15E2.5_H-V-hIgG4H-C (SEQ ID NO: 125): MERHWIFLLLLSVTAGVHSQVQLQQSGAELARPGASVKMSCKASGYTFTTYTMHWVKQRPGQGL EWIGYINPSSGYTNYNQKFKDKATLTADKSSSTASMQLSSLTSEDSAVYYCARERAVLVPYAMDY WGQGTSVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV LQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFP PKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSL SLSLGKAS Anti-Dectin_1_15E2.5_K-V-hIgGK-C (SEQ ID NO: 61): ATGCATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAATGTCCAGAGG ACAAATTGTTCTCACCCAGTCTCCAGCAGTCATGTCTGCATCTCCAGGGGAGAAGGTCACCATA ACCTGCACTGCCAGCTCAAGTTTAAGTTACATGCACTGGTTCCAGCAGAAGCCAGGCACTTCTC CCAAACTCTGGCTTTATAGCACATCCATCCTGGCTTCTGGAGTCCCTACTCGCTTCAGTGGCAGT GGATCTGGGACCTCTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATT ACTGCCAGCAAAGGAGTAGTTCCCCATTCACGTTCGGCTCGGGGACAAAGCTCGAGATCAAAC GAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACT GCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGG ATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCA CCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATG CCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGT GTTAG Anti-Dectin_1_15E2.5_K-V-hIgGK-C (SEQ ID NO: 126): MHFQVQIFSFLLISASVIMSRGQIVLTQSPAVMSASPGEKVTITCTASSSLSYMHWFQQKPGTSPKLW LYSTSILASGVPTRFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSSPFTFGSGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKA DYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-Dectin_1_2D8.2D4H-V-hIgG4H-C (SEQ ID NO: 62): ATGGGATGGACCTGGATCTTTATTTTAATCCTGTCAGTTACTACAGGTGTCCACTCTGAGGTCCA GCTGCAGCAGTCTGGACCTGAGCTGGAGAAGCCTGGCGCTTCAGTGAAGATATCCTGCAAGGCT TCTGGTTACTCCTTCACTGGCTACAACATGAACTGGGTGAAACAGAGCAATGGAAAGAGCCTTG AGTGGATTGGAAATATTGATCCTTACTATGGTGATACTAACTACAACCAGAAGTTCAAGGGCAA GGCCACATTGACTGTAGACAAATCCTCCAGCACAGCCTACATGCACCTCAAGAGCCTGACATCT GAGGACTCTGCAGTCTATTACTGTGCAAGACCCTACGGTAGTGAGGCCTACTTTGCTTACTGGG GCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGC GCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTC CCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTG GGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGA GTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCAC GTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGG CGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGT GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGT CTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCG AGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCT GACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC AGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATG CATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCT GA Anti-Dectin_1_2D8.2D4H-V-hIgG4H-C (SEQ ID NO: 127): MGWTWIFILILSVTTGVHSEVQLQQSGPELEKPGASVKISCKASGYSFTGYNMNWVKQSNGKSLEW IGNIDPYYGDTNYNQKFKGKATLTVDKSSSTAYMHLKSLTSEDSAVYYCARPYGSEAYFAYWGQG TLVTVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG KAS Anti-Dectin_1_2D8.2D4K-V-hIgGK-C (SEQ ID NO: 63): ATGGTGTCCACTTCTCAGCTCCTTGGACTTTTGCTTTTCTGGACTTCAGCCTCCAGATGTGACATT GTGATGACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGAGATAGAGTCTCTCTTTCCTGCAG GGCCAGCCAGAGTATTAGCGACTACTTACACTGGTATCAACAAAAATCACATGAGTCTCCAAGG CTTCTCATCAAATATGCTGCCCAATCCATCTCTGGGATCCCCTCCAGGTTCAGTGGCAGTGGATC AGGGTCAGATTTCACTCTCAGTATCAACGGTGTGGAACCTGAAGATGTTGGAGTGTATTACTGT CAAAATGGTCACAGCTTTCCGTACACGTTCGGAGGGGGGACCAAGCTCGAGATCAAACGAACT GTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTC TGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAAC GCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTAC AGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGCCTGC GAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG Anti-Dectin_1_2D8.2D4K-V-hIgGK-C (SEQ ID NO: 128): DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYAAQSISGIPSRFSGSGSGS DFTLSINGVEPEDVGVYYCQNGHSFPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC Anti-Langerin15B10H-LV-hIgG4H-C (SEQ ID NO: 64): ATGGAATGGAGGATCTTTCTCTTCATCCTGTCAGGAACTGCAGGTGTCCACTCCCAGGTTCAGCT GCGGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCTTCT GGATACACATTTACTGACTATGTTATAAGTTGGGTGAAGCAGAGAACTGGACAGGGCCTTGAGT GGATTGGAGATATTTATCCTGGAAGTGGTTATTCTTTCTACAATGAGAACTTCAAGGGCAAGGC CACACTGACTGCAGACAAATCCTCCACCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAG GACTCTGCGGTCTATTTCTGTGCAACCTACTATAACTACCCTTTTGCTTACTGGGGCCAAGGGAC TCTGGTCACTGTCTCTGCAGCCAAAACAACGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCA GGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGT GACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAG TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGA CCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCA AATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCT GTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTG GTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTG CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTC CTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAA GGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAG GTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTG GTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAAC AACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAA CCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCT GCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-Langerin15B10H-LV-hIgG4H-C (SEQ ID NO: 129): QVQLRQSGPELVKPGASVKMSCKASGYTFTDYVISWVKQRTGQGLEWIGDIYPGSGYSFYNENFKG KATLTADKSSTTAYMQLSSLTSEDSAVYFCATYYNYPFAYWGQGTLVTVSAAKTTGPSVFPLAPCS RSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTC NVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDP EVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTI SKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG SFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS. Anti-Langerin15B10K-LV-hIgGK-C (SEQ ID NO: 65): ATGAAGTTGCCTGTTAGGCTGTTGGTGCTGATGTTCTGGATTCCTGCTTCCAGCAGTGATGTTGT GATGACCCAAACTCCACTCTCCCTGCCTGTCCGTCTTGGAGATCAAGCCTCCATCTCTTGCAGAT CTAGTCAGAGCCTTGTACACAGTAATGGAAACACCTATTTACATTGGTACCTGCAGAAGCCAGG CCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTC AGTGGCAGTGGATCAGGGACAAATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTG GGACTTTATTTCTGCTCTCAAAGTACACATGTTCCGTACACGTTCGGAGGGGGGACCAAGCTCG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA ATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAG TGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC AAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA GGGGAGAGTGTTAG Anti-Langerin15B10K-LV-hIgGK-C (SEQ ID NO: 130): DVVMTQTPLSLPVRLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRF SGSGSGTNFTLKISRVEAEDLGLYFCSQSTHVPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV THQGLSSPVTKSFNRGEC Anti-Langerin2G3H-LV-hIgG4H-C (SEQ ID NO: 66): ATGACATTGAACATGCTGTTGGGGCTGAGGTGGGTTTTCTTTGTTGTTTTTTATCAAGGTGTGCA TTGTGAGGTGCAGCTTGTTGAGTCTGGTGGAGGATTGGTGCAGCCTAAAGGGTCATTGAAACTC TCATGTGCAGCCTCTGGATTAACCTTCAATATCTACGCCATGAACTGGGTCCGCCAGGCTCCAG

GAAAGGGTTTGGAATGGGTTGCTCGCATAAGAAATAAAAGTAATAATTATGCAACATATTATGC CGATTCAGTGAAAGACAGGTTCACCATCTCCAGAGATGATTCACAAAGCTTGCTCTATCTGCAA ATGAACAACTTGAAAACTGAGGACACAGCCATGTATTACTGTGTGGGACGGGACTGGTTTGATT ACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACGAAGGGCCCATCCGTCTTCCC CCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGAC TACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCT TCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGC AGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGAC AAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGG GACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGA GGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGT GGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTA CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC AAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAG CCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC TCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCG TGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGC TAGCTGA Anti-Langerin2G3H-LV-hIgG4H-C (SEQ ID NO: 131): MTLNMLLGLRWVFFVVFYQGVHCEVQLVESGGGLVQPKGSLKLSCAASGLTFNIYAMNWVRQAP GKGLEWVARIRNKSNNYATYYADSVKDRFTISRDDSQSLLYLQMNNLKTEDTAMYYCVGRDWFD YWGQGTLVTVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTV LHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPS DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSL SLSLGKAS Anti-Langerin2G3L-LV-hIgGK-C (SEQ ID NO: 67): ATGGCCTGGATTTCACTTATACTCTCTCTCCTGGCTCTCAGCTCAGGGGCCATTTCCCAGGCTGT TGTGACTCAGGAATCTGCACTCACCACATCACCTGGTGAAACAGTCACACTCACTTGTCGCTCA AGTACTGGGGCTGTTACAACTAGTAACTATGCCAACTGGGTCCAAGAAAAACCAGATCATTTAT TCACTGGTCTAATAGGTGGTACCAACAACCGAGTTTCAGGTGTTCCTGCCAGATTCTCAGGCTC CCTGATTGGAGACAAGGCTGCCCTCACCATCACAGGGGCACAGACTGAGGATGAGGCAATATA TTTCTGTGCTCTATGGTACAGCAACCATTGGGTGTTCGGTGGAGGAACCAAACTCGAGATCAAA CGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAAC TGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTG GATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGC ACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAT GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAG TGTTAG Anti-Langerin2G3L-LV-hIgGK-C (SEQ ID NO: 132): MAWISLILSLLALSSGAISQAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGL IGGTNNRVSGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHWVFGGGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-Lox_1_10F9H-LV-hIgG4H-C (SEQ ID NO: 68): ATGGAATGGACCTGGGTCTTTCTCTTCCTCCTGTCAGTAACTGCAGGTGTCCACTCCCAGGTTCA GCTGCAGCAGTCTGGAGCTGAGCTGATGAAGCCTGGGGCCTCAGTGAAGATATCCTGCAAGGC TACTGGCTACACATTCGGTAGCTACTGGATAGAGTGGGTAAAGCAGAGGCCTGGACATGGCCTT GAGTGGATTGGAGAGATTTTACCTGGAAGTGGTAATACTAACTACAATGAGAACTTCAAGGGC AAGGCCACATTCACTGCAGATACATCCTCCAACACAGCCTACATGCAACTCACCAGTCTGACAT CTGAGGACTCTGCCGTCTATTACTGTGCTAGGGCGGGGATTTATTGGGGCCAAGGGACTCTGGT CACTGTCTCTGCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGGAGC ACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGG TGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTC AGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTAC ACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATAT GGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGTTCC CCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGA CGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAA TGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCAC CGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCT CCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTA CACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAA AGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTA CAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCGTG GACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCAC AACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-Lox_1_10F9H-LV-hIgG4H-C (SEQ ID NO: 133): MEWTWVFLFLLSVTAGVHSQVQLQQSGAELMKPGASVKISCKATGYTFGSYWIEWVKQRPGHGLE WIGEILPGSGNTNYNENFKGKATFTADTSSNTAYMQLTSLTSEDSAVYYCARAGIYWGQGTLVTVS AAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSS VVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEY KCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti-Lox_1_10F9K-LV-hIgGK-C (SEQ ID NO: 69): ATGGAGAAAGACACACTCCTGCTATGGGTCCTGCTTCTCTGGGTTCCAGGTTCCACAGGTGACA TTGTGCTGACCCAATCTCCAGCTTTTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGC AGAGCCAGCGAAAGTGTTGATAATTATGGCATTAGTTTTATGAACTGGTTCCAACAGAAACCAG GACAGCCACCCAAACTCCTCATCTATGTTGCATCCAAGCAAGGATCCGGGGTCCCTGCCAGGTT TAGTGGCAGTGGGTCTGGGACAGACTTCAGCCTCAACATCCATCCTATGGAGGAGGATGATACT GCAATGTATTTCTGTCAGCAAAGTAAGGAGGTTCCTCGGACGTTCGGTGGAGGCACCAAGCTCG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA ATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAG TGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC AAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA GGGGAGAGTGTTAG Anti-Lox_1_10F9K-LV-hIgGK-C (SEQ ID NO: 134): MEKDTLLLWVLLLWVPGSTGDIVLTQSPAFLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQ PPKLLIYVASKQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPRTFGGGTKLEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-LOX-111C8H-LV-hIgG4H-C (SEQ ID NO: 70): ATGGAATGTAACTGGATACTTCCTTTTATTCTGTCGGTAACTTCAGGGGTCTACTCAGAGGTTCA GCTCCAGCAGTCTGGGACTGTGCTGGCAAGGCCTGGGGCTTCAGTGAAGATGTCCTGCAAGGCT TCTGGCTACACCTTTACCAGCTACTGGATGCACTGGGTAAAACAGAGGCCTGGACAGGGTCTGG AATGGATTGGCGCTATTTATCCTGGAAATAGTGATACTACCTACAACCAGAAGTTCAAGGGCAA GGCCAAACTGACTGCAGTCACATCCACCAGCACTGCCTACATGGAGCTCAGCAGCCTGACAAAT GAGGACTCTGCGGTCTATTACTGTACACCTACTTACTACTTTGACTACTGGGGCCAAGGCACCTC TCTCACAGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGCGCCCTGCTCCAGG AGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGA CGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTC CTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACC TACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAA TATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCATCAGTCTTCCTGT TCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGT GGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCA TAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCT CACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGG CCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGT GTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTC AAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAAC TACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTAACCG TGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGC ACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTGA Anti-LOX-111C8H-LV-hIgG4H-C (SEQ ID NO: 135): MECNWILPFILSVTSGVYSEVQLQQSGTVLARPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLE WIGAIYPGNSDTTYNQKFKGKAKLTAVTSTSTAYMELSSLTNEDSAVYYCTPTYYFDYWGQGTSLT VSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS Anti-LOX-111C8K-LV-hIgGK-C (SEQ ID NO: 71): ATGAGTCCTGCCCAATTCCTGTTTCTGTTAGTGCTCTGGATTCGGGAAACCAACGGTGATGTTGT GATGACCCAGACTCCACTCACTTTGTCGGTTACCATTGGACAACCAGCCTCCATCTCTTGCAAGT CAAGTCAGAGCCTCTTAGATAGTGATGGAAAGACATATTTGAATTGGTTCTTACAGAGGCCAGG

CCAGTCTCCAAAGCGCCTAATCTATCTGGTGTCTAAACTGGACTCTGGAGTCCCTGACAGGTTC ACTGGCAGTGGATCAGGGACAGATTTCACACTGAAAATCAGCAGAGTGGAGGCTGAGGATTTG GGAGTTTATTATTGCTGGCAAGGTACACATTTTCCGTGGACGTTCGGTGGAGGCACCAAGCTCG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA ATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAG TGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC AAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA GGGGAGAGTGTTAG Anti-LOX-111C8K-LV-hIgGK-C (SEQ ID NO: 136): MSPAQFLFLLVLWIRETNGDVVMTQTPLTLSVTIGQPASISCKSSQSLLDSDGKTYLNWFLQRPGQSP KRLIYLVSKLDSGVPDRFTGSGSGTDFTLKISRVEAEDLGVYYCWQGTHFPWTFGGGTKLEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-LOX-115C4H-LV-hIgG4H-C (SEQ ID NO: 72): ATGGGAGGGATCTGGATCTTTCTCTTCCTCCTGTCAGGAACTGCAGGTGCCCACTCTGAGATCC AGCTGCAGCAGACTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGATATCCTGCAAGG CTTCTGGTTATCCATTCACTGACTACATCATGGTCTGGGTGAAGCAGAGCCATGGAAAGAGCCT TGAGTGGATTGGAAATATTAGTCCTTACTATGGTACTACTAACTACAATCTGAAGTTCAAGGGC AAGGCCACATTGACTGTAGACAAATCTTCCAGCACAGCCTACATGCAGCTCAACAGTCTGACAT CTGAGGACTCTGCAGTCTATTACTGTGCAAGATCCCCTAACTGGGACGGGGCCTGGTTTGCTCA CTGGGGCCAAGGGGCTCTGGTCACTGTCTCTGCAGCCAAAACAAAGGGCCCATCCGTCTTCCCC CTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACT ACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGC AGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGAC AAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGG GACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGA GGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGT GGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTA CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC AAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAG CCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC TCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCG TGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGC TAGCTGATTAATTAA Anti-LOX-115C4H-LV-hIgG4H-C (SEQ ID NO: 137): MGGIWIFLFLLSGTAGAHSEIQLQQTGPELVKPGASVKISCKASGYPFTDYIMVWVKQSHGKSLEWI GNISPYYGTTNYNLKFKGKATLTVDKSSSTAYMQLNSLTSEDSAVYYCARSPNWDGAWFAHWGQ GALVTVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL GKAS Anti-LOX-115C4K-LV-hIgGK-C (SEQ ID NO: 73): ATGGAGACAGACACAATCCTGCTATGGGTGCTGCTGCTCTGGGTTCCAGGCTCCACTGGTGACA TTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCCTGC AAGGCCAGCCAAAGTGTTGATTATGATGGTGATAGTTATATGAACTGGTTCCAACAGAAACCAG GACAGCCACCCAAACTCCTCATCTATGCTGCATCCAATCTAGAATCTGGGATCCCAGCCAGGTT TAGTGGCAGTGGGTCTGGGACAGACTTCACCCTCAACATCCATCCTGTGGAGGAGGAGGATGCT GCAACCTATTACTGTCAGCAAAGTAATGAGGATCCATTCACGTTCGGCTCGGGGACAAAGCTCG AGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAA ATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAG TGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGC AAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACAC AAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACA GGGGAGAGTGTTAG Anti-LOX-115C4K-LV-hIgGK-C (SEQ ID NO: 138): METDTILLWVLLLWVPGSTGDIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWFQQKPGQ PPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-Marco_10B7.3G4H-LV-hIgG4H-C (SEQ ID NO: 74): ATGGCTGTCCTGGGGCTGCTTCTCTGCCTGGTGACGTTCCCAAGCTGTGTCCTGTCCCAGGTGCA GCTGAAGGAGTCAGGACCTGGCCTGGTGGCACCCTCACAGAGCCTGTCCATCACATGCACTGTC TCTGGGTTCTCATTATCCAGATATAGTGTATTTTGGGTTCGCCAGCCTCCAGGAAAGGGTCTGGA GTGGCTGGGATTGATATGGGGTGGTGGAAGCACAGACTATAATTCAGCTCTCAAATCCAGACTG AGCATCAGCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGAT GACACAGCCATGTACTACTGTGCCAGAATCTACTTTGATTACGACGGGGCTATGGACTACTGGG GTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACAACGGGCCCATCCGTCTTCCCCCTGGC GCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTC CCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTG GGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGA GTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCAC GTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGG CGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGT GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGT CTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCG AGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCT GACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC AGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATG CATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCTG Anti-Marco_10B7.3G4H-LV-hIgG4H-C (SEQ ID NO: 139): MAVLGLLLCLVTFPSCVLSQVQLKESGPGLVAPSQSLSITCTVSGFSLSRYSVFWVRQPPGKGLEWL GLIWGGGSTDYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCARIYFDYDGAMDYWGQGT SVTVSSAKTTGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDT LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS AntiMarco_10B7.3G4K_H-V-hIgGK-C (SEQ ID NO: 75): ATGCATCGCACCAGCATGGGCATCAAGATGGAGTCACGGATTCAGGCATTTGTATTCGTGTTTC TCTGGTTGTCTGGTGTTGGCGGAGACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCA GTAGGAGACAGGGTCAGCGTCACCTGCAAGGCCAGTCAGGATGTGACTTCTGCTGTAGCCTGGT ATCAACAAAAACCAGGGCAATCTCCTAAACTACTGATTTACTGGGCATCCACCCGGCACACTGG AGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTATACTCTCACCATCAGCAGTGGG CAGGCTGAAGACCTGGCACTTTATTACTGTCACCAATATTATAGCGCTCCTCGGACGTTCGGTG GAGGCACCAAGCTCGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATC TGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGA GAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTC ACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCA GACTACGAGAAACACAAAGTCTATGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTC ACAAAGAGCTTCAACAGGGGAGAGTGTTAG AntiMarco_10B7.3G4K_H-V-hIgGK-C (SEQ ID NO: 140): MHRTSMGIKMESRIQAFVFVFLWLSGVGGDIVMTQSHKFMSTSVGDRVSVTCKASQDVTSAVAWY QQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDYTLTISSGQAEDLALYYCHQYYSAPRTFGGGTK LEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-Marco_11A8.3C9_H-V-hIgG4H-C (SEQ ID NO: 76): ATGGAATGGAACTGGGTCGTTCTCTTCCTCCTGTCATTAACTGCAGGTGTCTATGCCCAGGGTCA GATGCAGCAGTCTGGAGCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCCTGCAAGACT TCTGGCTTCACCTTCAGCAGTAACTATATAAGTTGGTTGAAGCAAAAGCCTGGACAGAGTCTTG AGTGGATTGCATGGATTTATGCTGGAACTGGTGGTATTACCTATAATCAGAAGTTCAGAGGCAG GGCCCAACTGACTGTAGACACATCCTCCAGCACAGCCTACATGCAGTTCAGCAGCCTGACAACT GATGACTCTGCCATCTATTACTGTGCAAGACACGTGAGGGGTTACCATCCTATGGACTACTGGG GTCAAGGAACCTCAGTCACCGTCTCCTCAGCCAAAACGAAGGGCCCATCCGTCTTCCCCCTGGC GCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTC CCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGG CTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTG GGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGA GTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGGGACCAT CAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCAC GTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGG CGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGT

GGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGT CTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCG AGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCT GACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCA GCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC AGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATG CATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGCTAGCT GA Anti-Marco_11A8.3C9_H-V-hIgG4H-C (SEQ ID NO: 141): MEWNWVVLFLLSLTAGVYAQGQMQQSGAELVKPGASVKLSCKTSGFTFSSNYISWLKQKPGQSLE WIAWIYAGTGGITYNQKFRGRAQLTVDTSSSTAYMQFSSLTTDDSAIYYCARHVRGYHPMDYWGQ GTSVTVSSAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPK DTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG KAS Anti-Marco_11A8.3C9_H-V-hIgGK-C (SEQ ID NO: 77): ATGGAGTCACAGACTCAGGTCTTTGTATACATGTTGCTGTGGTTGTCTGGTGTTGATGGAGACAT TGTGATGACCCAGTCTCAAAAATTCATGTCCGCATCAGTAGGGGACAGGGTCAGCGTCACCTGC AGGGCCAGTCAGAATGTGGTTACTAATGTAGGCTGGTATCAACAGAAACCAGGGCAATCTCCT AAAGTACTGATTTACTCGGCATCCTTCCGGTACAGTGGAGTCCCTGATCGCTTCACAGGCAGTG GATCTGGGACAGATTTCACTCTCACCATCACCAATGTGCAGTCTGAAGACTTGGCAGAGTATTT CTGTCAGCAATATAACAACTATCCGTACACGTTCGGAGGGGGGACCAAGCTCGAGATCAAACG AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTG CCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGA TAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGC CTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTG TTAG Anti-Marco_11A8.3C9_H-V-hIgGK-C (SEQ ID NO: 142): MESQTQVFVYMLLWLSGVDGDIVMTQSQKFMSASVGDRVSVTCRASQNVVTNVGWYQQKPGQSP KVLIYSASFRYSGVPDRFTGSGSGTDFTLTITNVQSEDLAEYFCQQYNNYPYTFGGGTKLEIKRTVAA PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Anti-Marco_3H10.1F3_H-V-hIgG4H-C (SEQ ID NO: 78): ATGGGATGGAGCTATATCATCCTCTTTTTGGTAGCAACAGCTACAGATGTCCACTCCCAGGTCC AACTGCAGCAGCCTGGGGCTGAACTGGTGAAGCCTGGGGCTTCAGTGAAGCTGTCCTGCAAGG CTTCTGGCTACACCTTCACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGAGAAGGCCT TGAGTGGATTGGAGAGATTAATCCTAGCTACGGTCGTACTGACTACAATGGGAAGTTCAAGAAC AAGGCCACACTGACTGTAGCCAAATCCTCCAGCACAGCCTACATGCAACTCAGCAGCCTGACAT CTGAGGACTCTGCGGTCTATTACTGTGCAAGAGGAGATTACTACGGTAGTAGCTCGTTTGCTTA CTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCAGCCAAAACAAAGGGCCCATCCGTCTTCCCC CTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACT ACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGC AGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGAC AAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCACCCTGCCCAGCACCTGAGTTCGAAGGGG GACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGA GGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGT GGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTA CCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGC AAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAG CCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTC AGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCC TCTACAGCAGGCTAACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCG TGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAAGC TAGCTGA Anti-Marco_3H10.1F3_H-V-hIgG4H-C (SEQ ID NO: 143): MGWSYIILFLVATATDVHSQVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGEGLE WIGEINPSYGRTDYNGKFKNKATLTVAKSSSTAYMQLSSLTSEDSAVYYCARGDYYGSSSFAYWGQ GTLVTVSAAKTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKP KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSL GKAS Anti-Marco_3H10.1F3_K-V-hIgGK-C (SEQ ID NO: 79): ATGGAGTCACAGACTCAGGTCTTTGTATACATGTTGCTGTGGTTGTCTGGTGTTGATGGAGACAT TGTGATGACCCAGTCTCAAAAATTCATGTCCACATCATTAGGAGACAGGGTCAGCGTCACCTGC AAGGCCAGTCAGAATGTGGGTACTAATGTAGCCTGGTATCAACAGAAACCAGGGCACTCTCCT AAAGCACTGATTTACTCGGCATCCTACCGGTACAGTGGAGTCCCTGATCGCTTCACAGGCAGTG GATCTGGGACAGATTTCACTCTCACCATCAGCAATGTGCAGTCTGAAGACTTGGCAGAGTTTTT CTGTCAGCAATATAACAACTATCCGTACACGTTCGGAGGGGGGACCACGCTCGAGATCAAACG AACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTG CCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGA TAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCAC CTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTATGC CTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTG TTAG Anti-Marco_3H10.1F3_K-V-hIgGK-C (SEQ ID NO: 144): MESQTQVFVYMLLWLSGVDGDIVMTQSQKFMSTSLGDRVSVTCKASQNVGTNVAWYQQKPGHSP KALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEFFCQQYNNYPYTFGGGTTLEIKRTVAA PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0117] Humanized anti-CD40-HCV vaccine is: hAnti-CD40VK2-LV-hIgGK-C.times.hAnti-CD40VH3-LV-hIgG4H-C-Flex-v1-HelB-f1-- ProtB-f2-NS5BPalm, wherein the portion of HelB are underlined, the portions of ProtB are bold and the portions of NS5BPalm are italicized. The linker sequence (in bold italics) is flanked by the transition sequence "AS" that bracket the linker sequences

TABLE-US-00009 [hAnti-CD40VK2-LV-hIgGK-C] (SEQ ID NO: 158) DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAVKLLIYYTSILHSGVPSRFSGSGSG TDYTLTISSLQPEDFATYYCQQFNKLPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGEC hAnti-CD40VH3-LV-hIgG4H-C-Flex-v1-HelB-f1-ProtB-f2-NS5BPalm (SEQ ID NO: 159) EVQLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQAPGKGLEWVAYINSGGGSTYYPDTVK GRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGLPFHAMDYWGQGTLVTVSSAKTKGPSVFPL APCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS ASVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVAL GINAVAYYRGLDVSVIPTSGVVVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFSLDPTFTIETTTLP QDAVSRTQRRGRTGRGKPGIYRFVAPGERAS ASTPCTCGSSDL YLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVAKAVD FIPVENLETTMRSPVFTDNSSPPAVPQSAS ASVLDSHYQDVLKE VKAAASKVKANALYDVVSKLPLAVMGSSYGFQYSPGQRVEFLVQAWKSKKTPMGFSYDTRCFDSTVTESDI RTEEAIYQCCDLDPQARVAIKSLTERLYVGRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCTMLVCGD DLVVICESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITAS

[0118] Humanized anti-DCIR-HCV 1.sup.st generation vaccine is: [hAnti-DCIRVK4-LV-hIgGK-C].times.[hAnti-DCIRVH1-LV-hIgG4H-C-Flex-v1-HelB-- f1-ProtB-f2-NS5BPalm] wherein the portion of HelB are underlined, the portions of ProtB are bold and the portions of NS5BPalm are italicized. The linker sequence (in bold italics) is flanked by the transition sequence "AS" that bracket the linker sequences

TABLE-US-00010 hAnti-DCIRVK4-LV-hIgGK-C (SEQ ID NO: 160) DIVMTQSPDSLAVSLGERATINCRASESIHSYGNSFLHWYQQKPGQPPKLLIYLASNLESGVPSRFSG SGSRTDFTLTISSLQPEDFATYYCQQNNEDPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVT HQGLSSPVTKSFNRGEC hAnti-DCIRVH1-LV-hIgG4H-C-Flex-v1-HelB-f1-ProtB-f2-NS5BPalm (SEQ ID NO: 161) QVTLKESGPAIVKPTQTLTLTCSFSGFSLSTSGMGLSWIRQPSGKALEWLAHIYWDDDKRYNPSLKS RLTISKDTSKNQVVLTMTIVDTVDAATYYCARSSHYYGYGYGGYFDVWGQGTTVTVSSAKTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG LPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS ASVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKL VALGINAVAYYRGLDVSVIPTSGVVVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFSLDPTFTIET TTLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERAS ASTPCTCG SSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPAGHAVGIFRAAVCTRGVA KAVDFIPVENLETTMRSPVFTDNSSPPAVPQSAS ASVLDSHYQ DVLKEVKAAASKVKANALYDVVSKLPLAVMGSSYGFQYSPGQRVEFLVQAWKSKKTPMGFSYDTRCFDST VTESDIRTEEAIYQCCDLDPQARVAIKSLTERLYVGRCRASGVLTTSCGNTLTCYIKARAACRAAGLQDCTM LVCGDDLVVICESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITAS

[0119] Humanized anti-CD40-HCV vaccine is: hAnti-CD40VK2-LV-hIgGK-C-ViralHCVhelicasefgtB.times.hAnti-CD40VH3-LV-hIgG- 4H-C-Flex-v1-ProtB-f1-NS5BPalm, wherein the portion of ViralHCVhelicasefgtB are underlined, the portions of ProtB are bold and the portions of NS5BPalm are italicized. The linker sequence (in bold italics) is flanked by the transition sequence "AS" that bracket the linker sequences.

TABLE-US-00011 hAnti-CD40VK2-LV-hIgGK-C-ViralHCVhelicasefgtB (SEQ ID NO: 162) DIQMTQSPSSLSASVGDRVTITCSASQGISNYLNWYQQKPGKAVKLLIYYTSILHSGVPSRFSGSGSG TDYTLTISSLQPEDFATYYCQQFNKLPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLN NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLS SPVTKSFNRGECASVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELAAKLVA LGINAVAYYRGLDVSVIPTSGVVVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFSLDPTFTIETTTL PQDAVSRTQRRGRTGRGKPGIYRFVAPGERAS hAnti-CD40VH3-LV-hIgG4H-C-Flex-v1-ProtB-f1-NS5BPalm (SEQ ID NO: 163) EVQLVESGGGLVQPGGSLKLSCATSGFTFSDYYMYWVRQAPGKGLEWVAYINSGGGSTYYPDTVK GRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARRGLPFHAMDYWGQGTLVTVSSAKTKGPSVFPL APCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTK TYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS QEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSI EKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS ASTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLLCPA GHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPAVPQSAS ASVLDSHYQDVLKEVKAAASKVKANALYDVVSKLPLAVMGSSYGFQYSPGQRVEFLVQAW KSKKTPMGFSYDTRCFDSTVTESDIRTEEAIYQCCDLDPQARVAIKSLTERLYVGRCRASGVLTTSCGNTLT CYIKARAACRAAGLQDCTMLVCGDDLVVICESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLELITA S

[0120] Humanized anti-DCIR-HCV 2.sup.nd generation vaccine is: [hAnti-DCIRVK4-LV-hIgGK-C-ViralHCVhelicasefgtB].times.[hAnti-D CIRVH1-LV-hIgG4H-C--F lex-v1-ProtB-f1-NS5BPalm], wherein the portion of ViralHCVhelicasefgtB are underlined, the portions of ProtB are bold and the portions of NS5BPalm are italicized. The linker sequence (in bold italics) is flanked by the transition sequence "AS" that bracket the linker sequences.

TABLE-US-00012 hAnti-DCIRVK4-LV-hIgGK-C-ViralHCVhelicasefgtB (SEQ ID NO: 164) DIVMTQSPDSLAVSLGERATINCRASESIHSYGNSFLHWYQQKPGQPPKLLIYLASNLESGVPSRFSG SGSRTDFTLTISSLQPEDFATYYCQQNNEDPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVT HQGLSSPVTKSFNRGECASVTVPHPNIEEVALSTTGEIPFYGKAIPLEVIKGGRHLIFCHSKKKCDELA AKLVALGINAVAYYRGLDVSVIPTSGVVVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFSLDPTF TIETTTLPQDAVSRTQRRGRTGRGKPGIYRFVAPGERAS hAnti-DCIRVH1-LV-hIgG4H-C-Flex-v1-ProtB-f1-NS5BPalm (SEQ ID NO: 165) QVTLKESGPAIVKPTQTLTLTCSFSGFSLSTSGMGLSWIRQPSGKALEWLAHIYWDDDKRYNPSLKS RLTISKDTSKNQVVLTMTIVDTVDAATYYCARSSHYYGYGYGGYFDVWGQGTTVTVSSAKTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS LGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG LPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKAS ASTPCTCGSSDLYLVTRHADVIPVRRRGDSRGSLLSPRPISYLKGSSGGPLL CPAGHAVGIFRAAVCTRGVAKAVDFIPVENLETTMRSPVFTDNSSPPAVPQSAS ASVLDSHYQDVLKEVKAAASKVKANALYDVVSKLPLAVMGSSYGFQYSPGQRVEFLV QAWKSKKTPMGFSYDTRCFDSTVTESDIRTEEAIYQCCDLDPQARVAIKSLTERLYVGRCRASGVLTTSCGN TLTCYIKARAACRAAGLQDCTMLVCGDDLVVICESAGVQEDAASLRAFTEAMTRYSAPPGDPPQPEYDLEL ITAS

[0121] Linkers can be a small as 2 amino acids, e.g., AS, but can also be longer, e.g., SSVSPTTSVHPTPTSVPPTPTKSSP (SEQ ID NO.: 166); PTSTPADSSTITPTATPTATPTIKG (SEQ ID NO.: 167); TVTPTATATPSAIVTTITPTATTKP (SEQ ID NO.: 168); TNGSITVAATAPTVTPTVNATPSAA (SEQ ID NO.: 169) or QTPTNTISVTPTNNSTPTNNSNPKPNP (SEQ ID NO:170).

[0122] It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method, kit, reagent, or composition of the invention, and vice versa. Furthermore, compositions of the invention can be used to achieve methods of the invention.

[0123] It will be understood that particular embodiments described herein are shown by way of illustration and not as limitations of the invention. The principal features of this invention can be employed in various embodiments without departing from the scope of the invention. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the claims.

[0124] All publications and patent applications mentioned in the specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

[0125] The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one." The use of the term "or" in the claims is used to mean "and/or" unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and "and/or." Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.

[0126] As used in this specification and claim(s), the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include") or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0127] The term "or combinations thereof" as used herein refers to all permutations and combinations of the listed items preceding the term. For example, "A, B, C, or combinations thereof" is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if order is important in a particular context, also BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, expressly included are combinations that contain repeats of one or more item or term, such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth. The skilled artisan will understand that typically there is no limit on the number of items or terms in any combination, unless otherwise apparent from the context.

[0128] All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

[0129] U.S. Patent Application Publication No. 2009/0238822: Chimeric HCV Antigens for Eliciting an Immune Response. [0130] U.S. Patent Application Publication No. 2008/0241170: Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells. [0131] U.S. Patent Application Publication No. 2010/0239575: Anti-CD-40 Antibodies and Uses Thereof

Sequence CWU 1

1

1701191PRTHepatitis C virus 1Tyr Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys1 5 10 15Pro Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His Thr 20 25 30Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys Trp 35 40 45Val Ala Val Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Thr 50 55 60Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu65 70 75 80Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val 85 90 95Gly Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp 100 105 110Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala 115 120 125Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Val Val Ala Gln 130 135 140Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His145 150 155 160Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 165 170 175Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala 180 185 1902363PRTHepatitis C virus 2Glu Thr His Val Thr Gly Gly Ser Ala Ala Arg Thr Thr Ala Gly Leu1 5 10 15Ala Gly Leu Phe Thr Pro Gly Ala Lys Gln Asn Ile Gln Leu Ile Asn 20 25 30Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp 35 40 45Ser Leu Asn Thr Gly Trp Val Ala Gly Leu Phe Tyr Tyr His Lys Phe 50 55 60Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Pro Leu Thr65 70 75 80Asp Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser Gly 85 90 95Pro Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly 100 105 110Ile Val Pro Ala Lys Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro 115 120 125Ser Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr Tyr 130 135 140Asn Trp Gly Glu Asn Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg145 150 155 160Pro Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly 165 170 175Phe Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly Val Gly 180 185 190Asn Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro Glu 195 200 205Ala Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys 210 215 220Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Ile Asn225 230 235 240Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly Gly Val Glu His Arg 245 250 255Leu Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Glu 260 265 270Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln 275 280 285Trp Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser Thr 290 295 300Gly Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr Leu Tyr305 310 315 320Gly Val Gly Ser Ser Ile Ala Ser Trp Ala Ile Lys Trp Glu Tyr Val 325 330 335Val Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ser Cys Leu 340 345 350Trp Met Met Leu Leu Ile Ser Gln Ala Glu Ala 355 3603631PRTHepatitis C virus 3Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu Gly Cys1 5 10 15Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu 20 25 30Val Gln Ile Val Ser Thr Ala Ala Gln Thr Phe Leu Ala Thr Cys Ile 35 40 45Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr Ile 50 55 60Ala Ser Pro Lys Gly Pro Val Ile Gln Met Tyr Thr Asn Val Asp Gln65 70 75 80Asp Leu Val Gly Trp Pro Ala Pro Gln Gly Ala Arg Ser Leu Thr Pro 85 90 95Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp 100 105 110Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser 115 120 125Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu 130 135 140Cys Pro Ala Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr145 150 155 160Arg Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu 165 170 175Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala 180 185 190Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser 195 200 205Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys 210 215 220Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala225 230 235 240Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val 245 250 255Arg Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys 260 265 270Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile 275 280 285Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly 290 295 300Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu305 310 315 320Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile 325 330 335Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys 340 345 350Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys 355 360 365His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu 370 375 380Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile385 390 395 400Pro Thr Ser Gly Val Val Val Val Val Ala Thr Asp Ala Leu Met Thr 405 410 415Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val 420 425 430Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr 435 440 445Thr Thr Leu Pro Gln Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg 450 455 460Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu465 470 475 480Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp 485 490 495Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg 500 505 510Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His 515 520 525Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala 530 535 540His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu545 550 555 560Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro 565 570 575Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu 580 585 590His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu 595 600 605Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Thr Cys Met Ser 610 615 620Ala Asp Leu Glu Val Val Thr625 6304196PRTHepatitis C virus 4Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu Gly Cys1 5 10 15Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu 20 25 30Val Gln Ile Val Ser Thr Ala Ala Gln Thr Phe Leu Ala Thr Cys Ile 35 40 45Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr Ile 50 55 60Ala Ser Pro Lys Gly Pro Val Ile Gln Met Tyr Thr Asn Val Asp Gln65 70 75 80Asp Leu Val Gly Trp Pro Ala Pro Gln Gly Ala Arg Ser Leu Thr Pro 85 90 95Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp 100 105 110Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser 115 120 125Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu 130 135 140Cys Pro Ala Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr145 150 155 160Arg Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu 165 170 175Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala 180 185 190Val Pro Gln Ser 1955435PRTHepatitis C virus 5Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr1 5 10 15Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu 20 25 30Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys 35 40 45Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr 50 55 60Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp65 70 75 80Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys 85 90 95His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val Leu Asp 100 105 110Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr 115 120 125Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala 130 135 140Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu145 150 155 160Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys 165 170 175Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala 180 185 190Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly 195 200 205Val Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Phe Thr Gly 210 215 220Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val225 230 235 240Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr Thr Leu Pro 245 250 255Gln Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly 260 265 270Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser Gly 275 280 285Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala 290 295 300Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala Tyr305 310 315 320Met Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp 325 330 335Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser 340 345 350Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln 355 360 365Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln 370 375 380Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr385 390 395 400Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val Thr Leu Thr 405 410 415His Pro Ile Thr Lys Tyr Ile Met Thr Cys Met Ser Ala Asp Leu Glu 420 425 430Val Val Thr 4356591PRTHepatitis C virus 6 Ser Met Ser Tyr Ser Trp Thr Gly Ala Leu Val Thr Pro Cys Ala Ala1 5 10 15Glu Glu Gln Lys Leu Pro Ile Asn Ala Leu Ser Asn Ser Leu Leu Arg 20 25 30His His Asn Leu Val Tyr Ser Thr Thr Ser Arg Ser Ala Cys Gln Arg 35 40 45Gln Lys Lys Val Thr Phe Asp Arg Leu Gln Val Leu Asp Ser His Tyr 50 55 60Gln Asp Val Leu Lys Glu Val Lys Ala Ala Ala Ser Lys Val Lys Ala65 70 75 80Asn Leu Leu Ser Val Glu Glu Ala Cys Ser Leu Thr Pro Pro His Ser 85 90 95Ala Lys Ser Lys Phe Gly Tyr Gly Ala Lys Asp Val Arg Cys His Ala 100 105 110Arg Lys Ala Val Asn His Ile Asn Ser Val Trp Lys Asp Leu Leu Glu 115 120 125Asp Ser Val Thr Pro Ile Asp Thr Thr Ile Met Ala Lys Asn Glu Val 130 135 140Phe Cys Val Gln Pro Glu Lys Gly Gly Arg Lys Pro Ala Arg Leu Ile145 150 155 160Val Phe Pro Asp Leu Gly Val Arg Val Cys Glu Lys Met Ala Leu Tyr 165 170 175Asp Val Val Ser Lys Leu Pro Leu Ala Val Met Gly Ser Ser Tyr Gly 180 185 190Phe Gln Tyr Ser Pro Gly Gln Arg Val Glu Phe Leu Val Gln Ala Trp 195 200 205Lys Ser Lys Lys Thr Pro Met Gly Phe Ser Tyr Asp Thr Arg Cys Phe 210 215 220Asp Ser Thr Val Thr Glu Ser Asp Ile Arg Thr Glu Glu Ala Ile Tyr225 230 235 240Gln Cys Cys Asp Leu Asp Pro Gln Ala Arg Val Ala Ile Lys Ser Leu 245 250 255Thr Glu Arg Leu Tyr Val Gly Gly Pro Leu Thr Asn Ser Arg Gly Glu 260 265 270Asn Cys Gly Tyr Arg Arg Cys Arg Ala Ser Gly Val Leu Thr Thr Ser 275 280 285Cys Gly Asn Thr Leu Thr Cys Tyr Ile Lys Ala Arg Ala Ala Cys Arg 290 295 300Ala Ala Gly Leu Gln Asp Cys Thr Met Leu Val Cys Gly Asp Asp Leu305 310 315 320Val Val Ile Cys Glu Ser Ala Gly Val Gln Glu Asp Ala Ala Ser Leu 325 330 335Arg Ala Phe Thr Glu Ala Met Thr Arg Tyr Ser Ala Pro Pro Gly Asp 340 345 350Pro Pro Gln Pro Glu Tyr Asp Leu Glu Leu Ile Thr Ser Cys Ser Ser 355 360 365Asn Val Ser Val Ala His Asp Gly Ala Gly Lys Arg Val Tyr Tyr Leu 370 375 380Thr Arg Asp Pro Thr Thr Pro Leu Ala Arg Ala Ala Trp Glu Thr Ala385 390 395 400Arg His Thr Pro Val Asn Ser Trp Leu Gly Asn Ile Ile Met Phe Ala 405 410 415Pro Thr Leu Trp Ala Arg Met Ile Leu Met Thr His Phe Phe Ser Val 420 425 430Leu Ile Ala Arg Asp Gln Leu Glu Gln Ala Leu Asp Cys Glu Ile Tyr 435 440 445Gly Ala Cys Tyr Ser Ile Glu Pro Leu Asp Leu Pro Pro Ile Ile Gln 450 455 460Arg Leu His Gly Leu Ser Ala Phe Ser Leu His Ser Tyr Ser Pro Gly465 470 475 480Glu Ile Asn Arg Val Ala Ala Cys Leu Arg Lys Leu Gly Val Pro Pro 485 490 495Leu Arg Ala Trp Arg His Arg Ala Arg Ser Val Arg Ala Arg Leu Leu 500 505 510Ser Arg Gly Gly Arg Ala Ala Ile Cys Gly Lys Tyr Leu Phe Asn Trp 515 520 525Ala Val Arg Thr Lys Leu Lys Leu Thr Pro Ile Ala Ala Ala Gly Gln 530 535 540Leu Asp Leu Ser Gly Trp Phe Thr Ala Gly Tyr Ser Gly Gly Asp Ile545 550 555 560Tyr His Ser Val Ser His Ala Arg Pro Arg Trp Phe Trp Phe Cys Leu 565 570 575Leu Leu Leu Ala Ala Gly Val Gly Ile Tyr Leu Leu Pro Asn Arg 580 585 590767PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 7Thr Ser Val Gly Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr1 5 10 15Thr Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His 20 25 30Arg Met Ala Trp Asp Met Met Met Asn

Trp Ser Pro Thr Thr Ala Val 35 40 45Val Ala Gln Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala 50 55 60Gly Ala Ser658346PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 8Thr Ser Glu Thr His Val Thr Gly Gly Ser Ala Ala Arg Thr Thr Ala1 5 10 15Gly Leu Ala Gly Leu Phe Thr Pro Gly Ala Lys Gln Asn Ile Gln Leu 20 25 30Ile Asn Thr Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys 35 40 45Asn Asp Ser Leu Asn Thr Gly Trp Val Ala Gly Leu Phe Tyr Tyr His 50 55 60Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Pro65 70 75 80Leu Thr Asp Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly 85 90 95Ser Gly Pro Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro Pro Lys Pro 100 105 110Cys Gly Ile Val Pro Ala Lys Ser Val Cys Gly Pro Val Tyr Cys Phe 115 120 125Thr Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro 130 135 140Thr Tyr Asn Trp Gly Glu Asn Asp Thr Asp Val Phe Val Leu Asn Asn145 150 155 160Thr Arg Pro Pro Leu Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser 165 170 175Thr Gly Phe Thr Lys Val Cys Gly Ala Pro Pro Cys Val Ile Gly Gly 180 185 190Val Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His 195 200 205Pro Glu Ala Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro 210 215 220Arg Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr225 230 235 240Ile Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly Gly Val Glu 245 250 255His Arg Leu Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp 260 265 270Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr 275 280 285Thr Gln Trp Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu 290 295 300Ser Thr Gly Leu Ile His Leu His Gln Asn Ile Val Asp Val Gln Tyr305 310 315 320Leu Tyr Gly Val Gly Ser Ser Ile Ala Ser Trp Ala Ile Lys Trp Glu 325 330 335Tyr Val Val Leu Leu Phe Leu Leu Ala Ser 340 345968PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 9Thr Ser Ala Pro Ile Thr Ala Tyr Ala Gln Gln Thr Arg Gly Leu Leu1 5 10 15Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu 20 25 30Gly Glu Val Gln Ile Val Ser Thr Ala Ala Gln Thr Phe Leu Ala Thr 35 40 45Cys Ile Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg 50 55 60Thr Ile Ala Ser6510106PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 10Thr Ser Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr1 5 10 15Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly 20 25 30Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser Ser Gly 35 40 45Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Ile Phe Arg Ala 50 55 60Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val65 70 75 80Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser 85 90 95Ser Pro Pro Ala Val Pro Gln Ser Ala Ser 100 10511136PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 11Thr Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly Lys1 5 10 15Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu 20 25 30Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met 35 40 45Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr 50 55 60Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu65 70 75 80Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp 85 90 95Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr Val 100 105 110Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr 115 120 125Ala Thr Pro Pro Gly Ser Ala Ser 130 13512157PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 12Thr Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser1 5 10 15Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val 20 25 30Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys 35 40 45Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala 50 55 60Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Val Val65 70 75 80Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Phe Thr Gly Asp Phe 85 90 95Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe 100 105 110Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr Thr Leu Pro Gln Asp 115 120 125Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro 130 135 140Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Ala Ser145 150 15513154PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 13Thr Ser Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr1 5 10 15Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val 20 25 30Arg Leu Arg Ala Tyr Met Asn Thr Pro Gly Leu Pro Val Cys Gln Asp 35 40 45His Leu Glu Phe Trp Glu Gly Val Phe Thr Gly Leu Thr His Ile Asp 50 55 60Ala His Phe Leu Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr65 70 75 80Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro 85 90 95Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr 100 105 110Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn 115 120 125Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Thr Cys Met 130 135 140Ser Ala Asp Leu Glu Val Val Thr Ala Ser145 15014204PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 14Thr Ser Val Leu Asp Ser His Tyr Gln Asp Val Leu Lys Glu Val Lys1 5 10 15Ala Ala Ala Ser Lys Val Lys Ala Asn Ala Leu Tyr Asp Val Val Ser 20 25 30Lys Leu Pro Leu Ala Val Met Gly Ser Ser Tyr Gly Phe Gln Tyr Ser 35 40 45Pro Gly Gln Arg Val Glu Phe Leu Val Gln Ala Trp Lys Ser Lys Lys 50 55 60Thr Pro Met Gly Phe Ser Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val65 70 75 80Thr Glu Ser Asp Ile Arg Thr Glu Glu Ala Ile Tyr Gln Cys Cys Asp 85 90 95Leu Asp Pro Gln Ala Arg Val Ala Ile Lys Ser Leu Thr Glu Arg Leu 100 105 110Tyr Val Gly Arg Cys Arg Ala Ser Gly Val Leu Thr Thr Ser Cys Gly 115 120 125Asn Thr Leu Thr Cys Tyr Ile Lys Ala Arg Ala Ala Cys Arg Ala Ala 130 135 140Gly Leu Gln Asp Cys Thr Met Leu Val Cys Gly Asp Asp Leu Val Val145 150 155 160Ile Cys Glu Ser Ala Gly Val Gln Glu Asp Ala Ala Ser Leu Arg Ala 165 170 175Phe Thr Glu Ala Met Thr Arg Tyr Ser Ala Pro Pro Gly Asp Pro Pro 180 185 190Gln Pro Glu Tyr Asp Leu Glu Leu Ile Thr Ala Ser 195 200151409DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 15atgggcaggc ttacttcttc attcttgcta ctgattgtcc ctgcatatgt cctgtcccag 60gttactctga aagagtctgg ccctgggata ttgcagccct cccagaccct cagtctgacc 120tgttctttct ctgggttttc actgagcact tctggtatga gtgtaggctg gattcgtcag 180ccttcaggga agggtctgga gtggctggct cacatttggt ggaatgatga taagtactat 240aatccagtcc tgaaaagccg gctcacaatc tccaaggaga cctccaacaa ccaggtattc 300ctcaagatcg ccagtgtggt ctctgcagat actgccacat actactgtgc tcgattctat 360ggtaactgtc ttgactactg gggccaaggc accactctca cagtctcctc ggccaaaaca 420aagggcccat ccgtcttccc cctggcgccc tgctccagga gcacctccga gagcacagcc 480gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca 540ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac 600tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacgaagac ctacacctgc 660aacgtagatc acaagcccag caacaccaag gtggacaaga gagttgagtc caaatatggt 720cccccatgcc caccctgccc agcacctgag ttcgaagggg gaccatcagt cttcctgttc 780cccccaaaac ccaaggacac tctcatgatc tcccggaccc ctgaggtcac gtgcgtggtg 840gtggacgtga gccaggaaga ccccgaggtc cagttcaact ggtacgtgga tggcgtggag 900gtgcataatg ccaagacaaa gccgcgggag gagcagttca acagcacgta ccgtgtggtc 960agcgtcctca ccgtcctgca ccaggactgg ctgaacggca aggagtacaa gtgcaaggtc 1020tccaacaaag gcctcccgtc ctccatcgag aaaaccatct ccaaagccaa agggcagccc 1080cgagagccac aggtgtacac cctgccccca tcccaggagg agatgaccaa gaaccaggtc 1140agcctgacct gcctggtcaa aggcttctac cccagcgaca tcgccgtgga gtgggagagc 1200aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc cgacggctcc 1260ttcttcctct acagcaggct aaccgtggac aagagcaggt ggcaggaggg gaatgtcttc 1320tcatgctccg tgatgcatga ggctctgcac aaccactaca cacagaagag cctctccctg 1380tctctgggta aagctagctg attaattaa 140916705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 16atgatgtcct ctgctcagtt ccttggtctc ctgttgctct gttttcaagg taccagatgt 60gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 120atcagttgca gggcaagtca ggacattagc aattatttaa actggtatca gcagaaacca 180gatggaactg ttaaactcct gatctactac acatcaatat tacaattagg agtcccatca 240agattcagtg gcagtgggtc tgaaacagat tattctctca ccattagcaa cctggagcaa 300gaagatattg ccacttactt ttgccaacag ggtgattcgc ttccattcac gttcggctcg 360gggacaaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705171403DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 17atgagagcgc tgattctttt gtgcctgttc acagcctttc ctggtatcct gtctgatgtg 60cagcttcagg agtcaggacc tgacctggtg aaaccttctc agtcactttc actcacctgc 120actgtcactg gctactccat caccagtggt tatagctggc actggatccg gcagtttcca 180ggaaacaaac tggaatggat gggctacata ctcttcagtg gtagcactaa ctacaaccca 240tctctgaaaa gtcgaatctc tatcactcga gacacatcca agaaccagtt cttcctgcag 300ttgaattctg tgactactga ggacacagcc acatatttct gtgcaagatc taactatggt 360tcctttgctt cctggggcca agggactctg gtcactgtct ctgcagccaa aacaacgggc 420ccatccgtct tccccctggc gccctgctcc aggagcacct ccgagagcac agccgccctg 480ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc 540ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact ctactccctc 600agcagcgtgg tgaccgtgcc ctccagcagc ttgggcacga agacctacac ctgcaacgta 660gatcacaagc ccagcaacac caaggtggac aagagagttg agtccaaata tggtccccca 720tgcccaccct gcccagcacc tgagttcgaa gggggaccat cagtcttcct gttcccccca 780aaacccaagg acactctcat gatctcccgg acccctgagg tcacgtgcgt ggtggtggac 840gtgagccagg aagaccccga ggtccagttc aactggtacg tggatggcgt ggaggtgcat 900aatgccaaga caaagccgcg ggaggagcag ttcaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc tgcaccagga ctggctgaac ggcaaggagt acaagtgcaa ggtctccaac 1020aaaggcctcc cgtcctccat cgagaaaacc atctccaaag ccaaagggca gccccgagag 1080ccacaggtgt acaccctgcc cccatcccag gaggagatga ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctaccccagc gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca ggctaaccgt ggacaagagc aggtggcagg aggggaatgt cttctcatgc 1320tccgtgatgc atgaggctct gcacaaccac tacacacaga agagcctctc cctgtctctg 1380ggtaaagcta gctgattaat taa 140318708DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 18atggattttc aagtgcagat tttcagcttc ctgctaatca gtgcctcagt cataatatcc 60agaggacaaa ttgttctcac ccagtctcca gcaatcatgt ctgcatctcc aggggagaag 120gtcaccatga cctgcagtgc cagctcaagt gtaagtcaca tgcactggta ccagcagaag 180tcaggcactt cccccaaaag atggatttat gacacatcca gactggcttc tggagtccct 240gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagcatggag 300gctgaagatg ctgccactta ttactgccag cagtggagta gtcacccatg gtcgttcggt 360ggaggcacca aactcgagat caaacgaact gtggctgcac catctgtctt catcttcccg 420ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 540caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 600acgctgagca aagcagacta cgagaaacac aaagtctatg cctgcgaagt cacccatcag 660ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttag 708191415DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 19atggcttggg tgtggacctt gctattcctg atggcagctg cccaaagtgc ccaagcacag 60atccagttgg tgcagtctgg acctgagctg aagaagcctg gagagacagt caagatctcc 120tgcaaggctt ctgggtatac cttcacaaac tatggaatga actgggtgaa gcaggttcca 180ggaaaaggtt taaggtggat gggctggatg gacaccttca ctggagagcc aacatatgct 240gatgacttca agggacggtt tgccttctct ttggaaacct ctgccagcac tgcctatttg 300cagatcaaca gcctcaaaaa tgaggacacg gctacttatt tctgtgcaag aggggggatt 360ttacgactca actactttga ctactggggc caaggcacca ctctcacagt ctcctcagcc 420aaaacgaagg gcccatccgt cttccccctg gcgccctgct ccaggagcac ctccgagagc 480acagccgccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg 540aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga 600ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac gaagacctac 660acctgcaacg tagatcacaa gcccagcaac accaaggtgg acaagagagt tgagtccaaa 720tatggtcccc catgcccacc ctgcccagca cctgagttcg aagggggacc atcagtcttc 780ctgttccccc caaaacccaa ggacactctc atgatctccc ggacccctga ggtcacgtgc 840gtggtggtgg acgtgagcca ggaagacccc gaggtccagt tcaactggta cgtggatggc 900gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agttcaacag cacgtaccgt 960gtggtcagcg tcctcaccgt cctgcaccag gactggctga acggcaagga gtacaagtgc 1020aaggtctcca acaaaggcct cccgtcctcc atcgagaaaa ccatctccaa agccaaaggg 1080cagccccgag agccacaggt gtacaccctg cccccatccc aggaggagat gaccaagaac 1140caggtcagcc tgacctgcct ggtcaaaggc ttctacccca gcgacatcgc cgtggagtgg 1200gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac 1260ggctccttct tcctctacag caggctaacc gtggacaaga gcaggtggca ggaggggaat 1320gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacaca gaagagcctc 1380tccctgtctc tgggtaaagc tagctgatta attaa 141520705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 20atgaagtttc cttctcaact tctgctctta ctgctgtttg gaatcccagg catgatatgt 60gacatccaga tgacacaatc ttcatcctcc ttttctgtat ctctaggaga cagagtcacc 120attacttgca aggcaagtga ggacatatat aatcggttag gctggtatca gcagaaacca 180ggaaatgctc ctaggctctt aatatctggt gcaaccagtt tggaaactgg ggttccttca 240agattcagtg gcagtggatc tggaaaggat tacgctctca gcattaccag tcttcagact 300gaagatcttg ctacttatta ctgtcaacag tgttggactt ctccgtacac gttcggaggg 360gggaccaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705211398DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 21atgggatgga gctggatctt tctctttctc ttgtcaggaa ctggaggtgt cctctctgag 60gtccagctgc aacagtctgg acctgagctg gtgaagcctg gggcttcagt gaagatgtcc 120tgcaaggctt ctggatacac cttcactgac tactacatga agtgggtgaa gcagagccat 180ggaaagagcc ttgagtggat tggagatatt

aatcctaact atggtgatac tttctacaac 240cagaagttcg agggcaaggc cacattgact gtagacaaat cctccaggac agcctacatg 300cagctcaaca gcctgacatc tgaggactct gcagtctatt attgtggaag aggggactat 360ggatacttcg atgtctgggg cgcagggacc acggtcaccg tctcctcagc caaaacaaag 420ggcccatccg tcttccccct ggcgccctgc tccaggagca cctccgagag cacagccgcc 480ctgggctgcc tggtcaagga ctacttcccc gaaccggtga cggtgtcgtg gaactcaggc 540gccctgacca gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc 600ctcagcagcg tggtgaccgt gccctccagc agcttgggca cgaagaccta cacctgcaac 660gtagatcaca agcccagcaa caccaaggtg gacaagagag ttgagtccaa atatggtccc 720ccatgcccac cctgcccagc acctgagttc gaagggggac catcagtctt cctgttcccc 780ccaaaaccca aggacactct catgatctcc cggacccctg aggtcacgtg cgtggtggtg 840gacgtgagcc aggaagaccc cgaggtccag ttcaactggt acgtggatgg cgtggaggtg 900cataatgcca agacaaagcc gcgggaggag cagttcaaca gcacgtaccg tgtggtcagc 960gtcctcaccg tcctgcacca ggactggctg aacggcaagg agtacaagtg caaggtctcc 1020aacaaaggcc tcccgtcctc catcgagaaa accatctcca aagccaaagg gcagccccga 1080gagccacagg tgtacaccct gcccccatcc caggaggaga tgaccaagaa ccaggtcagc 1140ctgacctgcc tggtcaaagg cttctacccc agcgacatcg ccgtggagtg ggagagcaat 1200gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc 1260ttcctctaca gcaggctaac cgtggacaag agcaggtggc aggaggggaa tgtcttctca 1320tgctccgtga tgcatgaggc tctgcacaac cactacacac agaagagcct ctccctgtct 1380ctgggtaaag ctagctga 139822705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 22atggagacac attctcaggt ctttgtatac atgttgctgt ggttgtctgg tgttgaagga 60gacattgtga tgacccagtc tcacaaattc atgtccacat cagtaggaga cagggtcagc 120atcacctgca aggccagtca ggatgtgggt actgctgtag cctggtatca acagaaacca 180gggcaatctc ctaaactact gatttactgg gcatccaccc ggcacactgg agtccctgat 240cgcttcacag gcagtggatc tgggacagat ttcactctca ccattaacaa tgtgcagtct 300gaagacttgg cagattattt ctgtcagcaa tatagcagca atccgtacat gttcggaggg 360gggaccaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705231413DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 23atgggatgga gctggatctt tctctttctc ctgtcaggaa ctgcaggtgt cctctctgag 60gtccagctgc aacagtctgg acctgagttg gtgaagcctg gggcttcagt gaagatatcc 120tgcaagactt ctggatacac attcactgaa tacaccatgc actgggtgag gcagagccat 180ggaaagagcc ttgagtggat tggaggtatt aatcctatca atggtggtcc tacctacaac 240cagaagttca agggcaaggc cacattgact gttgacaagt cctccagcac agcctacatg 300gagctccgca gcctgacatc tgaggactct gcagtctatt actgtgcaag atgggactat 360ggtagtcgag atgttatgga ctactggggt caaggaacct cagtcaccgt ctcctcagcc 420aaaacgaagg gcccatccgt cttccccctg gcgccctgct ccaggagcac ctccgagagc 480acagccgccc tgggctgcct ggtcaaggac tacttccccg aaccggtacc ggtgacggtg 540tcgtggaact caggcgccct gaccagcggc gtgcacacct tcccggctgt cctacagtcc 600tcaggactct actccctcag cagcgtggtg accgtgccct ccagcagctt gggcacgaag 660acctacacct gcaacgtaga tcacaagccc agcaacacca aggtggacaa gagagttgag 720tccaaatatg gtcccccatg cccaccctgc ccagcacctg agttcgaagg gggaccatca 780gtcttcctgt tccccccaaa acccaaggac actctcatga tctcccggac ccctgaggtc 840acgtgcgtgg tggtggacgt gagccaggaa gaccccgagg tccagttcaa ctggtacgtg 900gatggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagtt caacagcacg 960taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaacgg caaggagtac 1020aagtgcaagg tctccaacaa aggcctcccg tcctccatcg agaaaaccat ctccaaagcc 1080aaagggcagc cccgagagcc acaggtgtac accctgcccc catcccagga ggagatgacc 1140aagaaccagg tcagcctgac ctgcctggtc aaaggcttct accccagcga catcgccgtg 1200gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac 1260tccgacggct ccttcttcct ctacagcagg ctaaccgtgg acaagagcag gtggcaggag 1320gggaatgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cacacagaag 1380agcctctccc tgtctctggg taaagctagc tga 141324705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 24atggaatcac agactctggt cttcatatcc atactgctct ggttatatgg tgctgatggg 60aacattgtaa tgactcaatc tcccaaatcc atgtccatgt cagtagggga gagggtcacc 120ttgagctgca aggccagtga gaatgtggga acttatgtat cctggtatca acagagacca 180gaacagtctc caaaactgct gatatacggg gcatccaacc ggtacactgg ggtccccgat 240cgcttcacag gcagtggatc tgcaacagat ttcactctga ccatcagcag tgtgcaggct 300gaggaccttg cagattatca ctgtggacag acttacagct atatattcac gttcggctcg 360gggacaaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705251404DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 25atgggatgga gccggatctt tctcttcctc ctgtcaataa ctgcaggtgt ccattgccag 60gtccaggtgc agcagtcggg acctgagttg gtgaagcctg gggcctcagt gaagatttcc 120tgcaaagcct ctggcgacgc attcagtagt tcttggatga actgggtgaa gcagaggcct 180ggacagggtc ttgagtggat tggacggatt tatcttggag atggagatat taattacaat 240gggaagttca agggcagggc cacactgact gcagacaaat cctccagcac agcctacatg 300cagctcagca gcctgacctc tgtggactct gcggtctatt tctgcgcgag gcagctcggg 360ctatggtatg ttatggacta ctggggtcaa ggaacctcag tcaccgtctc ctcagccaaa 420acaaagggcc catccgtctt ccccctggcg ccctgctcca ggagcacctc cgagagcaca 480gccgccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 540tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 600tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcacgaa gacctacacc 660tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agagagttga gtccaaatat 720ggtcccccat gcccaccctg cccagcacct gagttcgaag ggggaccatc agtcttcctg 780ttccccccaa aacccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 840gtggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 900gaggtgcata atgccaagac aaagccgcgg gaggagcagt tcaacagcac gtaccgtgtg 960gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 1020gtctccaaca aaggcctccc gtcctccatc gagaaaacca tctccaaagc caaagggcag 1080ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1140gtcagcctga cctgcctggt caaaggcttc taccccagcg acatcgccgt ggagtgggag 1200agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1260tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1320ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1380ctgtctctgg gtaaagctag ctga 140426705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 26atgagtgtgc ccactcaggt cctggggttg ctgctgctgt ggcttacagg tgccagatgt 60gacatccaga tggctcagtc tccagcctcc ctatctgcat ctgtgggaga aactgtcacc 120atcacatgtc gagcaagtga gaatatttac agttatttag catggtatca gcagaaacag 180ggaaaatctc ctcagctcct ggtctataat gcaaaaacct tagcagaagg tgtgccatca 240aggttcagtg gcagtggatc aggcacacag ttttctctga agatcaacag cctgcagcct 300gaagattttg ggagttatta ctgtcaacat cattatggtt ttccgtggac gttcggtgga 360ggcaccaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705271395DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 27atgaacttcg ggctcagctt gattttcctt gtcctcattt taaaaggtgt ccagtgtgag 60gtgcagctgg tggagtctgg gggagactta gtgaagcctg gagggtccct gaaactctcc 120tgtgcagcct ctggattcac tttcagtagc tatggcatgt cttgggttcg ccagactcca 180gacaagaggc tggagtgggt cgcagtcatt agtagtggtg gaagttccac cttctatcca 240gacagtgtga aggggcgatt caccatctcc agagacaatg ccaagaacac cctgtacctg 300caaatgagca gtctgaagtc tgaggacaca gccgtgtatt actgttcaag aggaggttac 360tactttgact actggggcca aggcaccact ctcacagtct ccgcagccaa aacaaagggc 420ccatccgtct tccccctggc gccctgctcc aggagcacct ccgagagcac agccgccctg 480ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc 540ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact ctactccctc 600agcagcgtgg tgaccgtgcc ctccagcagc ttgggcacga agacctacac ctgcaacgta 660gatcacaagc ccagcaacac caaggtggac aagagagttg agtccaaata tggtccccca 720tgcccaccct gcccagcacc tgagttcgaa gggggaccat cagtcttcct gttcccccca 780aaacccaagg acactctcat gatctcccgg acccctgagg tcacgtgcgt ggtggtggac 840gtgagccagg aagaccccga ggtccagttc aactggtacg tggatggcgt ggaggtgcat 900aatgccaaga caaagccgcg ggaggagcag ttcaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc tgcaccagga ctggctgaac ggcaaggagt acaagtgcaa ggtctccaac 1020aaaggcctcc cgtcctccat cgagaaaacc atctccaaag ccaaagggca gccccgagag 1080ccacaggtgt acaccctgcc cccatcccag gaggagatga ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctaccccagc gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca ggctaaccgt ggacaagagc aggtggcagg aggggaatgt cttctcatgc 1320tccgtgatgc atgaggctct gcacaaccac tacacacaga agagcctctc cctgtctctg 1380ggtaaagcta gctga 139528705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 28atgaggttcc aggttcaggt tctggggctc cttctgctct ggatatcagg tgcccagtgt 60gatgtccaga taacccagtc tccatcttat cttgctgcat ctcctggaga aaccattact 120attaattgca gggcaagcaa gaccattagc aaatatttag cctggtatca agagaaacct 180gagaaaactg ataagcttct tatctactct ggatccactt tgcaatctgg aattccatca 240aggttcagtg gcagtggatc tggtacagat ttcactctca ccatcagtgg cctggagcct 300gaagattttg caatgtatta ctgtcaacag cataatgaat acccgtggac gttcggtgga 360ggcaccaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705291389DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 29atgggatgga gctggatctt tctctttctc ctgtcaggaa ctgcaggtgt cctctctgag 60gtccagctgc aacagtctgg acctgagctg gtgaagcctg gggcttcagt gaagatatcc 120tgcaaggctt ctggttactc attcactggc tactacatgc actgggtgaa gcaaagccat 180gtaaagagcc ttgagtggat tggacgtatt aatccttaca atggtgctac tagctacaac 240cagaatttca aggacaaggc cagcttgact gtagataagt cctccagcac agcctacatg 300gagctccaca gcctgacatc tgaggactct gcagtctatt actgtgcaag agaggactac 360gtctactggg gccaaggcac cactctcaca gtctcctcag ccaaaacgaa gggcccatcc 420gtcttccccc tggcgccctg ctccaggagc acctccgaga gcacagccgc cctgggctgc 480ctggtcaagg actacttccc cgaaccggtg acggtgtcgt ggaactcagg cgccctgacc 540agcggcgtgc acaccttccc ggctgtccta cagtcctcag gactctactc cctcagcagc 600gtggtgaccg tgccctccag cagcttgggc acgaagacct acacctgcaa cgtagatcac 660aagcccagca acaccaaggt ggacaagaga gttgagtcca aatatggtcc cccatgccca 720ccctgcccag cacctgagtt cgaaggggga ccatcagtct tcctgttccc cccaaaaccc 780aaggacactc tcatgatctc ccggacccct gaggtcacgt gcgtggtggt ggacgtgagc 840caggaagacc ccgaggtcca gttcaactgg tacgtggatg gcgtggaggt gcataatgcc 900aagacaaagc cgcgggagga gcagttcaac agcacgtacc gtgtggtcag cgtcctcacc 960gtcctgcacc aggactggct gaacggcaag gagtacaagt gcaaggtctc caacaaaggc 1020ctcccgtcct ccatcgagaa aaccatctcc aaagccaaag ggcagccccg agagccacag 1080gtgtacaccc tgcccccatc ccaggaggag atgaccaaga accaggtcag cctgacctgc 1140ctggtcaaag gcttctaccc cagcgacatc gccgtggagt gggagagcaa tgggcagccg 1200gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt cttcctctac 1260agcaggctaa ccgtggacaa gagcaggtgg caggagggga atgtcttctc atgctccgtg 1320atgcatgagg ctctgcacaa ccactacaca cagaagagcc tctccctgtc tctgggtaaa 1380gctagctga 138930717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 30atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat 60gttgtgatga cccaaactcc actctccctg cctgtcagtc ttggagatca agcctccatc 120tcttgcagat ctagtcagag ccttgtacac agtaatggaa acacctattt acattggtac 180ctgcagaagc caggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct 240ggggtcccag acaggttcag tggcagtgga tcagggacag atttcgcact caagatcagt 300agagtggagg ctgaggatct gggagtttat ttctgctctc aaagtacaca tgttccgtgg 360acgttcggtg gaggcaccaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag 717311410DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 31atggaatgga gttggatatt tctctttctt ctgtcaggaa ctgcaggtgt ccactctgag 60gtccagctgc agcagtctgg acctgagctg gtaaagcctg gggcttcagt gaagatgtcc 120tgcaaggctt ctggatacac attcactgac tatgttttgc actgggtgaa acagaagcct 180gggcagggcc ttgagtggat tggatatatt aatccttaca atgatggtac taagtacaat 240gagaagttca aaggcaaggc cacactgact tcagacaaat cctccagcac agcctacatg 300gagctcagca gcctgacctc tgaggactct gcggtctatt actgtgcaag gggctatccg 360gcctactctg ggtatgctat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 420gccaaaacga agggcccatc cgtcttcccc ctggcgccct gctccaggag cacctccgag 480agcacagccg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 540tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 600ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacgaagacc 660tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc 720aaatatggtc ccccatgccc accctgccca gcacctgagt tcgaaggggg accatcagtc 780ttcctgttcc ccccaaaacc caaggacact ctcatgatct cccggacccc tgaggtcacg 840tgcgtggtgg tggacgtgag ccaggaagac cccgaggtcc agttcaactg gtacgtggat 900ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagttcaa cagcacgtac 960cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaacggcaa ggagtacaag 1020tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc caaagccaaa 1080gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccaggagga gatgaccaag 1140aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 1200tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 1260gacggctcct tcttcctcta cagcaggcta accgtggaca agagcaggtg gcaggagggg 1320aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc 1380ctctccctgt ctctgggtaa agctagctga 141032705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 32atgatgtcct ctgctcagtt ccttggtctc ctgttgctct gttttcaagg taccagatgt 60gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 120atcagttgca gggcaagtca ggacattagc aattatttaa actggtatca gcagaaacca 180gatggaactg ttaaactcct gatctactac acatcaagat tacactcagg agtcccatca 240aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa 300gaagatattg ccacttactt ttgccatcat ggtaatacgc ttccgtggac gttcggtgga 360ggcaccaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705331404DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 33atgaacttgg ggctcagctt gattttcctt gtccttgttt taaaaggtgt ccagtgtgaa 60gtgaagctgg tggagtctgg gggaggctta gtgcagcctg gagggtccct gaaactctcc 120tgtgcaacct ctggattcac tttcagtgac tattacatgt attgggttcg ccagactcca 180gagaagaggc tggagtgggt cgcatacatt aattctggtg gtggtagcac ctattatcca 240gacactgtaa agggccgatt caccatctcc agagacaatg ccaagaacac cctgtacctg 300caaatgagcc ggctgaagtc tgaggacaca gccatgtatt actgtgcaag acgggggtta 360ccgttccatg ctatggacta ttggggtcaa ggaacctcag tcaccgtctc ctcagccaaa 420acgaagggcc catccgtctt ccccctggcg ccctgctcca ggagcacctc cgagagcaca 480gccgccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 540tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 600tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcacgaa gacctacacc 660tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agagagttga gtccaaatat 720ggtcccccat gcccaccctg cccagcacct gagttcgaag ggggaccatc agtcttcctg 780ttccccccaa aacccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 840gtggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 900gaggtgcata atgccaagac aaagccgcgg gaggagcagt tcaacagcac gtaccgtgtg 960gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 1020gtctccaaca aaggcctccc gtcctccatc gagaaaacca tctccaaagc caaagggcag 1080ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1140gtcagcctga cctgcctggt caaaggcttc taccccagcg acatcgccgt ggagtgggag 1200agcaatgggc agccggagaa caactacaag

accacgcctc ccgtgctgga ctccgacggc 1260tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1320ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1380ctgtctctgg gtaaagctag ctga 140434705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 34atgatgtcct ctgctcagtt ccttggtctc ctgttgctct gttttcaagg taccagatgt 60gatatccaga tgacacagac tacatcctcc ctgtctgcct ctctaggaga cagagtcacc 120atcagttgca gtgcaagtca gggcattagc aattatttaa actggtatca gcagaaacca 180gatggaactg ttaaactcct gatctattac acatcaattt tacactcagg agtcccatca 240aggttcagtg gcagtgggtc tgggacagat tattctctca ccatcggcaa cctggaacct 300gaagatattg ccacttacta ttgtcagcag tttaataagc ttcctccgac gttcggtgga 360ggcaccaaac tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705351405DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 35atggattggc tgtggaactt gctattcctg atggcagctg cccaaagtgc ccaagcacag 60atccagttgg tgcagtctgg acctgagctg aagaagcctg gagagacagt caagatctcc 120tgcaaggctt ctgggtattc cttcacaaac tatggaatga actgggtgaa acaggctcca 180ggaaagggtt taaagtggat gggctggata aacacctaca ctggagagtc aacatatgct 240gatgacttca agggacggtt tgccttctct ttggaaacct ctgccagcac tgcctatttg 300cagatcagta acctcaaaaa tgaggacatg gctacatatt tctgtgctag aggggacttt 360aggtactact attttgacta ctggggccaa ggcaccactc tcacaggctc ctcagccaaa 420acgaagggcc catccgtctt ccccctggcg ccctgctcca ggagcacctc cgagagcaca 480gccgccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 540tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 600tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcacgaa gacctacacc 660tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agagagttga gtccaaatat 720ggtcccccat gcccaccctg cccagcacct gagttcgaag ggggaccatc agtcttcctg 780ttccccccaa aacccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 840gtggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 900gaggtgcata atgccaagac aaagccgcgg gaggagcagt tcaacagcac gtaccgtgtg 960gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 1020gtctccaaca aaggcctccc gtcctccatc gagaaaacca tctccaaagc caaagggcag 1080ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1140gtcagcctga cctgcctggt caaaggcttc taccccagcg acatcgccgt ggagtgggag 1200agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1260tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1320ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1380ctgtctctgg gtaaagctag ctgat 140536702DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 36atgagtgtgc tcactcaggt cctggcgttg ctgctgctgt ggcttacagg tgccagatgt 60gacatccaga tgactcagtc tccagcctcc ctatctgcat ctgtgggaga aactgtcacc 120atcacgtgtc gagcaagtgg gaatattcac aattatttag catggtatca gcagaaacag 180ggaaaatctc ctcagctcct ggtctataat gcaaaaacct tggcagatgg tgtgccatca 240aggttcagtg gcagtggatc aggaacacaa tattctctca agatcaacac cctgcagcct 300gaagattttg ggagttatta ctgtcaacat ttttgggatt cttggacgtt cggtggaggc 360accaagctcg agatcaaacg aactgtggct gcaccatctg tcttcatctt cccgccatct 420gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc 480agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag 540agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg 600agcaaagcag actacgagaa acacaaagtc tatgcctgcg aagtcaccca tcagggcctg 660agctcgcccg tcacaaagag cttcaacagg ggagagtgtt ag 702371398DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 37atggaatgga cctgggtctt tctcttcctc ctgtcagtaa ctgcaggtgt ccactcccag 60gttcagctgc agcagtctgg agctgagctg atgaagcctg gggcctcagt gaagatatcc 120tgcaaggcta ctggctacac attcagtagc tactggatag agtgggtaaa gcagaggcct 180ggacatggcc ttgagtggat tggagagatt ttacctggaa gtggtaggac taacgacaat 240gagaagttca agggcaaggc cacattcact gcagatacat cctccaagaa agcctacatg 300caactcagca gcctgacatc tgaggactct gccgtctatt attgtgcaag aaggggtggt 360tactcctttg cttactgggg ccaagggact ctggtcactg tctctgcagc caaaacaaag 420ggcccatccg tcttccccct ggcgccctgc tccaggagca cctccgagag cacagccgcc 480ctgggctgcc tggtcaagga ctacttcccc gaaccggtga cggtgtcgtg gaactcaggc 540gccctgacca gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc 600ctcagcagcg tggtgaccgt gccctccagc agcttgggca cgaagaccta cacctgcaac 660gtagatcaca agcccagcaa caccaaggtg gacaagagag ttgagtccaa atatggtccc 720ccatgcccac cctgcccagc acctgagttc gaagggggac catcagtctt cctgttcccc 780ccaaaaccca aggacactct catgatctcc cggacccctg aggtcacgtg cgtggtggtg 840gacgtgagcc aggaagaccc cgaggtccag ttcaactggt acgtggatgg cgtggaggtg 900cataatgcca agacaaagcc gcgggaggag cagttcaaca gcacgtaccg tgtggtcagc 960gtcctcaccg tcctgcacca ggactggctg aacggcaagg agtacaagtg caaggtctcc 1020aacaaaggcc tcccgtcctc catcgagaaa accatctcca aagccaaagg gcagccccga 1080gagccacagg tgtacaccct gcccccatcc caggaggaga tgaccaagaa ccaggtcagc 1140ctgacctgcc tggtcaaagg cttctacccc agcgacatcg ccgtggagtg ggagagcaat 1200gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc 1260ttcctctaca gcaggctaac cgtggacaag agcaggtggc aggaggggaa tgtcttctca 1320tgctccgtga tgcatgaggc tctgcacaac cactacacac agaagagcct ctccctgtct 1380ctgggtaaag ctagctga 1398381422DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 38atgaccatgt tctcactagc tcttctcctc agtcttcttc tcctctgtgt ctctgattct 60agggcagaaa caactgtgac ccagtctatg accatgttct cactagctct tctcctcagt 120cttcttctcc tctgtgtctc tgattctagg gcagaaacaa ctgtgaccca gtctccagca 180tccctgtcca tggctatagg ggaaaaagtc accatcagat gcgtaaccag cactgatatt 240gatgatgatg tgaactggta ccagcagaag ccaggggaac ctcctaaact ccttatttca 300gaaggcaata ctcttcgtcc tggagtccca tcccgattct ccagcagtgg ctatggtaca 360gattttgttt ttacaattga gaacatgctc tcagaagatg ttgcagatta ctactgtttg 420caaagtggta acttgccgta cacgttcgga ggggggacca agctcgagat caaacgaact 480gtggctgcac catctgtctt catcttcccg ccatctgatg agcagttgaa atctggaact 540gcctctgttg tgtgcctgct gaataacttc tatcccagag aggccaaagt acagtggaag 600gtggataacg ccctccaatc gggtaactcc caggagagtg tcacagagca ggacagcaag 660gacagcacct acagcctcag cagcaccctg acgctgagca aagcagacta cgagaaacac 720aaagtctatg cctgcgaagt cacccatcag ggcctgagct cgcccgtcac aaagagcttc 780aacaggggag agtgttagcc agcatccctg tccatggcta taggggaaaa agtcaccatc 840agatgcgtaa ccagcactga tattgatgat gatgtgaact ggtaccagca gaagccaggg 900gaacctccta aactccttat ttcagaaggc aatactcttc gtcctggagt cccatcccga 960ttctccagca gtggctatgg tacagatttt gtttttacaa ttgagaacat gctctcagaa 1020gatgttgcag attactactg tttgcaaagt ggtaacttgc cgtacacgtt cggagggggg 1080accaagctcg agatcaaacg aactgtggct gcaccatctg tcttcatctt cccgccatct 1140gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc 1200agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggtaa ctcccaggag 1260agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac cctgacgctg 1320agcaaagcag actacgagaa acacaaagtc tatgcctgcg aagtcaccca tcagggcctg 1380agctcgcccg tcacaaagag cttcaacagg ggagagtgtt ag 1422391404DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 39atggcttggg tgtggacctt gctattcctg atggcagctg cccaaagtgc ccaagcacag 60atccagttgg tgcagtctgg acctgagctg aagaagcctg gagagacagt caagatctcc 120tgcaaggctt ctgggtatac cttcacaaac tatggaatga actgggtgaa gcaggctcca 180ggaaagggtt taaagtgggt gggctggata aacaccttca ctggagagcc aacatatgtt 240gatgacttca agggacggtt tgccttctct ttggaaacct ctgccagcac tgcctatttg 300cagatcaaca acctcaaaaa tgaggacacg gctacatatt tctgtgcaag agggaatttt 360aggtactact actttgacta ctggggccaa ggcaccactc tcacagtctc ctcagccaaa 420acaaagggcc catccgtctt ccccctggcg ccctgctcca ggagcacctc cgagagcaca 480gccgccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 540tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 600tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcacgaa gacctacacc 660tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agagagttga gtccaaatat 720ggtcccccat gcccaccctg cccagcacct gagttcgaag ggggaccatc agtcttcctg 780ttccccccaa aacccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 840gtggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 900gaggtgcata atgccaagac aaagccgcgg gaggagcagt tcaacagcac gtaccgtgtg 960gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 1020gtctccaaca aaggcctccc gtcctccatc gagaaaacca tctccaaagc caaagggcag 1080ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1140gtcagcctga cctgcctggt caaaggcttc taccccagcg acatcgccgt ggagtgggag 1200agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1260tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1320ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1380ctgtctctgg gtaaagctag ctga 140440705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 40atgagtgtgc tcactcaggt cctggcgttg ctgctgctgt ggcttacagg tgccagatgt 60gacatccaga tgactcagtc cccagcctcc ctatctgcat ctgtgggaga aactgtcacc 120atcacatgtc gaacaagtgg gaatattcgc aattatttag catggtatca gcagaaacag 180ggaaaatctc ctcaactcct ggtctataat gcaaaaacct tagcagatgg tgtgccatca 240aggttcggtg gcagtggatc aggaacacaa tattctctca agatcaacag cctgcagcct 300gaagattttg ggaattatta ctgtcaacat ttttggagta gtccgtacac gttcggaggg 360gggaccaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705412811DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 41atgatgggat ggagctatat catcctcttt ttggtagcaa cagctacaga tgtccactcc 60caggtccaac tgcagcagcc tggggctgaa ctggtgaagc ctggggcttc agtgaagctg 120tcctgcaagg cttctggcta caccttcacc agctactgga tgcactgggt gaagcagagg 180cctggagaag gccttgagtg gattggagag attaatccta gctacggtcg tactgactac 240aatgagaagt tcaagaacaa ggccacactg actgtagcca aatcctccag cacagcctac 300atgcaactca gcagcctgac atctgaggac tctgcggtct attactgtgc aagaggagat 360tactacggta gtagctcgtt tgcttactgg ggccaaggga ctctggtcac tgtctctgca 420gccaaaacaa agggcccatc cgtcttcccc ctggcgccct gctccaggag cacctccgag 480agcacagccg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 540tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 600ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacgaagacc 660tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc 720aaatatggtc ccccatgccc accctgccca gcacctgagt tcgaaggggg accatcagtc 780ttcctgttcc ccccaaaacc caaggacact ctcatgatct cccggacccc tgaggtcacg 840tgcgtggtgg tggacgtgag ccaggaagac cccgaggtcc agttcaactg gtacgtggat 900ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagttcaa cagcacgtac 960cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaacggcaa ggagtacaag 1020tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc caaagccaaa 1080gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccaggagga gatgaccaag 1140aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 1200tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 1260gacggctcct tcttcctcta cagcaggcta accgtggaca agagcaggtg gcaggagggg 1320aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc 1380ctctccctgt ctctgggtaa agctagcgga tggagctata tcatcctctt tttggtagca 1440acagctacag atgtccactc ccaggtccaa ctgcagcagc ctggggctga actggtgaag 1500cctggggctt cagtgaagct gtcctgcaag gcttctggct acaccttcac cagctactgg 1560atgcactggg tgaagcagag gcctggagaa ggccttgagt ggattggaga gattaatcct 1620agctacggtc gtactgacta caatgggaag ttcaagaaca aggccacact gactgtagcc 1680aaatcctcca gcacagccta catgcaactc agcagcctga catctgagga ctctgcggtc 1740tattactgtg caagaggaga ttactacggt agtagctcgt ttgcttactg gggccaaggg 1800actctggtca ctgtctctgc agccaaaaca aagggcccat ccgtcttccc cctggcgccc 1860tgctccagga gcacctccga gagcacagcc gccctgggct gcctggtcaa ggactacttc 1920cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc 1980ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc 2040agcagcttgg gcacgaagac ctacacctgc aacgtagatc acaagcccag caacaccaag 2100gtggacaaga gagttgagtc caaatatggt cccccatgcc caccctgccc agcacctgag 2160ttcgaagggg gaccatcagt cttcctgttc cccccaaaac ccaaggacac tctcatgatc 2220tcccggaccc ctgaggtcac gtgcgtggtg gtggacgtga gccaggaaga ccccgaggtc 2280cagttcaact ggtacgtgga tggcgtggag gtgcataatg ccaagacaaa gccgcgggag 2340gagcagttca acagcacgta ccgtgtggtc agcgtcctca ccgtcctgca ccaggactgg 2400ctgaacggca aggagtacaa gtgcaaggtc tccaacaaag gcctcccgtc ctccatcgag 2460aaaaccatct ccaaagccaa agggcagccc cgagagccac aggtgtacac cctgccccca 2520tcccaggagg agatgaccaa gaaccaggtc agcctgacct gcctggtcaa aggcttctac 2580cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc 2640acgcctcccg tgctggactc cgacggctcc ttcttcctct acagcaggct aaccgtggac 2700aagagcaggt ggcaggaggg gaatgtcttc tcatgctccg tgatgcatga ggctctgcac 2760aaccactaca cacagaagag cctctccctg tctctgggta aagctagctg a 281142708DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 42atggattttc aagtgcagat tttcagcttc ctgctaatga gtgcctcagt cataatgtcc 60aggggacaaa ttgttctcac ccagtctcca gcactcatgt ctgcatctcc aggggagaag 120gtcaccatga cctgcagtgc cagctcaaat ataagttaca tgtactggta ccagcagaag 180ccaagatcct cccccaaacc ctggatttat ctcacatcca acctggcttc tggagtccct 240gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaaccag cagcatggag 300gctgaagatg ctgccactta ttgctgccag cagtggagta gtaacccacc cacgttcggt 360gctgggacca agctcgagat caaacgaact gtggctgcac catctgtctt catcttcccg 420ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 540caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 600acgctgagca aagcagacta cgagaaacac aaagtctatg cctgcgaagt cacccatcag 660ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttag 70843708DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 43atggattttc gagtgcagat tttcagcttc ctgctaatga gtgcctcagt cataatgtcc 60aggggacaaa ttgttctcac ccagtctcca gcactcatgt ctgcatctcc aggggagaag 120gtcaccatga cctgcagtgc cagctcaaat ataagttaca tgtactggta ccagcagaag 180ccaagatcct cccccaaacc ctggatttat ctcacatcca acctggcttc tggagtccct 240gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagcatggag 300gctgaagatg ctgccactta ttactgccag cagtggagta gtaacccacc cacgttcggt 360gctgggacca agctcgagat caaacgaact gtggctgcac catctgtctt catcttcccg 420ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 540caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 600acgctgagca aagcagacta cgagaaacac aaagtctatg cctgcgaagt cacccatcag 660ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttag 70844717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 44atggagacag acacactcct gctatgggtg ctgctgctct gggttccagg ttccacaggt 60gacattgtgc tgatccaatc tccagcttct ttggctgtgt ctctagggca gagggccacc 120atatcctgca gagccagtga aagtgttgat agttatgtca atagttttat gcactggtac 180cagcagaaac caggacagcc acccaaactc ctcatctatc gtgtatccaa cctagaatct 240gggatccctg ccaggttcag tggcagtggg tctaggacag acttcaccct caccattaat 300cctgtggagg ctgatgatgt tgcaacctat tactgtcagc aaagtaatga ggatccattc 360acgttcggct cggggacaaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag 717451398DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 45atggaatgta actggatact tccttttatt ctgtcggtaa tttcaggggt ctactcagag 60gttcagctcc agcagtctgg gactgtgctg gcaaggcctg gggcttccgt gaatatgtcc 120tgtaaggctg ctggctacag ctttaccagt tactgggtgt actgggtcaa acagaggcct 180ggacagggtc tggaatggat tggtgctatt taccctaaaa atagtagaac tagctacaac 240cagaagttcc aggacaaggc cacactgact gcagtcacat ccgccagcac tgcctacatg 300gagctcagca gcctgacaaa tgaggactct gcggtctatt actgtacaag acctcactat 360gattcgtttg gttactgggg ccaagggact ctggtcactg tctctgcagc caaaacaaag 420ggcccatccg tcttccccct ggcgccctgc tccaggagca cctccgagag cacagccgcc 480ctgggctgcc tggtcaagga ctacttcccc gaaccggtga cggtgtcgtg gaactcaggc 540gccctgacca gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc 600ctcagcagcg tggtgaccgt gccctccagc agcttgggca cgaagaccta cacctgcaac 660gtagatcaca agcccagcaa caccaaggtg gacaagagag ttgagtccaa atatggtccc 720ccatgcccac cctgcccagc acctgagttc gaagggggac catcagtctt cctgttcccc 780ccaaaaccca aggacactct catgatctcc cggacccctg aggtcacgtg cgtggtggtg 840gacgtgagcc aggaagaccc cgaggtccag

ttcaactggt acgtggatgg cgtggaggtg 900cataatgcca agacaaagcc gcgggaggag cagttcaaca gcacgtaccg tgtggtcagc 960gtcctcaccg tcctgcacca ggactggctg aacggcaagg agtacaagtg caaggtctcc 1020aacaaaggcc tcccgtcctc catcgagaaa accatctcca aagccaaagg gcagccccga 1080gagccacagg tgtacaccct gcccccatcc caggaggaga tgaccaagaa ccaggtcagc 1140ctgacctgcc tggtcaaagg cttctacccc agcgacatcg ccgtggagtg ggagagcaat 1200gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc 1260ttcctctaca gcaggctaac cgtggacaag agcaggtggc aggaggggaa tgtcttctca 1320tgctccgtga tgcatgaggc tctgcacaac cactacacac agaagagcct ctccctgtct 1380ctgggtaaag ctagctga 139846717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 46atggagacag acacactcct gctatgggtg ctgctgctct gggttccagg ttccacaggt 60gacattgtgc tgacccaatc tccagcttct ttggctgtgt ctctagggca gagggccacc 120atatcctgca gagccagtga aagtgtagat agttatggca ttagttttat gcactggtac 180cagcagaaac caggacagcc acccaaactc ctcatctatc gtgcatccaa ccaagaatct 240gggatccctg ccaggttcag tggcagtggg tctaggacag acttcaccct caccattaat 300cctgtggagg ctgatgatgt tgcaacctat tactgtcagc aaagtaatga ggatccgctc 360acgttcggtg ctgggaccaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag 717471422DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 47atgaacaggc ttacttcctc attgctgctg ctgattgtcc ctgcatatgt cctgtcccag 60gttactctga aagagtctgg ccctgggata ttgcagccct cccagaccct cagtctgact 120tgttctttct ctgggttttc actgagcact tctggtatgg gtgtgagctg gattcgtcag 180ccttcaggaa agggtctgga gtggctggca cacatttact gggatgatga caagcgctat 240aatccatccc tgaagagccg gctcacaatc tttaaggatc cctccagcaa ccaggtattc 300ctcaggatca ccagtgtgga cactgcagat actgccacat actactgtgc tcgaaactcc 360cattactacg gtagtactta cgggggatac ttcgatgtct ggggcgcagg gaccacggtc 420accgtctcct cagccaaaac aaagggccca tccgtcttcc ccctggcgcc ctgctccagg 480agcacctccg agagcacagc cgccctgggc tgcctggtca aggactactt ccccgaaccg 540gtgacggtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt cccggctgtc 600ctacagtcct caggactcta ctccctcagc agcgtggtga ccgtgccctc cagcagcttg 660ggcacgaaga cctacacctg caacgtagat cacaagccca gcaacaccaa ggtggacaag 720agagttgagt ccaaatatgg tcccccatgc ccaccctgcc cagcacctga gttcgaaggg 780ggaccatcag tcttcctgtt ccccccaaaa cccaaggaca ctctcatgat ctcccggacc 840cctgaggtca cgtgcgtggt ggtggacgtg agccaggaag accccgaggt ccagttcaac 900tggtacgtgg atggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagttc 960aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaacggc 1020aaggagtaca agtgcaaggt ctccaacaaa ggcctcccgt cctccatcga gaaaaccatc 1080tccaaagcca aagggcagcc ccgagagcca caggtgtaca ccctgccccc atcccaggag 1140gagatgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta ccccagcgac 1200atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc 1260gtgctggact ccgacggctc cttcttcctc tacagcaggc taaccgtgga caagagcagg 1320tggcaggagg ggaatgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac 1380acacagaaga gcctctccct gtctctgggt aaagctagct ga 142248717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 48atggagacag acacactcct gctatgggtg ctgctgctcg gggttccagg ttccacaggt 60aacattgtgc tgacccagtc tccaacttct ttcactgtgt ctcttgggca gagggccacc 120atatcctgca gagccagtga aagtgttcat agttatggca atagttttat gcactggtac 180cagcagaaac cagggcagcc acccaaactc ctcatctatc ttgcatccaa cgtagaatct 240ggggtccctg ccaggttcag tggtagtggg tccaggacag acttcaccct caccattgat 300cctgtggagg ctgatgatgc tgcaacctat tactgtcagc aaaatagtga ggatccgtgg 360acgttcggtg gaggcaccaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag 717491398DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 49atggaatgga cctgggtctt tctcttcctc ctgtcagtaa ctgcaggtgt ccactcccag 60gttcagctgc agcagtctgg aactgagctg atgaagcctg gggcctcagt gaagatatcc 120tgcaaggcta ctggctacac attcagtacc tactggatag agtgggtaaa gcagaggcct 180ggacatggcc ttgagtggat tggagagatt ttacctggaa gtggtaggac taacgacaat 240gagaagttca agggcaaggc cacaatcact gcagatacat cctccaagaa agcctacatg 300caactcagca gcctgacatc tgaggactct gccgtctatt actgtgcaag aaggggtggt 360tactcctttg ctttctgggg ccaagggact ctggtctctg tctctgcagc caaaacaaag 420ggcccatccg tcttccccct ggcgccctgc tccaggagca cctccgagag cacagccgcc 480ctgggctgcc tggtcaagga ctacttcccc gaaccggtga cggtgtcgtg gaactcaggc 540gccctgacca gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc 600ctcagcagcg tggtgaccgt gccctccagc agcttgggca cgaagaccta cacctgcaac 660gtagatcaca agcccagcaa caccaaggtg gacaagagag ttgagtccaa atatggtccc 720ccatgcccac cctgcccagc acctgagttc gaagggggac catcagtctt cctgttcccc 780ccaaaaccca aggacactct catgatctcc cggacccctg aggtcacgtg cgtggtggtg 840gacgtgagcc aggaagaccc cgaggtccag ttcaactggt acgtggatgg cgtggaggtg 900cataatgcca agacaaagcc gcgggaggag cagttcaaca gcacgtaccg tgtggtcagc 960gtcctcaccg tcctgcacca ggactggctg aacggcaagg agtacaagtg caaggtctcc 1020aacaaaggcc tcccgtcctc catcgagaaa accatctcca aagccaaagg gcagccccga 1080gagccacagg tgtacaccct gcccccatcc caggaggaga tgaccaagaa ccaggtcagc 1140ctgacctgcc tggtcaaagg cttctacccc agcgacatcg ccgtggagtg ggagagcaat 1200gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc 1260ttcctctaca gcaggctaac cgtggacaag agcaggtggc aggaggggaa tgtcttctca 1320tgctccgtga tgcatgaggc tctgcacaac cactacacac agaagagcct ctccctgtct 1380ctgggtaaag ctagctga 139850711DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 50atgaccatgt tctcactagc tcttctcctc agtcttcttc tcctctgtgt ctctgattct 60agggcagaaa caactgtgac ccagtctcca gcatccctgt ccatggctat aggagaaaaa 120gtcaccatca gatgcgtaac cagcactgat attgatgatg atgtgaactg gtaccagcag 180aagccagggg aacctcctaa gctccttatt tcagaaggca atactcttcg tgctggagtc 240ccatcccgat tctccagcag tggctatggt acagattttg tttttacaat tgagaacatg 300ctctcagaag atgttgcaga ttactactgt ttgcaaagtg gtaacttgcc gtacacgttc 360ggagggggga ccaagctcga gatcaaacga actgtggctg caccatctgt cttcatcttc 420ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac 480ttctatccca gagaggccaa agtacagtgg aaggtggata acgccctcca atcgggtaac 540tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct cagcagcacc 600ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct atgcctgcga agtcacccat 660cagggcctga gctcgcccgt cacaaagagc ttcaacaggg gagagtgtta g 711511422DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 51atgaacaggc ttacttcctc attgctgctg ctgattgtcc ctgcatatgt cctgtcccag 60gttactctga aagagtctgg ccctgggata ttgcagccct cccagaccct cagtctgact 120tgttctttct ctgggttttc actgagcact tctggtatgg gtctgagctg gattcgtcag 180ccttcaggaa agggtctgga gtggctggca cacatttact gggatgatga caagcgctat 240aacccatccc tgaagagccg gctcacaatc tccaaggata cctccagcaa ccaggttttc 300ctcaagatca ccattgtgga cactgcagat gctgccacat actactgtgc tcgaagctcc 360cattactacg gttatggcta cgggggatac ttcgatgtct ggggcgcagg gaccacggtc 420accgtctcct cagccaaaac gaagggccca tccgtcttcc ccctggcgcc ctgctccagg 480agcacctccg agagcacagc cgccctgggc tgcctggtca aggactactt ccccgaaccg 540gtgacggtgt cgtggaactc aggcgccctg accagcggcg tgcacacctt cccggctgtc 600ctacagtcct caggactcta ctccctcagc agcgtggtga ccgtgccctc cagcagcttg 660ggcacgaaga cctacacctg caacgtagat cacaagccca gcaacaccaa ggtggacaag 720agagttgagt ccaaatatgg tcccccatgc ccaccctgcc cagcacctga gttcgaaggg 780ggaccatcag tcttcctgtt ccccccaaaa cccaaggaca ctctcatgat ctcccggacc 840cctgaggtca cgtgcgtggt ggtggacgtg agccaggaag accccgaggt ccagttcaac 900tggtacgtgg atggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagttc 960aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaacggc 1020aaggagtaca agtgcaaggt ctccaacaaa ggcctcccgt cctccatcga gaaaaccatc 1080tccaaagcca aagggcagcc ccgagagcca caggtgtaca ccctgccccc atcccaggag 1140gagatgacca agaaccaggt cagcctgacc tgcctggtca aaggcttcta ccccagcgac 1200atcgccgtgg agtgggagag caatgggcag ccggagaaca actacaagac cacgcctccc 1260gtgctggact ccgacggctc cttcttcctc tacagcaggc taaccgtgga caagagcagg 1320tggcaggagg ggaatgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac 1380acacagaaga gcctctccct gtctctgggt aaagctagct ga 142252823DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 52atggagacag acacactcct gctatgggtg ctgctgctct gggttccagg ttccacaggt 60aacattgtgc tgacccaatc tccagcttct ttggctgtgt ctctagggca gagggccacc 120atatcctgca gagccagtga aagtattcat agttatggca atagttttct gcactggtac 180cagcagaaac caggacagcc acccaaactc ctcatctatc ttgcatccaa cctagaatct 240ggggtccctg ccaggttcag cggcagtggg tctaggacag acttcaccct caccattgat 300cctgtggagg ctgatgatgc tgcaacctat tactgtcagc aaaataatga ggatccgtgg 360acgttcggtg gaggcaccaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttaggcg 720gccgcactag cgcgggccgc attcgaagag ctcggtaccc ggggatcctc tagagtcgac 780ctgcaggcat gcaagctggc cgcgactcta gatcataatc agc 823531404DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 53atgaaatgca gctgggtcat cttcttcctg atggcagtgg ttacaggggt caattcagag 60gttcagctgc agcagtctgg ggctgagctt gtgaggccag gggccttagt caagttgtcc 120tgcaaagctt ctggcttcaa cattaatgac tactatatcc actgggtgaa gcagcggcct 180gaacagggcc tggagcggat tggatggatt gatcctgaca atggtaatac tatatatgac 240ccgaagttcc agggcaaggc cagtataaca gcagacacat cccccaacac agcctacctg 300cagctcagca gcctgacatc tgaggacact gccgtctatt actgtgctag aacccgatct 360cctatggtta cgacggggtt tgtttactgg ggccaaggga ctgtggtcac tgtctctgca 420gccaaaacga agggcccatc cgtcttcccc ctggcgccct gctccaggag cacctccgag 480agcacagccg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 540tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 600ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacgaagacc 660tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc 720aaatatggtc ccccatgccc accctgccca gcacctgagt tcgaaggggg accatcagtc 780ttcctgttcc ccccaaaacc caaggacact ctcatgatct cccggacccc tgaggtcacg 840tgcgtggtgg tggacgtgag ccaggaagac cccgaggtcc agttcaactg gtacgtggat 900ggcgtggagg tgcataatgc caagacraag ccgcgggagg agcagttcaa cagcacgtac 960cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaacggcaa ggagtacaag 1020tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc caaagccaaa 1080gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccaggagga gatgaccaag 1140aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 1200tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 1260gacggctcct tcttcctcta cagcaggcta accgtggaca agagcaggtg gcaggagggg 1320aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc 1380ctctccctgt ctctgggtaa atga 1404541425DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 54atggaaaggc actggatctt tctcttcctg ttttcagtaa ctgcaggtgt ccactcccag 60gtccagcttc agcagtctgg ggctgagctg gcaaaacctg gggcctcagt gaagatgtcc 120tgcaaggctt ctggctacac ctttactacc tactggatgc actgggtaaa acagaggcct 180ggacagggtc tggaatggat tggatacatt aatcctatca ctggttatac tgagtacaat 240cagaagttca aggacaaggc caccttgact gcagacaaat cctccagcac agcctacatg 300caactgagca gcctgacatc tgaggactct gcagtctatt actgtgcaag agagggttta 360agtgctatgg actattgggg tcagggaacc tcagtcaccg tcacctcagc caaaacaaca 420gccccatcgg tctatccact ggcccctgtg tgtggagata caactggctc ctcggtaact 480ctaggatgcc tggtcaaggg ttatttccct gagccagtga ccttgacctg gaactctgga 540tccctgtcca gtggtgtgca caccttccca gctgtcctgc agtctgacct ctacaccctc 600agcagctcag tgactgtaac ctcgagcacc tggcccagcc agaccgtcac ctgcagcgtt 660gctcacccag ccagcagcac cacggtggac aaaaaacttg agcccagcgg gcccatttca 720acaatcaacc cctgtcctcc atgcaaggag tgtcacaaat gcccagctcc taacctcgag 780ggtggaccat ccgtcttcat cttccctcca aatatcaagg atgtactcat gatctccctg 840acacccaagg tcacgtgtgt ggtggtggat gtgagcgagg atgacccaga cgtccagatc 900agctggtttg tgaacaacgt ggaagtacac acagctcaga cacaaaccca tagagaggat 960tacaacagta ctatccgggt ggtcagcacc ctccccatcc agcaccagga ctggatgagt 1020ggcaaggagt tcaaatgcaa ggtcaacaac aaagacctcc catcacccat cgagagaacc 1080atctcaaaaa ttaaagggct agtcagagct ccacaagtat acatcttgcc gccaccagca 1140gagcagttgt ccaggaaaga tgtcagtctc acttgcctgg tcgtgggctt caaccctgga 1200gacatcagtg tggagtggac cagcaatggg catacagagg agaactacaa ggacaccgca 1260ccagtcctgg actctgacgg ttcttacttc atatatagca agctcaatat gaaaacaagc 1320aagtgggaga aaacagattc cttctcatgc aacgtgagac acgagggtct gaaaaattac 1380tacctgaaga agaccatctc ccggtctccg ggtaaagcta gctga 142555717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 55atgggcatca agatggagtc acggattcag gcatttgtat tcgtgtttct ctggttgtct 60ggtgttggcg gagacattgt gatgacccag tctcacaaat tcatgtccac atcagtagga 120gacagggtca gcgtcacctg caaggccagt caggatgtga cttctgctgt agcctggtat 180caacaaaaac cagggcaatc tcctaaacta ctgatttact gggcatccac ccggcacact 240ggagtccctg atcgcttcac aggcagtgga tctgggacag attatactct caccatcagc 300agtgggcagg ctgaagacct ggcactttat tactgtcacc aatattatag cgctcctcgg 360acgttcggtg gaggcaccaa gctggaagtc aaacgggctg atgctgcacc aactgtatcc 420atcttcccac catccagtga gcagttaaca tctggaggtg cctcagtcgt gtgcttcttg 480aacaacttct accccaaaga catcaatgtc aagtggaaga ttgatggcag tgaacgacaa 540aatggcgtcc tgaacagttg gactgatcag gacagcaaag acagcaccta cagcatgagc 600agcaccctca cgttgaccaa ggacgagtat gaacgacata acagctatac ctgtgaggcc 660actcacaaga catcaacttc acccatcgtc aagagcttca ataggaatga gtgttag 717561398DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 56atggaaaggc actggatctt tctcttcctg ttttcagtaa ctgcaggtgt ccactcccag 60gtccagcttc agcagtctgg ggctgagctg gcaaaacctg gggcctcagt gaagatgtcc 120tgcaaggctt ctggctacac ctttactacc tactggatgc actgggtaaa acagaggcct 180ggacagggtc tggaatggat tggatacatt aatcctatca ctggttatac tgagtacaat 240cagaagttca aggacaaggc caccttgact gcagacaaat cctccagcac agcctacatg 300caactgagca gcctgacatc tgaggactct gcagtctatt actgtgcaag agagggttta 360agtgctatgg actattgggg tcagggaacc tcagtcaccg tcacctcagc caaaacaacg 420ggcccatccg tcttccccct ggcgccctgc tccaggagca cctccgagag cacagccgcc 480ctgggctgcc tggtcaagga ctacttcccc gaaccggtga cggtgtcgtg gaactcaggc 540gccctgacca gcggcgtgca caccttcccg gctgtcctac agtcctcagg actctactcc 600ctcagcagcg tggtgaccgt gccctccagc agcttgggca cgaagaccta cacctgcaac 660gtagatcaca agcccagcaa caccaaggtg gacaagagag ttgagtccaa atatggtccc 720ccatgcccac cctgcccagc acctgagttc gaagggggac catcagtctt cctgttcccc 780ccaaaaccca aggacactct catgatctcc cggacccctg aggtcacgtg cgtggtggtg 840gacgtgagcc aggaagaccc cgaggtccag ttcaactggt acgtggatgg cgtggaggtg 900cataatgcca agacaaagcc gcgggaggag cagttcaaca gcacgtaccg tgtggtcagc 960gtcctcaccg tcctgcacca ggactggctg aacggcaagg agtacaagtg caaggtctcc 1020aacaaaggcc tcccgtcctc catcgagaaa accatctcca aagccaaagg gcagccccga 1080gagccacagg tgtacaccct gcccccatcc caggaggaga tgaccaagaa ccaggtcagc 1140ctgacctgcc tggtcaaagg cttctacccc agcgacatcg ccgtggagtg ggagagcaat 1200gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc 1260ttcctctaca gcaggctaac cgtggacaag agcaggtggc aggaggggaa tgtcttctca 1320tgctccgtga tgcatgaggc tctgcacaac cactacacac agaagagcct ctccctgtct 1380ctgggtaaag ctagctga 139857717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 57atgggcatca agatggagtc acagattcag gcatttgtat tcgtgtttct ctggttgtct 60ggtgttggcg gagacattgt gatgacccag tctcacaaat tcatgtccac atcagtagga 120gacagggtca gcgtcacctg caaggccagt caggatgtga cttctgctgt agcctggtat 180caacaaaaac cagggcaatc tcctaaacta ctgatttact gggcatccac ccggcacact 240ggagtccctg atcgcttcac aggcagtgga tctgggacag attatactct caccatcagc 300agtgggcagg ctgaagacct ggcactttat tactgtcacc aatattatag cgctcctcgg 360acgttcggtg gaggcaccaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag 717581401DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 58atggctgtcc tggcactact cctctgcctg gtggctttcc caacttgtac cctgtcccag 60gtgcaactga aggagtcagg acctggcctg gtggcgccct cacagagcct gtccattacc 120tgctctgtct ctgggttctc attaagcaac tatgatataa gctggattcg ccagccacca 180ggaaagggtc tggagtggct tggagtaatg tggactggtg gaggcgcaaa ttataattca

240gctttcatgt ccagactgag catcaacaag gacaactcca agagccaagt ttttttaaaa 300atgaacaatc tgcaaactga tgacacagcc atttattact gtgtcagaga tgcggtgagg 360tactggaact tcgatgtctg gggcgcaggg accacggtca ccgtctcctc agccaaaacg 420aagggcccat ccgtcttccc cctggcgccc tgctccagga gcacctccga gagcacagcc 480gccctgggct gcctggtcaa ggactacttc cccgaaccgg tgacggtgtc gtggaactca 540ggcgccctga ccagcggcgt gcacaccttc ccggctgtcc tacagtcctc aggactctac 600tccctcagca gcgtggtgac cgtgccctcc agcagcttgg gcacgaagac ctacacctgc 660aacgtagatc acaagcccag caacaccaag gtggacaaga gagttgagtc caaatatggt 720cccccatgcc caccctgccc agcacctgag ttcgaagggg gaccatcagt cttcctgttc 780cccccaaaac ccaaggacac tctcatgatc tcccggaccc ctgaggtcac gtgcgtggtg 840gtggacgtga gccaggaaga ccccgaggtc cagttcaact ggtacgtgga tggcgtggag 900gtgcataatg ccaagacaaa gccgcgggag gagcagttca acagcacgta ccgtgtggtc 960agcgtcctca ccgtcctgca ccaggactgg ctgaacggca aggagtacaa gtgcaaggtc 1020tccaacaaag gcctcccgtc ctccatcgag aaaaccatct ccaaagccaa agggcagccc 1080cgagagccac aggtgtacac cctgccccca tcccaggagg agatgaccaa gaaccaggtc 1140agcctgacct gcctggtcaa aggcttctac cccagcgaca tcgccgtgga gtgggagagc 1200aatgggcagc cggagaacaa ctacaagacc acgcctcccg tgctggactc cgacggctcc 1260ttcttcctct acagcaggct aaccgtggac aagagcaggt ggcaggaggg gaatgtcttc 1320tcatgctccg tgatgcatga ggctctgcac aaccactaca cacagaagag cctctccctg 1380tctctgggta aagctagctg a 140159708DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 59atggattttc aagcgcagat tttcagcttc ctgctaatca gtgcttcagt cataatgtcc 60agaggacaaa ttgttctctc ccagtcacca gcaatcctgt ctgcatctcc aggggagaag 120gtcacaatga cttgcagggc cagctcaagt gtaagttaca tacactggta ccagcagaag 180ccaggatcct cccccaaacc ctggatttat gccacatccc acctggcttc tggagtccct 240gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaatcag cagagtggag 300gctgaagata ctgccactta ttactgccag cagtggagta gtaacccatt cacgttcggc 360tcggggacaa agctcgagat caaacgaact gtggctgcac catctgtctt catcttcccg 420ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 540caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 600acgctgagca aagcagacta cgagaaacac aaagtctatg cctgcgaagt cacccatcag 660ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttag 708601410DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 60atggaaaggc actggatctt tctactcctg ttgtcagtaa ctgcaggtgt ccactcccag 60gtccagctgc agcagtctgg ggctgaactg gcaagacctg gggcctcagt gaagatgtcc 120tgcaaggctt ctggctacac ctttactacc tacactatgc actgggtaaa acagaggcct 180ggacagggtc tggaatggat tggatacatt aatcctagca gtggttatac taattacaat 240cagaagttca aggacaaggc cacattgact gcagacaaat cctccagcac agcctccatg 300caactgagca gcctgacatc tgaggactct gcagtctatt actgtgcaag agagagggcg 360gtattagtcc cctatgctat ggactactgg ggtcaaggaa cctcagtcac cgtctcctca 420gccaaaacaa agggcccatc cgtcttcccc ctggcgccct gctccaggag cacctccgag 480agcacagccg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 540tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 600ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacgaagacc 660tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc 720aaatatggtc ccccatgccc accctgccca gcacctgagt tcgaaggggg accatcagtc 780ttcctgttcc ccccaaaacc caaggacact ctcatgatct cccggacccc tgaggtcacg 840tgcgtggtgg tggacgtgag ccaggaagac cccgaggtcc agttcaactg gtacgtggat 900ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagttcaa cagcacgtac 960cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaacggcaa ggagtacaag 1020tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc caaagccaaa 1080gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccaggagga gatgaccaag 1140aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 1200tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 1260gacggctcct tcttcctcta cagcaggcta accgtggaca agagcaggtg gcaggagggg 1320aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc 1380ctctccctgt ctctgggtaa agctagctga 141061708DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 61atgcattttc aagtgcagat tttcagcttc ctgctaatca gtgcctcagt cataatgtcc 60agaggacaaa ttgttctcac ccagtctcca gcagtcatgt ctgcatctcc aggggagaag 120gtcaccataa cctgcactgc cagctcaagt ttaagttaca tgcactggtt ccagcagaag 180ccaggcactt ctcccaaact ctggctttat agcacatcca tcctggcttc tggagtccct 240actcgcttca gtggcagtgg atctgggacc tcttactctc tcacaatcag ccgaatggag 300gctgaagatg ctgccactta ttactgccag caaaggagta gttccccatt cacgttcggc 360tcggggacaa agctcgagat caaacgaact gtggctgcac catctgtctt catcttcccg 420ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 540caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 600acgctgagca aagcagacta cgagaaacac aaagtctatg cctgcgaagt cacccatcag 660ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttag 708621404DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 62atgggatgga cctggatctt tattttaatc ctgtcagtta ctacaggtgt ccactctgag 60gtccagctgc agcagtctgg acctgagctg gagaagcctg gcgcttcagt gaagatatcc 120tgcaaggctt ctggttactc cttcactggc tacaacatga actgggtgaa acagagcaat 180ggaaagagcc ttgagtggat tggaaatatt gatccttact atggtgatac taactacaac 240cagaagttca agggcaaggc cacattgact gtagacaaat cctccagcac agcctacatg 300cacctcaaga gcctgacatc tgaggactct gcagtctatt actgtgcaag accctacggt 360agtgaggcct actttgctta ctggggccaa gggactctgg tcactgtctc tgcagccaaa 420acgaagggcc catccgtctt ccccctggcg ccctgctcca ggagcacctc cgagagcaca 480gccgccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 540tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 600tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcacgaa gacctacacc 660tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agagagttga gtccaaatat 720ggtcccccat gcccaccctg cccagcacct gagttcgaag ggggaccatc agtcttcctg 780ttccccccaa aacccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 840gtggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 900gaggtgcata atgccaagac aaagccgcgg gaggagcagt tcaacagcac gtaccgtgtg 960gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 1020gtctccaaca aaggcctccc gtcctccatc gagaaaacca tctccaaagc caaagggcag 1080ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1140gtcagcctga cctgcctggt caaaggcttc taccccagcg acatcgccgt ggagtgggag 1200agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1260tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1320ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1380ctgtctctgg gtaaagctag ctga 140463705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 63atggtgtcca cttctcagct ccttggactt ttgcttttct ggacttcagc ctccagatgt 60gacattgtga tgactcagtc tccagccacc ctgtctgtga ctccaggaga tagagtctct 120ctttcctgca gggccagcca gagtattagc gactacttac actggtatca acaaaaatca 180catgagtctc caaggcttct catcaaatat gctgcccaat ccatctctgg gatcccctcc 240aggttcagtg gcagtggatc agggtcagat ttcactctca gtatcaacgg tgtggaacct 300gaagatgttg gagtgtatta ctgtcaaaat ggtcacagct ttccgtacac gttcggaggg 360gggaccaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705641395DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 64atggaatgga ggatctttct cttcatcctg tcaggaactg caggtgtcca ctcccaggtt 60cagctgcggc agtctggacc tgagctggtg aagcctgggg cttcagtgaa gatgtcctgc 120aaggcttctg gatacacatt tactgactat gttataagtt gggtgaagca gagaactgga 180cagggccttg agtggattgg agatatttat cctggaagtg gttattcttt ctacaatgag 240aacttcaagg gcaaggccac actgactgca gacaaatcct ccaccacagc ctacatgcag 300ctcagcagcc tgacatctga ggactctgcg gtctatttct gtgcaaccta ctataactac 360ccttttgctt actggggcca agggactctg gtcactgtct ctgcagccaa aacaacgggc 420ccatccgtct tccccctggc gccctgctcc aggagcacct ccgagagcac agccgccctg 480ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc 540ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact ctactccctc 600agcagcgtgg tgaccgtgcc ctccagcagc ttgggcacga agacctacac ctgcaacgta 660gatcacaagc ccagcaacac caaggtggac aagagagttg agtccaaata tggtccccca 720tgcccaccct gcccagcacc tgagttcgaa gggggaccat cagtcttcct gttcccccca 780aaacccaagg acactctcat gatctcccgg acccctgagg tcacgtgcgt ggtggtggac 840gtgagccagg aagaccccga ggtccagttc aactggtacg tggatggcgt ggaggtgcat 900aatgccaaga caaagccgcg ggaggagcag ttcaacagca cgtaccgtgt ggtcagcgtc 960ctcaccgtcc tgcaccagga ctggctgaac ggcaaggagt acaagtgcaa ggtctccaac 1020aaaggcctcc cgtcctccat cgagaaaacc atctccaaag ccaaagggca gccccgagag 1080ccacaggtgt acaccctgcc cccatcccag gaggagatga ccaagaacca ggtcagcctg 1140acctgcctgg tcaaaggctt ctaccccagc gacatcgccg tggagtggga gagcaatggg 1200cagccggaga acaactacaa gaccacgcct cccgtgctgg actccgacgg ctccttcttc 1260ctctacagca ggctaaccgt ggacaagagc aggtggcagg aggggaatgt cttctcatgc 1320tccgtgatgc atgaggctct gcacaaccac tacacacaga agagcctctc cctgtctctg 1380ggtaaagcta gctga 139565717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 65atgaagttgc ctgttaggct gttggtgctg atgttctgga ttcctgcttc cagcagtgat 60gttgtgatga cccaaactcc actctccctg cctgtccgtc ttggagatca agcctccatc 120tcttgcagat ctagtcagag ccttgtacac agtaatggaa acacctattt acattggtac 180ctgcagaagc caggccagtc tccaaagctc ctgatctaca aagtttccaa ccgattttct 240ggggtcccag acaggttcag tggcagtgga tcagggacaa atttcacact caagatcagc 300agagtggagg ctgaggatct gggactttat ttctgctctc aaagtacaca tgttccgtac 360acgttcggag gggggaccaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag 717661410DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 66atgacattga acatgctgtt ggggctgagg tgggttttct ttgttgtttt ttatcaaggt 60gtgcattgtg aggtgcagct tgttgagtct ggtggaggat tggtgcagcc taaagggtca 120ttgaaactct catgtgcagc ctctggatta accttcaata tctacgccat gaactgggtc 180cgccaggctc caggaaaggg tttggaatgg gttgctcgca taagaaataa aagtaataat 240tatgcaacat attatgccga ttcagtgaaa gacaggttca ccatctccag agatgattca 300caaagcttgc tctatctgca aatgaacaac ttgaaaactg aggacacagc catgtattac 360tgtgtgggac gggactggtt tgattactgg ggccaaggga ctctggtcac tgtctctgca 420gccaaaacga agggcccatc cgtcttcccc ctggcgccct gctccaggag cacctccgag 480agcacagccg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 540tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 600ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacgaagacc 660tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc 720aaatatggtc ccccatgccc accctgccca gcacctgagt tcgaaggggg accatcagtc 780ttcctgttcc ccccaaaacc caaggacact ctcatgatct cccggacccc tgaggtcacg 840tgcgtggtgg tggacgtgag ccaggaagac cccgaggtcc agttcaactg gtacgtggat 900ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagttcaa cagcacgtac 960cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaacggcaa ggagtacaag 1020tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc caaagccaaa 1080gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccaggagga gatgaccaag 1140aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 1200tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 1260gacggctcct tcttcctcta cagcaggcta accgtggaca agagcaggtg gcaggagggg 1320aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc 1380ctctccctgt ctctgggtaa agctagctga 141067708DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 67atggcctgga tttcacttat actctctctc ctggctctca gctcaggggc catttcccag 60gctgttgtga ctcaggaatc tgcactcacc acatcacctg gtgaaacagt cacactcact 120tgtcgctcaa gtactggggc tgttacaact agtaactatg ccaactgggt ccaagaaaaa 180ccagatcatt tattcactgg tctaataggt ggtaccaaca accgagtttc aggtgttcct 240gccagattct caggctccct gattggagac aaggctgccc tcaccatcac aggggcacag 300actgaggatg aggcaatata tttctgtgct ctatggtaca gcaaccattg ggtgttcggt 360ggaggaacca aactcgagat caaacgaact gtggctgcac catctgtctt catcttcccg 420ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc 480tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc 540caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg 600acgctgagca aagcagacta cgagaaacac aaagtctatg cctgcgaagt cacccatcag 660ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgttag 708681386DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 68atggaatgga cctgggtctt tctcttcctc ctgtcagtaa ctgcaggtgt ccactcccag 60gttcagctgc agcagtctgg agctgagctg atgaagcctg gggcctcagt gaagatatcc 120tgcaaggcta ctggctacac attcggtagc tactggatag agtgggtaaa gcagaggcct 180ggacatggcc ttgagtggat tggagagatt ttacctggaa gtggtaatac taactacaat 240gagaacttca agggcaaggc cacattcact gcagatacat cctccaacac agcctacatg 300caactcacca gtctgacatc tgaggactct gccgtctatt actgtgctag ggcggggatt 360tattggggcc aagggactct ggtcactgtc tctgcagcca aaacgaaggg cccatccgtc 420ttccccctgg cgccctgctc caggagcacc tccgagagca cagccgccct gggctgcctg 480gtcaaggact acttccccga accggtgacg gtgtcgtgga actcaggcgc cctgaccagc 540ggcgtgcaca ccttcccggc tgtcctacag tcctcaggac tctactccct cagcagcgtg 600gtgaccgtgc cctccagcag cttgggcacg aagacctaca cctgcaacgt agatcacaag 660cccagcaaca ccaaggtgga caagagagtt gagtccaaat atggtccccc atgcccaccc 720tgcccagcac ctgagttcga agggggacca tcagtcttcc tgttcccccc aaaacccaag 780gacactctca tgatctcccg gacccctgag gtcacgtgcg tggtggtgga cgtgagccag 840gaagaccccg aggtccagtt caactggtac gtggatggcg tggaggtgca taatgccaag 900acaaagccgc gggaggagca gttcaacagc acgtaccgtg tggtcagcgt cctcaccgtc 960ctgcaccagg actggctgaa cggcaaggag tacaagtgca aggtctccaa caaaggcctc 1020ccgtcctcca tcgagaaaac catctccaaa gccaaagggc agccccgaga gccacaggtg 1080tacaccctgc ccccatccca ggaggagatg accaagaacc aggtcagcct gacctgcctg 1140gtcaaaggct tctaccccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag 1200aacaactaca agaccacgcc tcccgtgctg gactccgacg gctccttctt cctctacagc 1260aggctaaccg tggacaagag caggtggcag gaggggaatg tcttctcatg ctccgtgatg 1320catgaggctc tgcacaacca ctacacacag aagagcctct ccctgtctct gggtaaagct 1380agctga 138669717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 69atggagaaag acacactcct gctatgggtc ctgcttctct gggttccagg ttccacaggt 60gacattgtgc tgacccaatc tccagctttt ttggctgtgt ctctagggca gagggccacc 120atctcctgca gagccagcga aagtgttgat aattatggca ttagttttat gaactggttc 180caacagaaac caggacagcc acccaaactc ctcatctatg ttgcatccaa gcaaggatcc 240ggggtccctg ccaggtttag tggcagtggg tctgggacag acttcagcct caacatccat 300cctatggagg aggatgatac tgcaatgtat ttctgtcagc aaagtaagga ggttcctcgg 360acgttcggtg gaggcaccaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag 717701392DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 70atggaatgta actggatact tccttttatt ctgtcggtaa cttcaggggt ctactcagag 60gttcagctcc agcagtctgg gactgtgctg gcaaggcctg gggcttcagt gaagatgtcc 120tgcaaggctt ctggctacac ctttaccagc tactggatgc actgggtaaa acagaggcct 180ggacagggtc tggaatggat tggcgctatt tatcctggaa atagtgatac tacctacaac 240cagaagttca agggcaaggc caaactgact gcagtcacat ccaccagcac tgcctacatg 300gagctcagca gcctgacaaa tgaggactct gcggtctatt actgtacacc tacttactac 360tttgactact ggggccaagg cacctctctc acagtctcct cagccaaaac gaagggccca 420tccgtcttcc ccctggcgcc ctgctccagg agcacctccg agagcacagc cgccctgggc 480tgcctggtca aggactactt ccccgaaccg gtgacggtgt cgtggaactc aggcgccctg 540accagcggcg tgcacacctt cccggctgtc ctacagtcct caggactcta ctccctcagc 600agcgtggtga ccgtgccctc cagcagcttg ggcacgaaga cctacacctg caacgtagat 660cacaagccca gcaacaccaa ggtggacaag agagttgagt ccaaatatgg tcccccatgc 720ccaccctgcc cagcacctga gttcgaaggg ggaccatcag tcttcctgtt ccccccaaaa 780cccaaggaca ctctcatgat ctcccggacc cctgaggtca cgtgcgtggt ggtggacgtg 840agccaggaag accccgaggt ccagttcaac tggtacgtgg atggcgtgga ggtgcataat 900gccaagacaa agccgcggga ggagcagttc aacagcacgt accgtgtggt cagcgtcctc 960accgtcctgc accaggactg gctgaacggc aaggagtaca agtgcaaggt ctccaacaaa 1020ggcctcccgt cctccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagagcca 1080caggtgtaca ccctgccccc atcccaggag gagatgacca agaaccaggt cagcctgacc 1140tgcctggtca aaggcttcta ccccagcgac atcgccgtgg agtgggagag caatgggcag 1200ccggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc

1260tacagcaggc taaccgtgga caagagcagg tggcaggagg ggaatgtctt ctcatgctcc 1320gtgatgcatg aggctctgca caaccactac acacagaaga gcctctccct gtctctgggt 1380aaagctagct ga 139271717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 71atgagtcctg cccaattcct gtttctgtta gtgctctgga ttcgggaaac caacggtgat 60gttgtgatga cccagactcc actcactttg tcggttacca ttggacaacc agcctccatc 120tcttgcaagt caagtcagag cctcttagat agtgatggaa agacatattt gaattggttc 180ttacagaggc caggccagtc tccaaagcgc ctaatctatc tggtgtctaa actggactct 240ggagtccctg acaggttcac tggcagtgga tcagggacag atttcacact gaaaatcagc 300agagtggagg ctgaggattt gggagtttat tattgctggc aaggtacaca ttttccgtgg 360acgttcggtg gaggcaccaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag 717721415DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 72atgggaggga tctggatctt tctcttcctc ctgtcaggaa ctgcaggtgc ccactctgag 60atccagctgc agcagactgg acctgagctg gtgaagcctg gggcttcagt gaagatatcc 120tgcaaggctt ctggttatcc attcactgac tacatcatgg tctgggtgaa gcagagccat 180ggaaagagcc ttgagtggat tggaaatatt agtccttact atggtactac taactacaat 240ctgaagttca agggcaaggc cacattgact gtagacaaat cttccagcac agcctacatg 300cagctcaaca gtctgacatc tgaggactct gcagtctatt actgtgcaag atcccctaac 360tgggacgggg cctggtttgc tcactggggc caaggggctc tggtcactgt ctctgcagcc 420aaaacaaagg gcccatccgt cttccccctg gcgccctgct ccaggagcac ctccgagagc 480acagccgccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg 540aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga 600ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac gaagacctac 660acctgcaacg tagatcacaa gcccagcaac accaaggtgg acaagagagt tgagtccaaa 720tatggtcccc catgcccacc ctgcccagca cctgagttcg aagggggacc atcagtcttc 780ctgttccccc caaaacccaa ggacactctc atgatctccc ggacccctga ggtcacgtgc 840gtggtggtgg acgtgagcca ggaagacccc gaggtccagt tcaactggta cgtggatggc 900gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agttcaacag cacgtaccgt 960gtggtcagcg tcctcaccgt cctgcaccag gactggctga acggcaagga gtacaagtgc 1020aaggtctcca acaaaggcct cccgtcctcc atcgagaaaa ccatctccaa agccaaaggg 1080cagccccgag agccacaggt gtacaccctg cccccatccc aggaggagat gaccaagaac 1140caggtcagcc tgacctgcct ggtcaaaggc ttctacccca gcgacatcgc cgtggagtgg 1200gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac 1260ggctccttct tcctctacag caggctaacc gtggacaaga gcaggtggca ggaggggaat 1320gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacaca gaagagcctc 1380tccctgtctc tgggtaaagc tagctgatta attaa 141573717DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 73atggagacag acacaatcct gctatgggtg ctgctgctct gggttccagg ctccactggt 60gacattgtgc tgacccaatc tccagcttct ttggctgtgt ctctagggca gagggccacc 120atctcctgca aggccagcca aagtgttgat tatgatggtg atagttatat gaactggttc 180caacagaaac caggacagcc acccaaactc ctcatctatg ctgcatccaa tctagaatct 240gggatcccag ccaggtttag tggcagtggg tctgggacag acttcaccct caacatccat 300cctgtggagg aggaggatgc tgcaacctat tactgtcagc aaagtaatga ggatccattc 360acgttcggct cggggacaaa gctcgagatc aaacgaactg tggctgcacc atctgtcttc 420atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctatgc ctgcgaagtc 660acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttag 717741403DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 74atggctgtcc tggggctgct tctctgcctg gtgacgttcc caagctgtgt cctgtcccag 60gtgcagctga aggagtcagg acctggcctg gtggcaccct cacagagcct gtccatcaca 120tgcactgtct ctgggttctc attatccaga tatagtgtat tttgggttcg ccagcctcca 180ggaaagggtc tggagtggct gggattgata tggggtggtg gaagcacaga ctataattca 240gctctcaaat ccagactgag catcagcaag gacaactcca agagccaagt tttcttaaaa 300atgaacagtc tgcaaactga tgacacagcc atgtactact gtgccagaat ctactttgat 360tacgacgggg ctatggacta ctggggtcaa ggaacctcag tcaccgtctc ctcagccaaa 420acaacgggcc catccgtctt ccccctggcg ccctgctcca ggagcacctc cgagagcaca 480gccgccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 540tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 600tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcacgaa gacctacacc 660tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agagagttga gtccaaatat 720ggtcccccat gcccaccctg cccagcacct gagttcgaag ggggaccatc agtcttcctg 780ttccccccaa aacccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 840gtggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 900gaggtgcata atgccaagac aaagccgcgg gaggagcagt tcaacagcac gtaccgtgtg 960gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 1020gtctccaaca aaggcctccc gtcctccatc gagaaaacca tctccaaagc caaagggcag 1080ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1140gtcagcctga cctgcctggt caaaggcttc taccccagcg acatcgccgt ggagtgggag 1200agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1260tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1320ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1380ctgtctctgg gtaaagctag ctg 140375732DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 75atgcatcgca ccagcatggg catcaagatg gagtcacgga ttcaggcatt tgtattcgtg 60tttctctggt tgtctggtgt tggcggagac attgtgatga cccagtctca caaattcatg 120tccacatcag taggagacag ggtcagcgtc acctgcaagg ccagtcagga tgtgacttct 180gctgtagcct ggtatcaaca aaaaccaggg caatctccta aactactgat ttactgggca 240tccacccggc acactggagt ccctgatcgc ttcacaggca gtggatctgg gacagattat 300actctcacca tcagcagtgg gcaggctgaa gacctggcac tttattactg tcaccaatat 360tatagcgctc ctcggacgtt cggtggaggc accaagctcg agatcaaacg aactgtggct 420gcaccatctg tcttcatctt cccgccatct gatgagcagt tgaaatctgg aactgcctct 480gttgtgtgcc tgctgaataa cttctatccc agagaggcca aagtacagtg gaaggtggat 540aacgccctcc aatcgggtaa ctcccaggag agtgtcacag agcaggacag caaggacagc 600acctacagcc tcagcagcac cctgacgctg agcaaagcag actacgagaa acacaaagtc 660tatgcctgcg aagtcaccca tcagggcctg agctcgcccg tcacaaagag cttcaacagg 720ggagagtgtt ag 732761404DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 76atggaatgga actgggtcgt tctcttcctc ctgtcattaa ctgcaggtgt ctatgcccag 60ggtcagatgc agcagtctgg agctgagctg gtgaagcctg gggcttcagt gaagctgtcc 120tgcaagactt ctggcttcac cttcagcagt aactatataa gttggttgaa gcaaaagcct 180ggacagagtc ttgagtggat tgcatggatt tatgctggaa ctggtggtat tacctataat 240cagaagttca gaggcagggc ccaactgact gtagacacat cctccagcac agcctacatg 300cagttcagca gcctgacaac tgatgactct gccatctatt actgtgcaag acacgtgagg 360ggttaccatc ctatggacta ctggggtcaa ggaacctcag tcaccgtctc ctcagccaaa 420acgaagggcc catccgtctt ccccctggcg ccctgctcca ggagcacctc cgagagcaca 480gccgccctgg gctgcctggt caaggactac ttccccgaac cggtgacggt gtcgtggaac 540tcaggcgccc tgaccagcgg cgtgcacacc ttcccggctg tcctacagtc ctcaggactc 600tactccctca gcagcgtggt gaccgtgccc tccagcagct tgggcacgaa gacctacacc 660tgcaacgtag atcacaagcc cagcaacacc aaggtggaca agagagttga gtccaaatat 720ggtcccccat gcccaccctg cccagcacct gagttcgaag ggggaccatc agtcttcctg 780ttccccccaa aacccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 840gtggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 900gaggtgcata atgccaagac aaagccgcgg gaggagcagt tcaacagcac gtaccgtgtg 960gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 1020gtctccaaca aaggcctccc gtcctccatc gagaaaacca tctccaaagc caaagggcag 1080ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1140gtcagcctga cctgcctggt caaaggcttc taccccagcg acatcgccgt ggagtgggag 1200agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1260tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1320ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1380ctgtctctgg gtaaagctag ctga 140477705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 77atggagtcac agactcaggt ctttgtatac atgttgctgt ggttgtctgg tgttgatgga 60gacattgtga tgacccagtc tcaaaaattc atgtccgcat cagtagggga cagggtcagc 120gtcacctgca gggccagtca gaatgtggtt actaatgtag gctggtatca acagaaacca 180gggcaatctc ctaaagtact gatttactcg gcatccttcc ggtacagtgg agtccctgat 240cgcttcacag gcagtggatc tgggacagat ttcactctca ccatcaccaa tgtgcagtct 300gaagacttgg cagagtattt ctgtcagcaa tataacaact atccgtacac gttcggaggg 360gggaccaagc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 705781407DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 78atgggatgga gctatatcat cctctttttg gtagcaacag ctacagatgt ccactcccag 60gtccaactgc agcagcctgg ggctgaactg gtgaagcctg gggcttcagt gaagctgtcc 120tgcaaggctt ctggctacac cttcaccagc tactggatgc actgggtgaa gcagaggcct 180ggagaaggcc ttgagtggat tggagagatt aatcctagct acggtcgtac tgactacaat 240gggaagttca agaacaaggc cacactgact gtagccaaat cctccagcac agcctacatg 300caactcagca gcctgacatc tgaggactct gcggtctatt actgtgcaag aggagattac 360tacggtagta gctcgtttgc ttactggggc caagggactc tggtcactgt ctctgcagcc 420aaaacaaagg gcccatccgt cttccccctg gcgccctgct ccaggagcac ctccgagagc 480acagccgccc tgggctgcct ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg 540aactcaggcg ccctgaccag cggcgtgcac accttcccgg ctgtcctaca gtcctcagga 600ctctactccc tcagcagcgt ggtgaccgtg ccctccagca gcttgggcac gaagacctac 660acctgcaacg tagatcacaa gcccagcaac accaaggtgg acaagagagt tgagtccaaa 720tatggtcccc catgcccacc ctgcccagca cctgagttcg aagggggacc atcagtcttc 780ctgttccccc caaaacccaa ggacactctc atgatctccc ggacccctga ggtcacgtgc 840gtggtggtgg acgtgagcca ggaagacccc gaggtccagt tcaactggta cgtggatggc 900gtggaggtgc ataatgccaa gacaaagccg cgggaggagc agttcaacag cacgtaccgt 960gtggtcagcg tcctcaccgt cctgcaccag gactggctga acggcaagga gtacaagtgc 1020aaggtctcca acaaaggcct cccgtcctcc atcgagaaaa ccatctccaa agccaaaggg 1080cagccccgag agccacaggt gtacaccctg cccccatccc aggaggagat gaccaagaac 1140caggtcagcc tgacctgcct ggtcaaaggc ttctacccca gcgacatcgc cgtggagtgg 1200gagagcaatg ggcagccgga gaacaactac aagaccacgc ctcccgtgct ggactccgac 1260ggctccttct tcctctacag caggctaacc gtggacaaga gcaggtggca ggaggggaat 1320gtcttctcat gctccgtgat gcatgaggct ctgcacaacc actacacaca gaagagcctc 1380tccctgtctc tgggtaaagc tagctga 140779705DNAArtificial SequenceDescription of Artificial Sequence Synthetic polynucleotide 79atggagtcac agactcaggt ctttgtatac atgttgctgt ggttgtctgg tgttgatgga 60gacattgtga tgacccagtc tcaaaaattc atgtccacat cattaggaga cagggtcagc 120gtcacctgca aggccagtca gaatgtgggt actaatgtag cctggtatca acagaaacca 180gggcactctc ctaaagcact gatttactcg gcatcctacc ggtacagtgg agtccctgat 240cgcttcacag gcagtggatc tgggacagat ttcactctca ccatcagcaa tgtgcagtct 300gaagacttgg cagagttttt ctgtcagcaa tataacaact atccgtacac gttcggaggg 360gggaccacgc tcgagatcaa acgaactgtg gctgcaccat ctgtcttcat cttcccgcca 420tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat 480cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag 540gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg 600ctgagcaaag cagactacga gaaacacaaa gtctatgcct gcgaagtcac ccatcagggc 660ctgagctcgc ccgtcacaaa gagcttcaac aggggagagt gttag 70580466PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 80Met Gly Arg Leu Thr Ser Ser Phe Leu Leu Leu Ile Val Pro Ala Tyr1 5 10 15Val Leu Ser Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln 20 25 30Pro Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu 35 40 45Ser Thr Ser Gly Met Ser Val Gly Trp Ile Arg Gln Pro Ser Gly Lys 50 55 60Gly Leu Glu Trp Leu Ala His Ile Trp Trp Asn Asp Asp Lys Tyr Tyr65 70 75 80Asn Pro Val Leu Lys Ser Arg Leu Thr Ile Ser Lys Glu Thr Ser Asn 85 90 95Asn Gln Val Phe Leu Lys Ile Ala Ser Val Val Ser Ala Asp Thr Ala 100 105 110Thr Tyr Tyr Cys Ala Arg Phe Tyr Gly Asn Cys Leu Asp Tyr Trp Gly 115 120 125Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Lys Gly Pro Ser 130 135 140Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala145 150 155 160Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 165 170 175Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 180 185 190Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 195 200 205Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 210 215 220Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly225 230 235 240Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser 245 250 255Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 260 265 270Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 275 280 285Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 290 295 300Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val305 310 315 320Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 325 330 335Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 340 345 350Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 355 360 365Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 370 375 380Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser385 390 395 400Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 405 410 415Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 420 425 430Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 435 440 445Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 450 455 460Ala Ser46581234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 81Met Met Ser Ser Ala Gln Phe Leu Gly Leu Leu Leu Leu Cys Phe Gln1 5 10 15Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser 20 25 30Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp 35 40 45Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val 50 55 60Lys Leu Leu Ile Tyr Tyr Thr Ser Ile Leu Gln Leu Gly Val Pro Ser65 70 75 80Arg Phe Ser Gly Ser Gly Ser Glu Thr Asp Tyr Ser Leu Thr Ile Ser 85 90 95Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asp 100 105 110Ser Leu Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 23082464PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 82Met Arg Ala Leu Ile Leu Leu Cys Leu Phe Thr Ala Phe Pro Gly Ile1 5 10 15Leu Ser Asp Val Gln Leu Gln Glu Ser Gly Pro Asp Leu Val Lys Pro 20 25

30Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr 35 40 45Ser Gly Tyr Ser Trp His Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu 50 55 60Glu Trp Met Gly Tyr Ile Leu Phe Ser Gly Ser Thr Asn Tyr Asn Pro65 70 75 80Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln 85 90 95Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr 100 105 110Phe Cys Ala Arg Ser Asn Tyr Gly Ser Phe Ala Ser Trp Gly Gln Gly 115 120 125Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Gly Pro Ser Val Phe 130 135 140Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu145 150 155 160Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 165 170 175Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 180 185 190Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 195 200 205Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro 210 215 220Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro225 230 235 240Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe 245 250 255Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 260 265 270Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val 275 280 285Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 290 295 300Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val305 310 315 320Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 325 330 335Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser 340 345 350Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 355 360 365Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 370 375 380Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly385 390 395 400Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 405 410 415Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 420 425 430Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 435 440 445Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 450 455 46083235PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 83Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Ile Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Ile 20 25 30Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser 35 40 45Ser Ser Val Ser His Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser 50 55 60Pro Lys Arg Trp Ile Tyr Asp Thr Ser Arg Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Ser His Pro Trp Ser Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 115 120 125Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 130 135 140Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe145 150 155 160Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 165 170 175Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 180 185 190Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 195 200 205Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 210 215 220Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 23584468PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 84Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser1 5 10 15Ala Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys 20 25 30Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Val Pro Gly Lys Gly Leu 50 55 60Arg Trp Met Gly Trp Met Asp Thr Phe Thr Gly Glu Pro Thr Tyr Ala65 70 75 80Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser 85 90 95Thr Ala Tyr Leu Gln Ile Asn Ser Leu Lys Asn Glu Asp Thr Ala Thr 100 105 110Tyr Phe Cys Ala Arg Gly Gly Ile Leu Arg Leu Asn Tyr Phe Asp Tyr 115 120 125Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Lys Gly 130 135 140Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser145 150 155 160Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val 210 215 220Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys225 230 235 240Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly 245 250 255Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 260 265 270Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu 275 280 285Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 290 295 300Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg305 310 315 320Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 325 330 335Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu 340 345 350Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 355 360 365Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu 370 375 380Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp385 390 395 400Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 405 410 415Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp 420 425 430Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His 435 440 445Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu 450 455 460Gly Lys Ala Ser46585234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 85Met Lys Phe Pro Ser Gln Leu Leu Leu Leu Leu Leu Phe Gly Ile Pro1 5 10 15Gly Met Ile Cys Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser 20 25 30Val Ser Leu Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asp 35 40 45Ile Tyr Asn Arg Leu Gly Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro 50 55 60Arg Leu Leu Ile Ser Gly Ala Thr Ser Leu Glu Thr Gly Val Pro Ser65 70 75 80Arg Phe Ser Gly Ser Gly Ser Gly Lys Asp Tyr Ala Leu Ser Ile Thr 85 90 95Ser Leu Gln Thr Glu Asp Leu Ala Thr Tyr Tyr Cys Gln Gln Cys Trp 100 105 110Thr Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 23086464PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 86Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Gly Gly1 5 10 15Val Leu Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 20 25 30Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Asp Tyr Tyr Met Lys Trp Val Lys Gln Ser His Gly Lys Ser Leu 50 55 60Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Gly Asp Thr Phe Tyr Asn65 70 75 80Gln Lys Phe Glu Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Arg 85 90 95Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Gly Arg Gly Asp Tyr Gly Tyr Phe Asp Val Trp Gly Ala 115 120 125Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Lys Gly Pro Ser Val 130 135 140Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala145 150 155 160Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 165 170 175Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 180 185 190Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 195 200 205Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 210 215 220Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro225 230 235 240Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val 245 250 255Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 260 265 270Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 275 280 285Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 290 295 300Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser305 310 315 320Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 325 330 335Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 340 345 350Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 355 360 365Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 370 375 380Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn385 390 395 400Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 405 410 415Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 420 425 430Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 435 440 445His Asn His Tyr Thr Gln Lys Ser Leu Leu Ser Leu Gly Lys Ala Ser 450 455 46087234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 87Met Glu Thr His Ser Gln Val Phe Val Tyr Met Leu Leu Trp Leu Ser1 5 10 15Gly Val Glu Gly Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser 20 25 30Thr Ser Val Gly Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp 35 40 45Val Gly Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro 50 55 60Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp65 70 75 80Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn 85 90 95Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Ser 100 105 110Ser Asn Pro Tyr Met Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 23088469PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 88Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly1 5 10 15Val Leu Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 20 25 30Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe 35 40 45Thr Glu Tyr Thr Met His Trp Val Arg Ser His Gly Lys Ser Leu Glu 50 55 60Trp Ile Gly Gly Ile Asn Pro Ile Asn Gly Gly Pro Thr Tyr Asn Gln65 70 75 80Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr 85 90 95Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr 100 105 110Tyr Cys Ala Arg Trp Asp Tyr Gly Ser Arg Asp Val Met Asp Tyr Trp 115 120 125Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Lys Gly Pro 130 135 140Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr145 150 155 160Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Pro 165 170 175Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn 210 215 220Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser225 230 235 240Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly 245 250 255Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 260 265 270Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln 275 280 285Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 290 295 300His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr305 310 315 320Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 325 330 335Lys Glu Tyr Lys

Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile 340 345 350Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 355 360 365Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser 370 375 380Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu385 390 395 400Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 405 410 415Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val 420 425 430Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met 435 440 445His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 450 455 460Leu Gly Lys Ala Ser46589234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 89Met Glu Thr His Ser Gln Val Phe Val Tyr Met Leu Leu Trp Leu Ser1 5 10 15Gly Val Glu Gly Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser 20 25 30Met Ser Val Gly Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn 35 40 45Val Gly Thr Tyr Val Ser Trp Tyr Gln Gln Arg Pro Glu Gln Ser Pro 50 55 60Lys Leu Leu Ile Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp65 70 75 80Arg Phe Thr Gly Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser 85 90 95Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Thr Tyr 100 105 110Ser Tyr Ile Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 23090467PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 90Met Gly Trp Ser Arg Ile Phe Leu Phe Leu Leu Ser Ile Thr Ala Gly1 5 10 15Val His Cys Gln Val Gln Val Gln Gln Ser Gly Pro Glu Leu Val Lys 20 25 30Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Asp Ala Phe 35 40 45Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 50 55 60Glu Trp Ile Gly Arg Ile Tyr Leu Gly Asp Gly Asp Ile Asn Tyr Asn65 70 75 80Gly Lys Phe Lys Gly Arg Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser 85 90 95Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Val Asp Ser Ala Val 100 105 110Tyr Phe Cys Ala Arg Gln Leu Gly Leu Trp Tyr Val Met Asp Tyr Trp 115 120 125Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Lys Gly Pro 130 135 140Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr145 150 155 160Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 165 170 175Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 180 185 190Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 195 200 205Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 210 215 220His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr225 230 235 240Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro 245 250 255Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 260 265 270Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 275 280 285Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 290 295 300Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val305 310 315 320Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 325 330 335Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 340 345 350Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 355 360 365Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 370 375 380Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu385 390 395 400Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 405 410 415Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 420 425 430Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 435 440 445Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 450 455 460Lys Ala Ser46591234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 91Met Ser Val Pro Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr1 5 10 15Gly Ala Arg Cys Asp Ile Gln Met Ala Gln Ser Pro Ala Ser Leu Ser 20 25 30Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn 35 40 45Ile Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro 50 55 60Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser65 70 75 80Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn 85 90 95Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr 100 105 110Gly Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 23092464PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 92Met Asn Phe Gly Leu Ser Leu Ile Phe Leu Val Leu Ile Leu Lys Gly1 5 10 15Val Gln Cys Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys 20 25 30Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 35 40 45Ser Ser Tyr Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu 50 55 60Glu Trp Val Ala Val Ile Ser Ser Gly Gly Ser Ser Thr Phe Tyr Pro65 70 75 80Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 85 90 95Thr Leu Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Val 100 105 110Tyr Tyr Cys Ser Arg Gly Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 115 120 125Thr Thr Leu Thr Val Ser Ala Ala Lys Thr Lys Gly Pro Ser Val Phe 130 135 140Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu145 150 155 160Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 165 170 175Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 180 185 190Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 195 200 205Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro 210 215 220Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro225 230 235 240Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe 245 250 255Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 260 265 270Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val 275 280 285Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 290 295 300Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val305 310 315 320Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 325 330 335Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser 340 345 350Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 355 360 365Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 370 375 380Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly385 390 395 400Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp 405 410 415Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 420 425 430Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 435 440 445Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 450 455 46093234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 93Met Arg Phe Gln Val Gln Val Leu Gly Leu Leu Leu Leu Trp Ile Ser1 5 10 15Gly Ala Gln Cys Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala 20 25 30Ala Ser Pro Gly Glu Thr Ile Thr Ile Asn Cys Arg Ala Ser Lys Thr 35 40 45Ile Ser Lys Tyr Leu Ala Trp Tyr Gln Glu Lys Pro Glu Lys Thr Asp 50 55 60Lys Leu Leu Ile Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser65 70 75 80Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 85 90 95Gly Leu Glu Pro Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln His Asn 100 105 110Glu Tyr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 23094462PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 94Met Gly Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly1 5 10 15Val Leu Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 20 25 30Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe 35 40 45Thr Gly Tyr Tyr Met His Trp Val Lys Gln Ser His Val Lys Ser Leu 50 55 60Glu Trp Ile Gly Arg Ile Asn Pro Tyr Asn Gly Ala Thr Ser Tyr Asn65 70 75 80Gln Asn Phe Lys Asp Lys Ala Ser Leu Thr Val Asp Lys Ser Ser Ser 85 90 95Thr Ala Tyr Met Glu Leu His Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Glu Asp Tyr Val Tyr Trp Gly Gln Gly Thr Thr 115 120 125Leu Thr Val Ser Ser Ala Lys Thr Lys Gly Pro Ser Val Phe Pro Leu 130 135 140Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys145 150 155 160Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 165 170 175Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 180 185 190Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 195 200 205Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 210 215 220Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro225 230 235 240Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe 245 250 255Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 260 265 270Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 275 280 285Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 290 295 300Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr305 310 315 320Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 325 330 335Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 340 345 350Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 355 360 365Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 370 375 380Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro385 390 395 400Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 405 410 415Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 420 425 430Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 435 440 445Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 450 455 46095238PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 95Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala1 5 10 15Ser Ser Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val 20 25 30Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu 35 40 45Val His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro 50 55 60Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser65 70 75 80Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ala 85 90 95Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys 100 105 110Ser Gln Ser Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 115 120 125Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170 175Ala Leu Gln Ser

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 180 185 190Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 23596469PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 96Met Glu Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly1 5 10 15Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys 20 25 30Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Asp Tyr Val Leu His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu 50 55 60Glu Trp Ile Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn65 70 75 80Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser 85 90 95Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Gly Tyr Pro Ala Tyr Ser Gly Tyr Ala Met Asp 115 120 125Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Lys 130 135 140Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu145 150 155 160Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn 210 215 220Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser225 230 235 240Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly 245 250 255Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 260 265 270Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln 275 280 285Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 290 295 300His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr305 310 315 320Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 325 330 335Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile 340 345 350Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 355 360 365Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser 370 375 380Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu385 390 395 400Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 405 410 415Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val 420 425 430Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met 435 440 445His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 450 455 460Leu Gly Lys Ala Ser46597234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 97Met Met Ser Ser Ala Gln Phe Leu Gly Leu Leu Leu Leu Cys Phe Gln1 5 10 15Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser 20 25 30Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp 35 40 45Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val 50 55 60Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser65 70 75 80Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser 85 90 95Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys His His Gly Asn 100 105 110Thr Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 23098467PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 98Met Asn Leu Gly Leu Ser Leu Ile Phe Leu Val Leu Val Leu Lys Gly1 5 10 15Val Gln Cys Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln 20 25 30Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe 35 40 45Ser Asp Tyr Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu 50 55 60Glu Trp Val Ala Tyr Ile Asn Ser Gly Gly Gly Ser Thr Tyr Tyr Pro65 70 75 80Asp Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn 85 90 95Thr Leu Tyr Leu Gln Met Ser Arg Leu Lys Ser Glu Asp Thr Ala Met 100 105 110Tyr Tyr Cys Ala Arg Arg Gly Leu Pro Phe His Ala Met Asp Tyr Trp 115 120 125Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Lys Gly Pro 130 135 140Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr145 150 155 160Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 165 170 175Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 180 185 190Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 195 200 205Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 210 215 220His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr225 230 235 240Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro 245 250 255Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 260 265 270Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 275 280 285Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 290 295 300Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val305 310 315 320Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 325 330 335Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 340 345 350Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 355 360 365Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 370 375 380Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu385 390 395 400Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 405 410 415Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 420 425 430Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 435 440 445Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 450 455 460Lys Ala Ser46599234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 99Met Met Ser Ser Ala Gln Phe Leu Gly Leu Leu Leu Leu Cys Phe Gln1 5 10 15Gly Thr Arg Cys Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser 20 25 30Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly 35 40 45Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val 50 55 60Lys Leu Leu Ile Tyr Tyr Thr Ser Ile Leu His Ser Gly Val Pro Ser65 70 75 80Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Gly 85 90 95Asn Leu Glu Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Phe Asn 100 105 110Lys Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230100467PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 100Met Asp Trp Leu Trp Asn Leu Leu Phe Leu Met Ala Ala Ala Gln Ser1 5 10 15Ala Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys 20 25 30Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe 35 40 45Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu 50 55 60Lys Trp Met Gly Trp Ile Asn Thr Tyr Thr Gly Glu Ser Thr Tyr Ala65 70 75 80Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser 85 90 95Thr Ala Tyr Leu Gln Ile Ser Asn Leu Lys Asn Glu Asp Met Ala Thr 100 105 110Tyr Phe Cys Ala Arg Gly Asp Phe Arg Tyr Tyr Tyr Phe Asp Tyr Trp 115 120 125Gly Gln Gly Thr Thr Leu Thr Gly Ser Ser Ala Lys Thr Lys Gly Pro 130 135 140Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr145 150 155 160Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 165 170 175Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 180 185 190Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 195 200 205Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 210 215 220His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr225 230 235 240Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro 245 250 255Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 260 265 270Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 275 280 285Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 290 295 300Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val305 310 315 320Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 325 330 335Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 340 345 350Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 355 360 365Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 370 375 380Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu385 390 395 400Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 405 410 415Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 420 425 430Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 435 440 445Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 450 455 460Lys Ala Ser465101233PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 101Met Ser Val Leu Thr Gln Val Leu Ala Leu Leu Leu Leu Trp Leu Thr1 5 10 15Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser 20 25 30Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn 35 40 45Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro 50 55 60Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser65 70 75 80Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn 85 90 95Thr Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp 100 105 110Asp Ser Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr 115 120 125Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro145 150 155 160Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly 165 170 175Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr 180 185 190Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 195 200 205Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val 210 215 220Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230102465PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 102Met Glu Trp Thr Trp Val Phe Leu Phe Leu Leu Ser Val Thr Ala Gly1 5 10 15Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys 20 25 30Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe 35 40 45Ser Ser Tyr Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu 50 55 60Glu Trp Ile Gly Glu Ile Leu Pro Gly Ser Gly Arg Thr Asn Asp Asn65 70 75 80Glu Lys Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Lys 85 90 95Lys Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Arg Gly Gly Tyr Ser Phe Ala Tyr Trp Gly Gln 115 120 125Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Lys Gly Pro Ser Val 130 135 140Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala145 150 155 160Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 165 170 175Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 180 185 190Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 195 200 205Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 210 215 220Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro225 230 235 240Pro Cys Pro Pro

Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val 245 250 255Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 260 265 270Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 275 280 285Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 290 295 300Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser305 310 315 320Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 325 330 335Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 340 345 350Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 355 360 365Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 370 375 380Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn385 390 395 400Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 405 410 415Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 420 425 430Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 435 440 445His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala 450 455 460Ser465103236PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 103Met Thr Met Phe Ser Leu Ala Leu Leu Leu Ser Leu Leu Leu Leu Cys1 5 10 15Val Ser Asp Ser Arg Ala Glu Thr Thr Val Thr Gln Ser Pro Ala Ser 20 25 30Leu Ser Met Ala Ile Gly Glu Lys Val Thr Ile Arg Cys Val Thr Ser 35 40 45Thr Asp Ile Asp Asp Asp Val Asn Trp Tyr Gln Gln Lys Pro Gly Glu 50 55 60Pro Pro Lys Leu Leu Ile Ser Glu Gly Asn Thr Leu Arg Pro Gly Val65 70 75 80Pro Ser Arg Phe Ser Ser Ser Gly Tyr Gly Thr Asp Phe Val Phe Thr 85 90 95Ile Glu Asn Met Leu Ser Glu Asp Val Ala Asp Tyr Tyr Cys Leu Gln 100 105 110Ser Gly Asn Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 115 120 125Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 130 135 140Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn145 150 155 160Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 165 170 175Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 180 185 190Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 195 200 205Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 210 215 220Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235104467PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 104Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser1 5 10 15Ala Gln Ala Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys 20 25 30Pro Gly Glu Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Asn Tyr Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu 50 55 60Lys Trp Val Gly Trp Ile Asn Thr Phe Thr Gly Glu Pro Thr Tyr Val65 70 75 80Asp Asp Phe Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser 85 90 95Thr Ala Tyr Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr 100 105 110Tyr Phe Cys Ala Arg Gly Asn Phe Arg Tyr Tyr Tyr Phe Asp Tyr Trp 115 120 125Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr Lys Gly Pro 130 135 140Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr145 150 155 160Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 165 170 175Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 180 185 190Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 195 200 205Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 210 215 220His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr225 230 235 240Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro 245 250 255Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 260 265 270Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 275 280 285Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 290 295 300Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val305 310 315 320Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 325 330 335Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 340 345 350Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 355 360 365Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 370 375 380Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu385 390 395 400Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 405 410 415Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 420 425 430Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 435 440 445Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 450 455 460Lys Ala Ser465105234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 105Met Ser Val Leu Thr Gln Val Leu Ala Leu Leu Leu Leu Trp Leu Thr1 5 10 15Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser 20 25 30Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Thr Ser Gly Asn 35 40 45Ile Arg Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro 50 55 60Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser65 70 75 80Arg Phe Gly Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn 85 90 95Ser Leu Gln Pro Glu Asp Phe Gly Asn Tyr Tyr Cys Gln His Phe Trp 100 105 110Ser Ser Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230106469PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 106Met Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr1 5 10 15Asp Val His Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val 20 25 30Lys Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr 35 40 45Phe Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Glu Gly 50 55 60Leu Glu Trp Ile Gly Glu Ile Asn Pro Ser Tyr Gly Arg Thr Asp Tyr65 70 75 80Asn Glu Lys Phe Lys Asn Lys Ala Thr Leu Thr Val Ala Lys Ser Ser 85 90 95Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala 100 105 110Val Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Ser Ser Phe Ala 115 120 125Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Lys 130 135 140Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu145 150 155 160Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn 210 215 220Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser225 230 235 240Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly 245 250 255Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 260 265 270Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln 275 280 285Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 290 295 300His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr305 310 315 320Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 325 330 335Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile 340 345 350Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 355 360 365Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser 370 375 380Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu385 390 395 400Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 405 410 415Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val 420 425 430Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met 435 440 445His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 450 455 460Leu Gly Lys Ala Ser465107235PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 107Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Met Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Leu 20 25 30Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser 35 40 45Ser Asn Ile Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Leu Thr Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Thr 85 90 95Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Cys Cys Gln Gln Trp 100 105 110Ser Ser Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys 115 120 125Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 130 135 140Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe145 150 155 160Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 165 170 175Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 180 185 190Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 195 200 205Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 210 215 220Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235108235PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 108Met Asp Phe Arg Val Gln Ile Phe Ser Phe Leu Leu Met Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Leu 20 25 30Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser 35 40 45Ser Asn Ile Ser Tyr Met Tyr Trp Tyr Gln Gln Lys Pro Arg Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Leu Thr Ser Asn Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Ser Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys 115 120 125Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 130 135 140Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe145 150 155 160Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 165 170 175Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 180 185 190Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 195 200 205Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 210 215 220Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235109238PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 109Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1 5 10 15Gly Ser Thr Gly Asp Ile Val Leu Ile Gln Ser Pro Ala Ser Leu Ala 20 25 30Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45Val Asp Ser Tyr Val Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro 50 55 60Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Val Ser Asn Leu Glu Ser65 70 75 80Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr 85 90 95Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys 100 105 110Gln Gln Ser Asn Glu Asp Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu 115 120 125Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170 175Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 180 185 190Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235110465PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 110Met Glu Cys Asn Trp Ile Leu Pro Phe Ile Leu Ser Val Ile Ser Gly1 5 10 15Val Tyr Ser Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg 20 25 30Pro Gly Ala Ser Val Asn Met Ser Cys Lys Ala Ala Gly Tyr Ser Phe 35 40 45Thr Ser Tyr Trp Val Tyr Trp Val Lys Gln Arg

Pro Gly Gln Gly Leu 50 55 60Glu Trp Ile Gly Ala Ile Tyr Pro Lys Asn Ser Arg Thr Ser Tyr Asn65 70 75 80Gln Lys Phe Gln Asp Lys Ala Thr Leu Thr Ala Val Thr Ser Ala Ser 85 90 95Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Thr Arg Pro His Tyr Asp Ser Phe Gly Tyr Trp Gly Gln 115 120 125Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Lys Gly Pro Ser Val 130 135 140Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala145 150 155 160Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 165 170 175Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 180 185 190Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 195 200 205Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 210 215 220Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro225 230 235 240Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val 245 250 255Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 260 265 270Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 275 280 285Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 290 295 300Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser305 310 315 320Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 325 330 335Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 340 345 350Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 355 360 365Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 370 375 380Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn385 390 395 400Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 405 410 415Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 420 425 430Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 435 440 445His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala 450 455 460Ser465111238PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 111Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1 5 10 15Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 20 25 30Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45Val Asp Ser Tyr Gly Ile Ser Phe Met His Trp Tyr Gln Gln Lys Pro 50 55 60Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Gln Glu Ser65 70 75 80Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr 85 90 95Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys 100 105 110Gln Gln Ser Asn Glu Asp Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu 115 120 125Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170 175Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 180 185 190Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235112473PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 112Asn Arg Leu Thr Ser Ser Leu Leu Leu Leu Ile Val Pro Ala Tyr Val1 5 10 15Leu Ser Gln Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln 20 25 30Pro Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu 35 40 45Ser Thr Ser Gly Met Gly Val Ser Trp Ile Arg Gln Pro Ser Gly Lys 50 55 60Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr65 70 75 80Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Phe Lys Asp Pro Ser Ser 85 90 95Asn Gln Val Phe Leu Arg Ile Thr Ser Val Asp Thr Ala Asp Thr Ala 100 105 110Thr Tyr Tyr Cys Ala Arg Asn Ser His Tyr Tyr Gly Ser Thr Tyr Gly 115 120 125Gly Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser 130 135 140Ala Lys Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg145 150 155 160Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 165 170 175Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 180 185 190Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 195 200 205Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 210 215 220Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys225 230 235 240Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 245 250 255Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 290 295 300Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe305 310 315 320Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325 330 335Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 340 345 350Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 370 375 380Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp385 390 395 400Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 435 440 445Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450 455 460Leu Ser Leu Ser Leu Gly Lys Ala Ser465 470113238PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 113Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Gly Val Pro1 5 10 15Gly Ser Thr Gly Asn Ile Val Leu Thr Gln Ser Pro Thr Ser Phe Thr 20 25 30Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45Val His Ser Tyr Gly Asn Ser Phe Met His Trp Tyr Gln Gln Lys Pro 50 55 60Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Val Glu Ser65 70 75 80Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr 85 90 95Leu Thr Ile Asp Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr Tyr Cys 100 105 110Gln Gln Asn Ser Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 115 120 125Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170 175Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 180 185 190Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235114465PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 114Met Glu Trp Thr Trp Val Phe Leu Phe Leu Leu Ser Val Thr Ala Gly1 5 10 15Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Thr Glu Leu Met Lys 20 25 30Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe 35 40 45Ser Thr Tyr Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu 50 55 60Glu Trp Ile Gly Glu Ile Leu Pro Gly Ser Gly Arg Thr Asn Asp Asn65 70 75 80Glu Lys Phe Lys Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Lys 85 90 95Lys Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Arg Gly Gly Tyr Ser Phe Ala Phe Trp Gly Gln 115 120 125Gly Thr Leu Val Ser Val Ser Ala Ala Lys Thr Lys Gly Pro Ser Val 130 135 140Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala145 150 155 160Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 165 170 175Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 180 185 190Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 195 200 205Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 210 215 220Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro225 230 235 240Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val 245 250 255Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 260 265 270Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 275 280 285Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 290 295 300Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser305 310 315 320Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 325 330 335Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 340 345 350Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 355 360 365Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 370 375 380Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn385 390 395 400Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 405 410 415Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 420 425 430Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 435 440 445His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala 450 455 460Ser465115236PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 115Met Thr Met Phe Ser Leu Ala Leu Leu Leu Ser Leu Leu Leu Leu Cys1 5 10 15Val Ser Asp Ser Arg Ala Glu Thr Thr Val Thr Gln Ser Pro Ala Ser 20 25 30Leu Ser Met Ala Ile Gly Glu Lys Val Thr Ile Arg Cys Val Thr Ser 35 40 45Thr Asp Ile Asp Asp Asp Val Asn Trp Tyr Gln Gln Lys Pro Gly Glu 50 55 60Pro Pro Lys Leu Leu Ile Ser Glu Gly Asn Thr Leu Arg Ala Gly Val65 70 75 80Pro Ser Arg Phe Ser Ser Ser Gly Tyr Gly Thr Asp Phe Val Phe Thr 85 90 95Ile Glu Asn Met Leu Ser Glu Asp Val Ala Asp Tyr Tyr Cys Leu Gln 100 105 110Ser Gly Asn Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 115 120 125Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp 130 135 140Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn145 150 155 160Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu 165 170 175Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp 180 185 190Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr 195 200 205Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser 210 215 220Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235116473PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 116Met Asn Arg Leu Thr Ser Ser Leu Leu Leu Leu Ile Val Pro Ala Tyr1 5 10 15Val Leu Ser Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln 20 25 30Pro Ser Gln Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu 35 40 45Ser Thr Ser Gly Met Gly Leu Ser Trp Ile Arg Gln Pro Ser Gly Lys 50 55 60Gly Leu Glu Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr65 70 75 80Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser 85 90 95Asn Gln Val Phe Leu Lys Ile Thr Ile Val Asp Thr Ala Asp Ala Ala 100 105 110Thr Tyr Tyr Cys Ala Arg Ser Ser His Tyr Tyr Gly Tyr Gly Tyr Gly 115 120 125Gly Tyr Phe Asp Val Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser 130 135 140Ala Lys Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg145 150 155 160Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 165 170 175Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 180 185 190Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 195 200 205Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 210 215 220Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys225 230 235 240Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 245 250 255Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 290 295 300Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe305 310 315 320Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 325 330 335Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu

340 345 350Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 370 375 380Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp385 390 395 400Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 435 440 445Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 450 455 460Leu Ser Leu Ser Leu Gly Lys Ala Ser465 470117238PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 117Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1 5 10 15Gly Ser Thr Gly Asn Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 20 25 30Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45Ile His Ser Tyr Gly Asn Ser Phe Leu His Trp Tyr Gln Gln Lys Pro 50 55 60Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser65 70 75 80Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr 85 90 95Leu Thr Ile Asp Pro Val Glu Ala Asp Asp Ala Ala Thr Tyr Tyr Cys 100 105 110Gln Gln Asn Asn Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 115 120 125Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170 175Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 180 185 190Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235118467PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 118Met Lys Cys Ser Trp Val Ile Phe Phe Leu Met Ala Val Val Thr Gly1 5 10 15Val Asn Ser Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg 20 25 30Pro Gly Ala Leu Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn Ile 35 40 45Asn Asp Tyr Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu 50 55 60Glu Arg Ile Gly Trp Ile Asp Pro Asp Asn Gly Asn Thr Ile Tyr Asp65 70 75 80Pro Lys Phe Gln Gly Lys Ala Ser Ile Thr Ala Asp Thr Ser Pro Asn 85 90 95Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val 100 105 110Tyr Tyr Cys Ala Arg Thr Arg Ser Pro Met Val Thr Thr Gly Phe Val 115 120 125Tyr Trp Gly Gln Gly Thr Val Val Thr Val Ser Ala Ala Lys Thr Lys 130 135 140Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu145 150 155 160Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn 210 215 220Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser225 230 235 240Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly 245 250 255Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 260 265 270Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln 275 280 285Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 290 295 300His Asn Ala Lys Xaa Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr305 310 315 320Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 325 330 335Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile 340 345 350Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 355 360 365Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser 370 375 380Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu385 390 395 400Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 405 410 415Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val 420 425 430Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met 435 440 445His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 450 455 460Leu Gly Lys465119474PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 119Met Glu Arg His Trp Ile Phe Leu Phe Leu Phe Ser Val Thr Ala Gly1 5 10 15Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Lys 20 25 30Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Thr Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 50 55 60Glu Trp Ile Gly Tyr Ile Asn Pro Ile Thr Gly Tyr Thr Glu Tyr Asn65 70 75 80Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser 85 90 95Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Glu Gly Leu Ser Ala Met Asp Tyr Trp Gly Gln 115 120 125Gly Thr Ser Val Thr Val Thr Ser Ala Lys Thr Thr Ala Pro Ser Val 130 135 140Tyr Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr145 150 155 160Leu Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr 165 170 175Trp Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val 180 185 190Leu Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser 195 200 205Ser Thr Trp Pro Ser Gln Thr Val Thr Cys Ser Val Ala His Pro Ala 210 215 220Ser Ser Thr Thr Val Asp Lys Lys Leu Glu Pro Ser Gly Pro Ile Ser225 230 235 240Thr Ile Asn Pro Cys Pro Pro Cys Lys Glu Cys His Lys Cys Pro Ala 245 250 255Pro Asn Leu Glu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Asn Ile 260 265 270Lys Asp Val Leu Met Ile Ser Leu Thr Pro Lys Val Thr Cys Val Val 275 280 285Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val 290 295 300Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp305 310 315 320Tyr Asn Ser Thr Ile Arg Val Val Ser Thr Leu Pro Ile Gln His Gln 325 330 335Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp 340 345 350Leu Pro Ser Pro Ile Glu Arg Thr Ile Ser Lys Ile Lys Gly Leu Val 355 360 365Arg Ala Pro Gln Val Tyr Ile Leu Pro Pro Pro Ala Glu Gln Leu Ser 370 375 380Arg Lys Asp Val Ser Leu Thr Cys Leu Val Val Gly Phe Asn Pro Gly385 390 395 400Asp Ile Ser Val Glu Trp Thr Ser Asn Gly His Thr Glu Glu Asn Tyr 405 410 415Lys Asp Thr Ala Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Ile Tyr 420 425 430Ser Lys Leu Asn Met Lys Thr Ser Lys Trp Glu Lys Thr Asp Ser Phe 435 440 445Ser Cys Asn Val Arg His Glu Gly Leu Lys Asn Tyr Tyr Leu Lys Lys 450 455 460Thr Ile Ser Arg Ser Pro Gly Lys Ala Ser465 470120234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 120Met Glu Ser Arg Ile Gln Ala Phe Val Phe Val Phe Leu Trp Leu Ser1 5 10 15Gly Val Gly Gly Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser 20 25 30Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asp 35 40 45Val Thr Ser Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro 50 55 60Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp65 70 75 80Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser 85 90 95Ser Gly Gln Ala Glu Asp Leu Ala Leu Tyr Tyr Cys His Gln Tyr Tyr 100 105 110Ser Ala Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Val Lys Arg 115 120 125Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln 130 135 140Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr145 150 155 160Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln 165 170 175Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg 195 200 205His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro 210 215 220Ile Val Lys Ser Phe Asn Arg Asn Glu Cys225 230121465PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 121Met Glu Arg His Trp Ile Phe Leu Phe Leu Phe Ser Val Thr Ala Gly1 5 10 15Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Lys 20 25 30Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Thr Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 50 55 60Glu Trp Ile Gly Tyr Ile Asn Pro Ile Thr Gly Tyr Thr Glu Tyr Asn65 70 75 80Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser 85 90 95Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Glu Gly Leu Ser Ala Met Asp Tyr Trp Gly Gln 115 120 125Gly Thr Ser Val Thr Val Thr Ser Ala Lys Thr Thr Gly Pro Ser Val 130 135 140Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala145 150 155 160Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 165 170 175Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 180 185 190Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 195 200 205Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 210 215 220Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro225 230 235 240Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val 245 250 255Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 260 265 270Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 275 280 285Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 290 295 300Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser305 310 315 320Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 325 330 335Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 340 345 350Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 355 360 365Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 370 375 380Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn385 390 395 400Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 405 410 415Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 420 425 430Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 435 440 445His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala 450 455 460Ser465122234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 122Met Glu Ser Gln Ile Gln Ala Phe Val Phe Val Phe Leu Trp Leu Ser1 5 10 15Gly Val Gly Gly Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser 20 25 30Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asp 35 40 45Val Thr Ser Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro 50 55 60Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp65 70 75 80Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser 85 90 95Ser Gly Gln Ala Glu Asp Leu Ala Leu Tyr Tyr Cys His Gln Tyr Tyr 100 105 110Ser Ala Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230123466PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 123Met Ala Val Leu Ala Leu Leu Leu Cys Leu Val Ala Phe Pro Thr Cys1 5 10 15Thr Leu Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala 20 25 30Pro Ser Gln Ser Leu Ser Ile Thr Cys Ser Val Ser Gly Phe Ser Leu 35 40 45Ser Asn Tyr Asp Ile Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu 50 55 60Glu Trp Leu Gly Val Met Trp Thr Gly Gly Gly Ala Asn Tyr Asn Ser65 70 75 80Ala Phe Met Ser Arg Leu Ser Ile Asn Lys Asp Asn Ser Lys Ser Gln 85 90 95Val Phe Leu Lys Met Asn Asn Leu Gln Thr Asp Asp Thr Ala Ile Tyr 100 105 110Tyr Cys Val Arg Asp Ala Val Arg Tyr Trp Asn Phe Asp Val Trp Gly 115 120 125Ala Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr Lys Gly Pro Ser 130 135 140Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala145 150 155 160Ala Leu

Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 165 170 175Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 180 185 190Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 195 200 205Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 210 215 220Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly225 230 235 240Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser 245 250 255Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 260 265 270Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 275 280 285Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 290 295 300Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val305 310 315 320Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 325 330 335Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 340 345 350Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 355 360 365Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 370 375 380Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser385 390 395 400Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 405 410 415Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 420 425 430Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 435 440 445Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 450 455 460Ala Ser465124235PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 124Met Asp Phe Gln Ala Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile 20 25 30Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser 35 40 45Ser Ser Val Ser Tyr Ile His Trp Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60Pro Lys Pro Trp Ile Tyr Ala Thr Ser His Leu Ala Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Val Glu Ala Glu Asp Thr Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110Ser Ser Asn Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 115 120 125Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 130 135 140Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe145 150 155 160Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 165 170 175Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 180 185 190Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 195 200 205Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 210 215 220Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235125469PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 125Met Glu Arg His Trp Ile Phe Leu Leu Leu Leu Ser Val Thr Ala Gly1 5 10 15Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg 20 25 30Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Thr Tyr Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 50 55 60Glu Trp Ile Gly Tyr Ile Asn Pro Ser Ser Gly Tyr Thr Asn Tyr Asn65 70 75 80Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser 85 90 95Thr Ala Ser Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Glu Arg Ala Val Leu Val Pro Tyr Ala Met Asp 115 120 125Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Lys 130 135 140Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu145 150 155 160Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn 210 215 220Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser225 230 235 240Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly 245 250 255Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 260 265 270Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln 275 280 285Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 290 295 300His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr305 310 315 320Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 325 330 335Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile 340 345 350Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 355 360 365Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser 370 375 380Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu385 390 395 400Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 405 410 415Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val 420 425 430Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met 435 440 445His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 450 455 460Leu Gly Lys Ala Ser465126235PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 126Met His Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser1 5 10 15Val Ile Met Ser Arg Gly Gln Ile Val Leu Thr Gln Ser Pro Ala Val 20 25 30Met Ser Ala Ser Pro Gly Glu Lys Val Thr Ile Thr Cys Thr Ala Ser 35 40 45Ser Ser Leu Ser Tyr Met His Trp Phe Gln Gln Lys Pro Gly Thr Ser 50 55 60Pro Lys Leu Trp Leu Tyr Ser Thr Ser Ile Leu Ala Ser Gly Val Pro65 70 75 80Thr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95Ser Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Arg 100 105 110Ser Ser Ser Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 115 120 125Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 130 135 140Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe145 150 155 160Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 165 170 175Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 180 185 190Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 195 200 205Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 210 215 220Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235127467PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 127Met Gly Trp Thr Trp Ile Phe Ile Leu Ile Leu Ser Val Thr Thr Gly1 5 10 15Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys 20 25 30Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe 35 40 45Thr Gly Tyr Asn Met Asn Trp Val Lys Gln Ser Asn Gly Lys Ser Leu 50 55 60Glu Trp Ile Gly Asn Ile Asp Pro Tyr Tyr Gly Asp Thr Asn Tyr Asn65 70 75 80Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser 85 90 95Thr Ala Tyr Met His Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Pro Tyr Gly Ser Glu Ala Tyr Phe Ala Tyr Trp 115 120 125Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Lys Gly Pro 130 135 140Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr145 150 155 160Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 165 170 175Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 180 185 190Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 195 200 205Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 210 215 220His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr225 230 235 240Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro 245 250 255Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 260 265 270Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 275 280 285Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 290 295 300Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val305 310 315 320Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 325 330 335Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 340 345 350Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 355 360 365Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 370 375 380Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu385 390 395 400Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 405 410 415Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 420 425 430Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 435 440 445Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 450 455 460Lys Ala Ser465128214PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 128Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly1 5 10 15Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asp Tyr 20 25 30Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 35 40 45Lys Tyr Ala Ala Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Gly Val Glu Pro65 70 75 80Glu Asp Val Gly Val Tyr Tyr Cys Gln Asn Gly His Ser Phe Pro Tyr 85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys 210129446PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 129Gln Val Gln Leu Arg Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala1 5 10 15Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30Val Ile Ser Trp Val Lys Gln Arg Thr Gly Gln Gly Leu Glu Trp Ile 35 40 45Gly Asp Ile Tyr Pro Gly Ser Gly Tyr Ser Phe Tyr Asn Glu Asn Phe 50 55 60Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr65 70 75 80Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys 85 90 95Ala Thr Tyr Tyr Asn Tyr Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105 110Val Thr Val Ser Ala Ala Lys Thr Thr Gly Pro Ser Val Phe Pro Leu 115 120 125Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys 130 135 140Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser145 150 155 160Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn 195 200 205Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro 210 215 220Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe225 230 235 240Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 245 250 255Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe 260 265 270Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 275 280 285Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val305 310 315 320Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln 340 345 350Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser385 390 395 400Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu 405 410 415Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 435 440 445130219PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 130Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Arg Leu Gly1 5 10 15Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser

20 25 30Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asn Phe Thr Leu Lys Ile65 70 75 80Ser Arg Val Glu Ala Glu Asp Leu Gly Leu Tyr Phe Cys Ser Gln Ser 85 90 95Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln145 150 155 160Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215131469PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 131Met Thr Leu Asn Met Leu Leu Gly Leu Arg Trp Val Phe Phe Val Val1 5 10 15Phe Tyr Gln Gly Val His Cys Glu Val Gln Leu Val Glu Ser Gly Gly 20 25 30Gly Leu Val Gln Pro Lys Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser 35 40 45Gly Leu Thr Phe Asn Ile Tyr Ala Met Asn Trp Val Arg Gln Ala Pro 50 55 60Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Arg Asn Lys Ser Asn Asn65 70 75 80Tyr Ala Thr Tyr Tyr Ala Asp Ser Val Lys Asp Arg Phe Thr Ile Ser 85 90 95Arg Asp Asp Ser Gln Ser Leu Leu Tyr Leu Gln Met Asn Asn Leu Lys 100 105 110Thr Glu Asp Thr Ala Met Tyr Tyr Cys Val Gly Arg Asp Trp Phe Asp 115 120 125Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Lys 130 135 140Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu145 150 155 160Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro 165 170 175Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr 180 185 190Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val 195 200 205Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn 210 215 220Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser225 230 235 240Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly 245 250 255Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 260 265 270Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln 275 280 285Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val 290 295 300His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr305 310 315 320Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 325 330 335Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile 340 345 350Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 355 360 365Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser 370 375 380Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu385 390 395 400Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 405 410 415Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val 420 425 430Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met 435 440 445His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 450 455 460Leu Gly Lys Ala Ser465132235PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 132Met Ala Trp Ile Ser Leu Ile Leu Ser Leu Leu Ala Leu Ser Ser Gly1 5 10 15Ala Ile Ser Gln Ala Val Val Thr Gln Glu Ser Ala Leu Thr Thr Ser 20 25 30Pro Gly Glu Thr Val Thr Leu Thr Cys Arg Ser Ser Thr Gly Ala Val 35 40 45Thr Thr Ser Asn Tyr Ala Asn Trp Val Gln Glu Lys Pro Asp His Leu 50 55 60Phe Thr Gly Leu Ile Gly Gly Thr Asn Asn Arg Val Ser Gly Val Pro65 70 75 80Ala Arg Phe Ser Gly Ser Leu Ile Gly Asp Lys Ala Ala Leu Thr Ile 85 90 95Thr Gly Ala Gln Thr Glu Asp Glu Ala Ile Tyr Phe Cys Ala Leu Trp 100 105 110Tyr Ser Asn His Trp Val Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 115 120 125Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 130 135 140Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe145 150 155 160Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 165 170 175Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 180 185 190Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 195 200 205Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 210 215 220Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235133461PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 133Met Glu Trp Thr Trp Val Phe Leu Phe Leu Leu Ser Val Thr Ala Gly1 5 10 15Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys 20 25 30Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe 35 40 45Gly Ser Tyr Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu 50 55 60Glu Trp Ile Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asn Tyr Asn65 70 75 80Glu Asn Phe Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser Asn 85 90 95Thr Ala Tyr Met Gln Leu Thr Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Ala Gly Ile Tyr Trp Gly Gln Gly Thr Leu Val 115 120 125Thr Val Ser Ala Ala Lys Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 130 135 140Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu145 150 155 160Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly 165 170 175Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser 180 185 190Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu 195 200 205Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr 210 215 220Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro225 230 235 240Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro 245 250 255Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr 260 265 270Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn 275 280 285Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg 290 295 300Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val305 310 315 320Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 325 330 335Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys 340 345 350Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu 355 360 365Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 370 375 380Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu385 390 395 400Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe 405 410 415Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly 420 425 430Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr 435 440 445Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 450 455 460134238PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 134Met Glu Lys Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro1 5 10 15Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Phe Leu Ala 20 25 30Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser 35 40 45Val Asp Asn Tyr Gly Ile Ser Phe Met Asn Trp Phe Gln Gln Lys Pro 50 55 60Gly Gln Pro Pro Lys Leu Leu Ile Tyr Val Ala Ser Lys Gln Gly Ser65 70 75 80Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser 85 90 95Leu Asn Ile His Pro Met Glu Glu Asp Asp Thr Ala Met Tyr Phe Cys 100 105 110Gln Gln Ser Lys Glu Val Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu 115 120 125Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170 175Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 180 185 190Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235135463PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 135Met Glu Cys Asn Trp Ile Leu Pro Phe Ile Leu Ser Val Thr Ser Gly1 5 10 15Val Tyr Ser Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg 20 25 30Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu 50 55 60Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn65 70 75 80Gln Lys Phe Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Thr Ser 85 90 95Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Thr Pro Thr Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 115 120 125Ser Leu Thr Val Ser Ser Ala Lys Thr Lys Gly Pro Ser Val Phe Pro 130 135 140Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly145 150 155 160Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 165 170 175Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 180 185 190Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 195 200 205Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 210 215 220Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys225 230 235 240Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu 245 250 255Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 260 265 270Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln 275 280 285Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 290 295 300Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu305 310 315 320Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 325 330 335Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys 340 345 350Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 355 360 365Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 370 375 380Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln385 390 395 400Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 405 410 415Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln 420 425 430Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 435 440 445His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 450 455 460136238PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 136Met Ser Pro Ala Gln Phe Leu Phe Leu Leu Val Leu Trp Ile Arg Glu1 5 10 15Thr Asn Gly Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val 20 25 30Thr Ile Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu 35 40 45Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro 50 55 60Gly Gln Ser Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser65 70 75 80Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr 85 90 95Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys 100 105 110Trp Gln Gly Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu 115 120 125Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170 175Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 180 185 190Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235137468PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 137Met Gly Gly Ile Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly1 5 10 15Ala His Ser Glu Ile Gln Leu Gln Gln Thr Gly Pro Glu Leu Val Lys 20 25 30Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Pro Phe 35 40 45Thr Asp Tyr Ile Met Val Trp Val Lys Gln Ser His Gly Lys Ser Leu 50 55 60Glu Trp Ile Gly Asn Ile Ser Pro Tyr Tyr Gly Thr Thr Asn Tyr Asn65 70 75 80Leu Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser 85 90 95Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser

Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Ser Pro Asn Trp Asp Gly Ala Trp Phe Ala His 115 120 125Trp Gly Gln Gly Ala Leu Val Thr Val Ser Ala Ala Lys Thr Lys Gly 130 135 140Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser145 150 155 160Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val 210 215 220Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys225 230 235 240Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly 245 250 255Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 260 265 270Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu 275 280 285Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 290 295 300Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg305 310 315 320Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 325 330 335Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu 340 345 350Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 355 360 365Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu 370 375 380Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp385 390 395 400Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 405 410 415Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp 420 425 430Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His 435 440 445Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu 450 455 460Gly Lys Ala Ser465138238PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 138Met Glu Thr Asp Thr Ile Leu Leu Trp Val Leu Leu Leu Trp Val Pro1 5 10 15Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 20 25 30Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser 35 40 45Val Asp Tyr Asp Gly Asp Ser Tyr Met Asn Trp Phe Gln Gln Lys Pro 50 55 60Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser65 70 75 80Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 85 90 95Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys 100 105 110Gln Gln Ser Asn Glu Asp Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu 115 120 125Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro 130 135 140Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu145 150 155 160Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn 165 170 175Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser 180 185 190Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala 195 200 205Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly 210 215 220Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230 235139467PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 139Met Ala Val Leu Gly Leu Leu Leu Cys Leu Val Thr Phe Pro Ser Cys1 5 10 15Val Leu Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala 20 25 30Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu 35 40 45Ser Arg Tyr Ser Val Phe Trp Val Arg Gln Pro Pro Gly Lys Gly Leu 50 55 60Glu Trp Leu Gly Leu Ile Trp Gly Gly Gly Ser Thr Asp Tyr Asn Ser65 70 75 80Ala Leu Lys Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln 85 90 95Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Met Tyr 100 105 110Tyr Cys Ala Arg Ile Tyr Phe Asp Tyr Asp Gly Ala Met Asp Tyr Trp 115 120 125Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Thr Gly Pro 130 135 140Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr145 150 155 160Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 165 170 175Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 180 185 190Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 195 200 205Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 210 215 220His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr225 230 235 240Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro 245 250 255Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 260 265 270Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 275 280 285Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 290 295 300Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val305 310 315 320Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 325 330 335Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 340 345 350Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 355 360 365Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 370 375 380Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu385 390 395 400Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 405 410 415Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 420 425 430Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 435 440 445Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 450 455 460Lys Ala Ser465140243PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 140Met His Arg Thr Ser Met Gly Ile Lys Met Glu Ser Arg Ile Gln Ala1 5 10 15Phe Val Phe Val Phe Leu Trp Leu Ser Gly Val Gly Gly Asp Ile Val 20 25 30Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val 35 40 45Ser Val Thr Cys Lys Ala Ser Gln Asp Val Thr Ser Ala Val Ala Trp 50 55 60Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala65 70 75 80Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser 85 90 95Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Gly Gln Ala Glu Asp Leu 100 105 110Ala Leu Tyr Tyr Cys His Gln Tyr Tyr Ser Ala Pro Arg Thr Phe Gly 115 120 125Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val 130 135 140Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser145 150 155 160Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln 165 170 175Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val 180 185 190Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu 195 200 205Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 210 215 220Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg225 230 235 240Gly Glu Cys 141467PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 141Met Glu Trp Asn Trp Val Val Leu Phe Leu Leu Ser Leu Thr Ala Gly1 5 10 15Val Tyr Ala Gln Gly Gln Met Gln Gln Ser Gly Ala Glu Leu Val Lys 20 25 30Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Phe Thr Phe 35 40 45Ser Ser Asn Tyr Ile Ser Trp Leu Lys Gln Lys Pro Gly Gln Ser Leu 50 55 60Glu Trp Ile Ala Trp Ile Tyr Ala Gly Thr Gly Gly Ile Thr Tyr Asn65 70 75 80Gln Lys Phe Arg Gly Arg Ala Gln Leu Thr Val Asp Thr Ser Ser Ser 85 90 95Thr Ala Tyr Met Gln Phe Ser Ser Leu Thr Thr Asp Asp Ser Ala Ile 100 105 110Tyr Tyr Cys Ala Arg His Val Arg Gly Tyr His Pro Met Asp Tyr Trp 115 120 125Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Lys Thr Lys Gly Pro 130 135 140Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr145 150 155 160Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr 165 170 175Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro 180 185 190Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr 195 200 205Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp 210 215 220His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr225 230 235 240Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro 245 250 255Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 260 265 270Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp 275 280 285Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 290 295 300Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val305 310 315 320Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 325 330 335Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys 340 345 350Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 355 360 365Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr 370 375 380Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu385 390 395 400Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 405 410 415Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys 420 425 430Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu 435 440 445Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 450 455 460Lys Ala Ser465142234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 142Met Glu Ser Gln Thr Gln Val Phe Val Tyr Met Leu Leu Trp Leu Ser1 5 10 15Gly Val Asp Gly Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser 20 25 30Ala Ser Val Gly Asp Arg Val Ser Val Thr Cys Arg Ala Ser Gln Asn 35 40 45Val Val Thr Asn Val Gly Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro 50 55 60Lys Val Leu Ile Tyr Ser Ala Ser Phe Arg Tyr Ser Gly Val Pro Asp65 70 75 80Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr 85 90 95Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn 100 105 110Asn Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230143468PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 143Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Asp1 5 10 15Val His Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys 20 25 30Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45Thr Ser Tyr Trp Met His Trp Val Lys Gln Arg Pro Gly Glu Gly Leu 50 55 60Glu Trp Ile Gly Glu Ile Asn Pro Ser Tyr Gly Arg Thr Asp Tyr Asn65 70 75 80Gly Lys Phe Lys Asn Lys Ala Thr Leu Thr Val Ala Lys Ser Ser Ser 85 90 95Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110Tyr Tyr Cys Ala Arg Gly Asp Tyr Tyr Gly Ser Ser Ser Phe Ala Tyr 115 120 125Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Lys Gly 130 135 140Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser145 150 155 160Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 165 170 175Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 180 185 190Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 195 200 205Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val 210 215 220Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys225 230 235 240Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly 245 250 255Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 260 265 270Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu 275 280 285Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 290 295 300Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg305 310 315 320Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 325 330 335Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu 340 345 350Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 355 360 365Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu 370 375 380Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp385 390

395 400Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 405 410 415Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp 420 425 430Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His 435 440 445Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu 450 455 460Gly Lys Ala Ser465144234PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 144Met Glu Ser Gln Thr Gln Val Phe Val Tyr Met Leu Leu Trp Leu Ser1 5 10 15Gly Val Asp Gly Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser 20 25 30Thr Ser Leu Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn 35 40 45Val Gly Thr Asn Val Ala Trp Tyr Gln Gln Lys Pro Gly His Ser Pro 50 55 60Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp65 70 75 80Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 85 90 95Asn Val Gln Ser Glu Asp Leu Ala Glu Phe Phe Cys Gln Gln Tyr Asn 100 105 110Asn Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Thr Leu Glu Ile Lys Arg 115 120 125Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150 155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225 230145335DNAHepatitis C virus 145actagtactc cttgtacctg cggctcatcc gacctgtacc tggtcacccg gcacgcagac 60gtcattcctg tacgccgacg cggggatagt agggggagcc tgctctctcc aagacccata 120tcctacctca agggcagcag cggtggacca ctgctgtgtc ccgctggtca tgctgtggga 180atatttaggg ccgcagtgtg taccagaggc gtggccaaag ctgttgattt tattcccgtc 240gaaaatcttg aaacaaccat gagaagccca gtgttcacag acaactcatc tcccccagca 300gtgccgcaga gtgctagctg agaattcgcg gccgc 335146488DNAHepatitis C virus 146actagtgtga ctgtgcccca ccccaatatc gaagaggtgg cccttagtac taccggggaa 60attcctttct acgggaaggc catccctctc gaggttatta aaggagggcg acatctgatt 120ttttgccact ccaagaagaa gtgtgacgag ctggccgcga aactggttgc cttgggcatc 180aacgctgtcg catactatcg gggactggat gtatcagtga tacccaccag cggagtggta 240gttgtcgtcg ctacagacgc attgatgacc ggctttacag gagatttcga ctccgtcatc 300gactgtaaca catgcgtgac tcagacagtg gatttcagcc ttgacccgac gtttacgatt 360gagaccacca ctctccctca ggatgctgtg tctaggaccc aaagacgcgg tcgcacaggc 420cggggcaaac caggcatcta taggttcgtg gcaccagggg aaagagctag ctgagaattc 480gcggccgc 488147629DNAHepatitis C virus 147actagtgtgc tggactctca ctaccaggat gtcctgaagg aagtaaaagc agccgcttct 60aaagtcaaag cgaacgctct gtacgatgtc gtttccaaac tgccgctggc tgtcatgggc 120tcttcctacg gctttcagta ttccccgggt cagcgcgttg agttcctggt ccaggcgtgg 180aaatccaaaa agactccgat gggtttttcc tatgacactc gctgcttcga cagcaccgtt 240accgaaagcg acattcgcac cgaggaagca atctaccagt gctgcgacct ggacccacag 300gcccgcgtgg cgatcaaatc tctgaccgaa cgcctgtacg ttggccgctg tcgcgcttcc 360ggtgttctga cgacctcctg cggtaatacg ctgacctgct acatcaaagc acgcgctgcc 420tgtcgcgcag ccggtctgca ggactgcacc atgctggtgt gtggcgatga cctggtggtg 480atctgcgaaa gcgctggcgt gcaggaagac gcagcaagcc tgcgcgcttt caccgaagct 540atgactcgct actctgcgcc gccgggtgac ccgccgcagc cagaatacga tctggagctg 600atcaccgcta gctaagaatt cgcggccgc 62914842DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 148gagctcggat ccactagtac tccttgtacc tgcggctcat cc 4214948DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 149gcccgcggcc gcgaattctc agctagcact ctgcggcact gctggggg 4815039DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 150tctaaagtca aagcgaacgc tctgtacgat gtcgtttcc 3915139DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 151accggaagcg cgacagcggc caacgtacag gcgttcggt 3915239DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 152accgaacgcc tgtacgttgg ccgctgtcgc gcttccggt 3915338DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 153gcggccgcga attcttagct agcggtgatc agctccag 38154100DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 154caagcccaac cccactagtg tgctggactc tcactaccag gatgtcctga aggaagtaaa 60agcagccgct tctaaagtca aagcgaacgc tctgtacgat 100155100DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 155atcgtacaga gcgttcgctt tgactttaga agcggctgct tttacttcct tcaggacatc 60ctggtagtga gagtccagca cactagtggg gttgggcttg 10015613DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 156caagcccaac ccc 1315738DNAArtificial SequenceDescription of Artificial Sequence Synthetic primer 157gcggccgcga attcttagct agcggtgatc agctccag 38158214PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 158Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Val Lys Leu Leu Ile 35 40 45Tyr Tyr Thr Ser Ile Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Lys Leu Pro Pro 85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys 210159992PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 159Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Lys Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Tyr Ile Asn Ser Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Arg Gly Leu Pro Phe His Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser Ala Lys Thr Lys Gly Pro Ser Val Phe 115 120 125Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu 130 135 140Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp145 150 155 160Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro 195 200 205Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro 210 215 220Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe225 230 235 240Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val 260 265 270Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys305 310 315 320Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser 325 330 335Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp385 390 395 400Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 405 410 415Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 435 440 445Gln Thr Pro Thr Asn Thr Ile Ser Val Thr Pro Thr Asn Asn Ser Thr 450 455 460Pro Thr Asn Asn Ser Asn Pro Lys Pro Asn Pro Ala Ser Val Thr Val465 470 475 480Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile 485 490 495Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg 500 505 510His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala 515 520 525Lys Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu 530 535 540Asp Val Ser Val Ile Pro Thr Ser Gly Val Val Val Val Val Ala Thr545 550 555 560Asp Ala Leu Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp 565 570 575Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr 580 585 590Phe Thr Ile Glu Thr Thr Thr Leu Pro Gln Asp Ala Val Ser Arg Thr 595 600 605Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe 610 615 620Val Ala Pro Gly Glu Arg Ala Ser Ser Ser Val Ser Pro Thr Thr Ser625 630 635 640Val His Pro Thr Pro Thr Ser Val Pro Pro Thr Pro Thr Lys Ser Ser 645 650 655Pro Ala Ser Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val 660 665 670Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg 675 680 685Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser Ser 690 695 700Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Ile Phe Arg705 710 715 720Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile Pro 725 730 735Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn 740 745 750Ser Ser Pro Pro Ala Val Pro Gln Ser Ala Ser Pro Thr Ser Thr Pro 755 760 765Ala Asp Ser Ser Thr Ile Thr Pro Thr Ala Thr Pro Thr Ala Thr Pro 770 775 780Thr Ile Lys Gly Ala Ser Val Leu Asp Ser His Tyr Gln Asp Val Leu785 790 795 800Lys Glu Val Lys Ala Ala Ala Ser Lys Val Lys Ala Asn Ala Leu Tyr 805 810 815Asp Val Val Ser Lys Leu Pro Leu Ala Val Met Gly Ser Ser Tyr Gly 820 825 830Phe Gln Tyr Ser Pro Gly Gln Arg Val Glu Phe Leu Val Gln Ala Trp 835 840 845Lys Ser Lys Lys Thr Pro Met Gly Phe Ser Tyr Asp Thr Arg Cys Phe 850 855 860Asp Ser Thr Val Thr Glu Ser Asp Ile Arg Thr Glu Glu Ala Ile Tyr865 870 875 880Gln Cys Cys Asp Leu Asp Pro Gln Ala Arg Val Ala Ile Lys Ser Leu 885 890 895Thr Glu Arg Leu Tyr Val Gly Arg Cys Arg Ala Ser Gly Val Leu Thr 900 905 910Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr Ile Lys Ala Arg Ala Ala 915 920 925Cys Arg Ala Ala Gly Leu Gln Asp Cys Thr Met Leu Val Cys Gly Asp 930 935 940Asp Leu Val Val Ile Cys Glu Ser Ala Gly Val Gln Glu Asp Ala Ala945 950 955 960Ser Leu Arg Ala Phe Thr Glu Ala Met Thr Arg Tyr Ser Ala Pro Pro 965 970 975Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu Glu Leu Ile Thr Ala Ser 980 985 990160218PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 160Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1 5 10 15Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Glu Ser Ile His Ser Tyr 20 25 30Gly Asn Ser Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 50 55 60Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Ser65 70 75 80Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Asn Asn 85 90 95Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser145 150 155 160Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215161998PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 161Gln Val Thr Leu Lys Glu Ser Gly Pro Ala Ile Val Lys Pro Thr Gln1 5 10 15Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30Gly Met Gly Leu Ser Trp Ile Arg Gln Pro Ser Gly Lys Ala Leu Glu 35 40 45Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser 50 55 60Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val65 70 75 80Val Leu Thr Met Thr Ile Val Asp Thr Val Asp Ala Ala Thr Tyr Tyr 85 90 95Cys Ala Arg Ser Ser His Tyr Tyr Gly Tyr Gly Tyr Gly Gly Tyr Phe 100 105 110Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr 115 120 125Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser 130 135 140Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu145 150 155 160Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His

165 170 175Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys 195 200 205Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu 210 215 220Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu225 230 235 240Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr 290 295 300Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn305 310 315 320Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser 325 330 335Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val 355 360 365Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro385 390 395 400Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 405 410 415Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 420 425 430Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445Ser Leu Gly Lys Ala Ser Gln Thr Pro Thr Asn Thr Ile Ser Val Thr 450 455 460Pro Thr Asn Asn Ser Thr Pro Thr Asn Asn Ser Asn Pro Lys Pro Asn465 470 475 480Pro Ala Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu 485 490 495Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Leu Glu 500 505 510Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys 515 520 525Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly Ile Asn Ala Val 530 535 540Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ser Gly Val545 550 555 560Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Phe Thr Gly Asp 565 570 575Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp 580 585 590Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr Thr Leu Pro Gln 595 600 605Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg Gly Lys 610 615 620Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu Arg Ala Ser Ser Ser625 630 635 640Val Ser Pro Thr Thr Ser Val His Pro Thr Pro Thr Ser Val Pro Pro 645 650 655Thr Pro Thr Lys Ser Ser Pro Ala Ser Thr Pro Cys Thr Cys Gly Ser 660 665 670Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val Ile Pro Val Arg 675 680 685Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser 690 695 700Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His705 710 715 720Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys 725 730 735Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser 740 745 750Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Ala 755 760 765Ser Pro Thr Ser Thr Pro Ala Asp Ser Ser Thr Ile Thr Pro Thr Ala 770 775 780Thr Pro Thr Ala Thr Pro Thr Ile Lys Gly Ala Ser Val Leu Asp Ser785 790 795 800His Tyr Gln Asp Val Leu Lys Glu Val Lys Ala Ala Ala Ser Lys Val 805 810 815Lys Ala Asn Ala Leu Tyr Asp Val Val Ser Lys Leu Pro Leu Ala Val 820 825 830Met Gly Ser Ser Tyr Gly Phe Gln Tyr Ser Pro Gly Gln Arg Val Glu 835 840 845Phe Leu Val Gln Ala Trp Lys Ser Lys Lys Thr Pro Met Gly Phe Ser 850 855 860Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val Thr Glu Ser Asp Ile Arg865 870 875 880Thr Glu Glu Ala Ile Tyr Gln Cys Cys Asp Leu Asp Pro Gln Ala Arg 885 890 895Val Ala Ile Lys Ser Leu Thr Glu Arg Leu Tyr Val Gly Arg Cys Arg 900 905 910Ala Ser Gly Val Leu Thr Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr 915 920 925Ile Lys Ala Arg Ala Ala Cys Arg Ala Ala Gly Leu Gln Asp Cys Thr 930 935 940Met Leu Val Cys Gly Asp Asp Leu Val Val Ile Cys Glu Ser Ala Gly945 950 955 960Val Gln Glu Asp Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr 965 970 975Arg Tyr Ser Ala Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu 980 985 990Glu Leu Ile Thr Ala Ser 995162371PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 162Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Val Lys Leu Leu Ile 35 40 45Tyr Tyr Thr Ser Ile Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Phe Asn Lys Leu Pro Pro 85 90 95Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln145 150 155 160Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205Phe Asn Arg Gly Glu Cys Ala Ser Val Thr Val Pro His Pro Asn Ile 210 215 220Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys225 230 235 240Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys 245 250 255His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu 260 265 270Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile 275 280 285Pro Thr Ser Gly Val Val Val Val Val Ala Thr Asp Ala Leu Met Thr 290 295 300Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val305 310 315 320Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr 325 330 335Thr Thr Leu Pro Gln Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg 340 345 350Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val Ala Pro Gly Glu 355 360 365Arg Ala Ser 370163810PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 163Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Lys Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Tyr Ile Asn Ser Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Arg Gly Leu Pro Phe His Ala Met Asp Tyr Trp Gly Gln Gly 100 105 110Thr Leu Val Thr Val Ser Ser Ala Lys Thr Lys Gly Pro Ser Val Phe 115 120 125Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu 130 135 140Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp145 150 155 160Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro 195 200 205Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro 210 215 220Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe225 230 235 240Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro 245 250 255Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val 260 265 270Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr 275 280 285Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val 290 295 300Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys305 310 315 320Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser 325 330 335Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 340 345 350Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 355 360 365Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 370 375 380Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp385 390 395 400Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp 405 410 415Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 420 425 430Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys Ala Ser 435 440 445Gln Thr Pro Thr Asn Thr Ile Ser Val Thr Pro Thr Asn Asn Ser Thr 450 455 460Pro Thr Asn Asn Ser Asn Pro Lys Pro Asn Pro Ala Ser Thr Pro Cys465 470 475 480Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val 485 490 495Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro 500 505 510Arg Pro Ile Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys 515 520 525Pro Ala Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg 530 535 540Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr545 550 555 560Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 565 570 575Pro Gln Ser Ala Ser Ser Ser Val Ser Pro Thr Thr Ser Val His Pro 580 585 590Thr Pro Thr Ser Val Pro Pro Thr Pro Thr Lys Ser Ser Pro Ala Ser 595 600 605Val Leu Asp Ser His Tyr Gln Asp Val Leu Lys Glu Val Lys Ala Ala 610 615 620Ala Ser Lys Val Lys Ala Asn Ala Leu Tyr Asp Val Val Ser Lys Leu625 630 635 640Pro Leu Ala Val Met Gly Ser Ser Tyr Gly Phe Gln Tyr Ser Pro Gly 645 650 655Gln Arg Val Glu Phe Leu Val Gln Ala Trp Lys Ser Lys Lys Thr Pro 660 665 670Met Gly Phe Ser Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val Thr Glu 675 680 685Ser Asp Ile Arg Thr Glu Glu Ala Ile Tyr Gln Cys Cys Asp Leu Asp 690 695 700Pro Gln Ala Arg Val Ala Ile Lys Ser Leu Thr Glu Arg Leu Tyr Val705 710 715 720Gly Arg Cys Arg Ala Ser Gly Val Leu Thr Thr Ser Cys Gly Asn Thr 725 730 735Leu Thr Cys Tyr Ile Lys Ala Arg Ala Ala Cys Arg Ala Ala Gly Leu 740 745 750Gln Asp Cys Thr Met Leu Val Cys Gly Asp Asp Leu Val Val Ile Cys 755 760 765Glu Ser Ala Gly Val Gln Glu Asp Ala Ala Ser Leu Arg Ala Phe Thr 770 775 780Glu Ala Met Thr Arg Tyr Ser Ala Pro Pro Gly Asp Pro Pro Gln Pro785 790 795 800Glu Tyr Asp Leu Glu Leu Ile Thr Ala Ser 805 810164375PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 164Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1 5 10 15Glu Arg Ala Thr Ile Asn Cys Arg Ala Ser Glu Ser Ile His Ser Tyr 20 25 30Gly Asn Ser Phe Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ser 50 55 60Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Ser65 70 75 80Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Asn Asn 85 90 95Glu Asp Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser145 150 155 160Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Ala Ser Val Thr Val Pro 210 215 220His Pro Asn Ile Glu Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro225 230 235 240Phe Tyr Gly Lys Ala Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His 245 250 255Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys 260 265 270Leu Val Ala Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp 275 280 285Val Ser Val Ile Pro Thr Ser Gly Val Val Val Val Val Ala Thr Asp 290 295 300Ala Leu Met Thr Gly Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys305 310 315 320Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe 325 330 335Thr Ile Glu Thr Thr Thr Leu Pro Gln Asp Ala Val Ser Arg Thr Gln 340 345 350Arg Arg Gly Arg Thr Gly Arg Gly Lys Pro Gly Ile Tyr Arg Phe Val 355 360 365Ala Pro Gly Glu Arg Ala Ser 370 375165816PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 165Gln Val Thr Leu Lys Glu Ser Gly Pro Ala Ile Val Lys Pro Thr Gln1 5 10 15Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30Gly Met Gly Leu Ser Trp Ile

Arg Gln Pro Ser Gly Lys Ala Leu Glu 35 40 45Trp Leu Ala His Ile Tyr Trp Asp Asp Asp Lys Arg Tyr Asn Pro Ser 50 55 60Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val65 70 75 80Val Leu Thr Met Thr Ile Val Asp Thr Val Asp Ala Ala Thr Tyr Tyr 85 90 95Cys Ala Arg Ser Ser His Tyr Tyr Gly Tyr Gly Tyr Gly Gly Tyr Phe 100 105 110Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Lys Thr 115 120 125Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser 130 135 140Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu145 150 155 160Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 165 170 175Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 180 185 190Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys 195 200 205Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu 210 215 220Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu225 230 235 240Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 245 250 255Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 275 280 285Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr 290 295 300Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn305 310 315 320Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser 325 330 335Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 340 345 350Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val 355 360 365Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 370 375 380Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro385 390 395 400Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 405 410 415Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 420 425 430Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 435 440 445Ser Leu Gly Lys Ala Ser Gln Thr Pro Thr Asn Thr Ile Ser Val Thr 450 455 460Pro Thr Asn Asn Ser Thr Pro Thr Asn Asn Ser Asn Pro Lys Pro Asn465 470 475 480Pro Ala Ser Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val 485 490 495Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg 500 505 510Gly Ser Leu Leu Ser Pro Arg Pro Ile Ser Tyr Leu Lys Gly Ser Ser 515 520 525Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Ile Phe Arg 530 535 540Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Ile Pro545 550 555 560Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn 565 570 575Ser Ser Pro Pro Ala Val Pro Gln Ser Ala Ser Ser Ser Val Ser Pro 580 585 590Thr Thr Ser Val His Pro Thr Pro Thr Ser Val Pro Pro Thr Pro Thr 595 600 605Lys Ser Ser Pro Ala Ser Val Leu Asp Ser His Tyr Gln Asp Val Leu 610 615 620Lys Glu Val Lys Ala Ala Ala Ser Lys Val Lys Ala Asn Ala Leu Tyr625 630 635 640Asp Val Val Ser Lys Leu Pro Leu Ala Val Met Gly Ser Ser Tyr Gly 645 650 655Phe Gln Tyr Ser Pro Gly Gln Arg Val Glu Phe Leu Val Gln Ala Trp 660 665 670Lys Ser Lys Lys Thr Pro Met Gly Phe Ser Tyr Asp Thr Arg Cys Phe 675 680 685Asp Ser Thr Val Thr Glu Ser Asp Ile Arg Thr Glu Glu Ala Ile Tyr 690 695 700Gln Cys Cys Asp Leu Asp Pro Gln Ala Arg Val Ala Ile Lys Ser Leu705 710 715 720Thr Glu Arg Leu Tyr Val Gly Arg Cys Arg Ala Ser Gly Val Leu Thr 725 730 735Thr Ser Cys Gly Asn Thr Leu Thr Cys Tyr Ile Lys Ala Arg Ala Ala 740 745 750Cys Arg Ala Ala Gly Leu Gln Asp Cys Thr Met Leu Val Cys Gly Asp 755 760 765Asp Leu Val Val Ile Cys Glu Ser Ala Gly Val Gln Glu Asp Ala Ala 770 775 780Ser Leu Arg Ala Phe Thr Glu Ala Met Thr Arg Tyr Ser Ala Pro Pro785 790 795 800Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu Glu Leu Ile Thr Ala Ser 805 810 81516625PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 166Ser Ser Val Ser Pro Thr Thr Ser Val His Pro Thr Pro Thr Ser Val1 5 10 15Pro Pro Thr Pro Thr Lys Ser Ser Pro 20 2516725PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 167Pro Thr Ser Thr Pro Ala Asp Ser Ser Thr Ile Thr Pro Thr Ala Thr1 5 10 15Pro Thr Ala Thr Pro Thr Ile Lys Gly 20 2516825PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 168Thr Val Thr Pro Thr Ala Thr Ala Thr Pro Ser Ala Ile Val Thr Thr1 5 10 15Ile Thr Pro Thr Ala Thr Thr Lys Pro 20 2516925PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 169Thr Asn Gly Ser Ile Thr Val Ala Ala Thr Ala Pro Thr Val Thr Pro1 5 10 15Thr Val Asn Ala Thr Pro Ser Ala Ala 20 2517027PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 170Gln Thr Pro Thr Asn Thr Ile Ser Val Thr Pro Thr Asn Asn Ser Thr1 5 10 15Pro Thr Asn Asn Ser Asn Pro Lys Pro Asn Pro 20 25

Claims

1. An immunostimulatory composition for generating an immune response for a prophylaxis, a therapy, or any combination thereof against a Hepatitis C infection in a human or animal subject comprising: one or more antibodies or fragments thereof specific for a dendritic cell (DC); and one or more HCV antigens attached to the one or more antibodies or fragments thereof.

2. The composition of claim 1, further comprising at least one Toll-Like Receptor (TLR) agonist selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists.

3. The composition of claim 1, further comprising an optional pharmaceutically acceptable carrier that is effective, in combination, to produce the immune response for prophylaxis, for therapy, or any combination thereof in the human or animal subject in need of immunostimulation.

4. The composition of claim 1, wherein the antibody or fragment specific for the DC is specific for a DC specific cell surface receptor selected from an antibody that specifically binds to MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN-.gamma. receptor and IL-2 receptor, ICAM-1, Fc.gamma. receptor, LOX-1, and ASPGR.

5. The composition of claim 1, wherein the HCV antigens comprise a peptide sequence derived from a HCV 1a genotype protein or a fragment thereof.

6. The composition of claim 1, wherein the HCV antigens are selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, and a fragment thereof.

7. The composition of claim 1, wherein the one or more HCV antigens are selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or a fragment thereof.

8. The composition of claim 1, wherein the composition comprises a recombinant antibody that comprises a fusion protein and the one or more HCV antigens at a C-terminal position relative to the one or more antibody or fragment thereof; a recombinant antibody or fragment thereof specific for the DC and one or more HCV antigens are fused to a C-terminus of a heavy chain of the antibody; a recombinant antibody or fragment thereof specific for the DC and one or more HCV antigens are fused to a C-terminus of a light chain of the antibody; or a recombinant antibody or fragment thereof specific for the DC and three HCV antigens or antigenic domains fused to the C-terminus of the heavy chain of the antibody or two HCV antigens or antigenic domains fused to the heavy chain of the antibody and one HCV antigen or antigenic domain fused to the light chain of the antibody.

9. The composition of claim 1, wherein the one or more HCV antigens are selected from the group consisting of SEQ ID NO: 12-linker A-SEQ ID NO: 13, SEQ ID NO: 12-linker A-SEQ ID NO: 11, SEQ ID NO: 12-linker B-SEQ ID NO: 14, SEQ ID NO: 14-linker B-SEQ ID NO: 12, SEQ ID NO: 12-linker B-SEQ ID NO: 10, SEQ ID NO: 10-linker B-SEQ ID NO: 12, SEQ ID NO: 9-linker B-SEQ ID NO: 10, SEQ ID NO: 10-linker B-SEQ ID NO: 9, SEQ ID NO: 10-linker B-SEQ ID NO: 14, SEQ ID NO: 14-linker B-SEQ ID NO: 10, SEQ ID NO: 9-linker B-SEQ ID NO: 12, SEQ ID NO: 12-linker B-SEQ ID NO: 9, SEQ ID NO: 8-linker B-E1b. SEQ ID NO: 12-linkerB-SEQ ID NO: 10-linker C-SEQ ID NO: 14, SEQ ID NO: 12-linker B-SEQ ID NO: 14-linker C-SEQ ID NO: 10, SEQ ID NO: 10-linker B-SEQ ID NO: 12-linker C-SEQ ID NO: 14, SEQ ID NO: 10-linker B-SEQ ID NO: 14-linker C-SEQ ID NO: 12, SEQ ID NO: 14-linker B-SEQ ID NO: 12-linker C-SEQ ID NO: 10, SEQ ID NO: 14-linker B-SEQ ID NO: 10-linker C-SEQ ID NO: 12, and SEQ ID NO: 12-linker B-SEQ ID NO: 10-linker C-SEQ ID NO: 14-linker D-SEQ ID NO: 8.

10. The composition of claim 1, wherein the one or more HCV antigens are attached to a C-terminus of a light chain of the recombinant antibody and selected from a group consisting of: SEQ ID NO: 9; SEQ ID NO: 11; or SEQ ID NO: 9 fused to the C-terminus of a light chain and SEQ ID NO: 10-linker B-SEQ ID NO: 12-linker C-SEQ ID NO: 14 fused to the C-terminus of the heavy chain of the antibody.

11. The composition of claim 1, wherein the one or more HCV antigen are chemically coupled to the one or more antibodies or fragments thereof or are attached to the one or more antibodies or fragments thereof via an affinity association.

12. The composition of claim 1, wherein the DC-specific antibody is humanized.

13. The composition of claim 1, wherein the one or more HCV antigens are selected from antibodies having a heavy and a light chain combination of sequences SEQ ID NOS: 80 and 81; 82 and 83; 84 and 85; 86 and 87; 88 and 89; 90 and 91; 92 and 93; 94 and 95; 96 and 97; 98 and 99; 100 and 101; 102 and 103; 104 and 105; 106 and 107; 108 and 109; 110 and 111; 112 and 113; 114 and 115; 116 and 117; 118 and 119; 120 and 121; 122 and 123; 124 and 125; 126 and 127; 128 and 129; 130 and 131; 132 and 134; 136 and 137; 138 and 139; 140 and 141; 158 and 159; 160 and 161; 162 and 163; 164 and 165.

14. A vaccine comprising: one or more antibodies or fragments thereof specific for a dendritic cell (DC); and one or more HCV antigens attached to the one or more antibodies or fragments thereof and optionally a pharmaceutically acceptable carrier or an adjuvant that is effective, in combination, to produce an immune response for prophylaxis, for therapy, or any combination thereof in a subject in need of immunostimulation.

15. The vaccine of claim 14, further comprising at least one Toll-Like Receptor (TLR) agonist selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists.

16. The vaccine of claim 14, wherein the HCV antigen comprises a peptide sequence derived from a HCV 1a genotype protein or a fragment thereof, protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, and a fragment thereof.

17. The vaccine of claim 14, wherein the one or more HCV antigens is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or a fragment thereof.

18. The vaccine of claim 14, wherein the composition comprises a recombinant antibody that comprises a fusion protein and the one or more HCV antigens are at a C-terminal position relative to the one or more antibody or fragment thereof within a fusion protein; one or more HCV antigens are fused to a C-terminus of a heavy chain of the antibody; one or more HCV antigens are fused to a C-terminus of a light chain of the one or more antibody or fragment thereof specific for a dendritic cell; or one or more HCV antigens or antigenic domains fused to a C-terminus of the heavy chain of the antibody and at least one HCV antigen or antigenic domain fused to the C-terminus of the light chain of the antibody.

19. The vaccine of claim 14, wherein the vaccine comprises a recombinant antibody or fragment thereof specific for the DC and three HCV antigens or antigenic domains fused to the C-terminus of the heavy chain of the antibody or two HCV antigens or antigenic domains fused to the heavy chain of the antibody and one HCV antigen or antigenic domain fused to the light chain of the antibody.

20. The vaccine of claim 14, wherein the one or more HCV antigens are selected from the group consisting of SEQ ID NO: 12-linker A-SEQ ID NO: 13, SEQ ID NO: 12-linker A-SEQ ID NO: 11, SEQ ID NO: 12-linker B-SEQ ID NO: 14, SEQ ID NO: 14-linker B-SEQ ID NO: 12, SEQ ID NO: 12-linker B-SEQ ID NO: 10, SEQ ID NO: 10-linker B-SEQ ID NO: 12, SEQ ID NO: 9-linker B-SEQ ID NO: 10, SEQ ID NO: 10-linker B-SEQ ID NO: 9, SEQ ID NO: 10-linker B-SEQ ID NO: 14, SEQ ID NO: 14-linker B-SEQ ID NO: 10, SEQ ID NO: 9-linker B-SEQ ID NO: 12, SEQ ID NO: 12-linker B-SEQ ID NO: 9, SEQ ID NO: 8-linker B-E1b. SEQ ID NO: 12-linkerB-SEQ ID NO: 10-linker C-SEQ ID NO: 14, SEQ ID NO: 12-linker B-SEQ ID NO: 14-linker C-SEQ ID NO: 10, SEQ ID NO: 10-linker B-SEQ ID NO: 12-linker C-SEQ ID NO: 14, SEQ ID NO: 10-linker B-SEQ ID NO: 14-linker C--SEQ ID NO: 12, SEQ ID NO: 14-linker B-SEQ ID NO: 12-linker C-SEQ ID NO: 10, SEQ ID NO: 14-linker B-SEQ ID NO: 10-linker C-SEQ ID NO: 12, and SEQ ID NO: 12-linker B-SEQ ID NO: 10-linker C-SEQ ID NO: 14-linker D-SEQ ID NO: 8.

21. The vaccine of claim 14, wherein the one or more HCV antigens are chemically coupled to the one or more antibodies or fragments thereof or are attached to the one or more antibodies or fragments thereof via an affinity association.

22. The vaccine of claim 14, wherein the DC-specific antibody is humanized.

23. The vaccine of claim 14, wherein the vaccine comprises an antibody with a heavy and a light chain combination of sequences SEQ ID NOS: 80 and 81; 82 and 83; 84 and 85; 86 and 87; 88 and 89; 90 and 91; 92 and 93; 94 and 95; 96 and 97; 98 and 99; 100 and 101; 102 and 103; 104 and 105; 106 and 107; 108 and 109; 110 and 111; 112 and 113; 114 and 115; 116 and 117; 118 and 119; 120 and 121; 122 and 123; 124 and 125; 126 and 127; 128 and 129; 130 and 131; 132 and 134; 136 and 137; 138 and 139; 140 and 141; 158 and 159; 160 and 161; 162 and 163; 164 and 165.

24. A Hepatitis C vaccine (HCV) comprising a fusion protein comprising: one or more antibodies or fragments thereof specific for a dendritic cell (DC); one or more HCV antigens located C-terminal of the antibodies or fragments thereof; at least one Toll-Like Receptor (TLR) agonist which is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists; and one or more optional pharmaceutically acceptable carriers and adjuvants, wherein the vaccine is effective to produce an immune response, for a prophylaxis, a therapy, or any combination thereof against hepatitis C in a human or an animal subject in need thereof.

25. The vaccine of claim 24, wherein the vaccine comprises one or more optional agents selected from the group consisting of an agonistic anti-CD40 antibody, an agonistic anti-CD40 antibody fragment, a CD40 ligand (CD40L) polypeptide, a CD40L polypeptide fragment, anti-4-1BB antibody, an anti-4-1BB antibody fragment, 4-1BB ligand polypeptide, a 4-1BB ligand polypeptide fragment, IFN-.gamma., TNF-.alpha., type 1 cytokines, type 2 cytokines or combinations and modifications thereof.

26. The vaccine of claim 24, wherein the antibody or fragment specific for the DC is selected from an antibody that specifically binds to MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CD11b, CD14, CD15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN-.gamma. receptor and IL-2 receptor, ICAM-1, Fc.gamma. receptor, LOX-1, and ASPGR.

27. A method for increasing effectiveness of Hepatitis C virus (HCV) antigen presentation by an antigen presenting cell (APC) comprising the steps of: providing an antibody conjugate comprising a dendritic cell (DC) specific antibody or a fragment thereof and one or more native or engineered HCV antigenic peptides; providing one or more APCs; and contacting the APC with the conjugate, wherein the antibody-antigen complex is processed and presented for T cell recognition.

28. The method of claim 27, wherein the antigen presenting cell comprises a dendritic cell (DC).

29. The method of claim 27, wherein the DC-specific antibody or fragment is selected from an antibody that specifically binds to MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CD11b, CD 14, CD 15, CD 16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN-.gamma. receptor and IL-2 receptor, ICAM-1, Fc.gamma. receptor, LOX-1, and ASPGR.

30. The method of claim 27, wherein the one or more native or engineered HCV antigenic peptide is selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, E1b, and a fragment thereof.

31. The method of claim 27, wherein the DC-specific antibody is humanized.

32. A method for increasing effectiveness of antigen presentation by an antigen presenting cell (APC) comprising the steps of: isolating and purifying one or more dendritic cell (DC)-specific antibodies or a fragments thereof; providing one or more HCV antigens or antigenic peptides; loading or chemically coupling the one or more HCV antigens or antigenic peptides to the DC-specific antibody to form an antibody-antigen conjugate; and contacting the antigen presenting cell with the conjugate, wherein the antibody-antigen complex is processed and presented for T cell recognition.

33. The method of claim 32, further comprising the optional steps of: adding one or more optional agents selected from the group consisting of an agonistic anti-CD40 antibody, an agonistic anti-CD40 antibody fragment, a CD40 ligand (CD40L) polypeptide, a CD40L polypeptide fragment, anti-4-1BB antibody, an anti-4-1BB antibody fragment, 4-1BB ligand polypeptide, a 4-1BB ligand polypeptide fragment, IFN-.gamma., TNF-.alpha., type 1 cytokines, type 2 cytokines or combinations and modifications thereof to the antibody-antigen conjugate and the TLR agonist prior to contacting the antigen presenting cells; and measuring a level of one or more agents selected from the group consisting of IFN-.gamma., TNF-.alpha., IL-12p40, IL-4, IL-5, and IL-13, wherein a change in the level of the one or more agents is indicative of the increase in the effectiveness antigen presentation by the antigen presenting cell.

34. The method of claim 32, wherein the APC comprises a dendritic cell (DC).

35. The method of claim 32, wherein the DC-specific antibody or fragment is selected from an antibody that specifically binds to MHC class I, MHC class II, CD1, CD2, CD3, CD4, CD8, CD11b, CD14, CD 15, CD16, CD19, CD20, CD29, CD31, CD40, CD43, CD44, CD45, CD54, CD56, CD57, CD58, CD83, CD86, CMRF-44, CMRF-56, DCIR, DC-ASPGR, CLEC-6, CD40, BDCA-2, MARCO, DEC-205, mannose receptor, Langerin, DECTIN-1, B7-1, B7-2, IFN-.gamma. receptor and IL-2 receptor, ICAM-1, Fc.gamma. receptor, LOX-1, and ASPGR.

36. The method of claim 32, wherein the HCV antigen is selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, and a fragment thereof.

37. The method of claim 32, wherein the one or more HCV antigens is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and a fragment thereof.

38. The method of claim 32, wherein the DC-specific antibody is humanized.

39. The method of claim 32, further comprising the optional step of adding one or more optional agents selected from the group consisting of an agonistic anti-CD40 antibody, an agonistic anti-CD40 antibody fragment, a CD40 ligand (CD40L) polypeptide, a CD40L polypeptide fragment, anti-4-1BB antibody, an anti-4-1BB antibody fragment, 4-1BB ligand polypeptide, a 4-1BB ligand polypeptide fragment, IFN-.gamma., TNF-.alpha., type 1 cytokines, type 2 cytokines or combinations and modifications thereof.

40. The method of claim 32, further comprising adding at least one Toll-Like Receptor (TLR) agonist which is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, and TLR8 agonists.

41. A Hepatitis C virus antigen presenting dendritic cell (DC) comprising one or more isolated dendritic cells (DCs) in contact with a fusion protein comprising an antibody or fragment thereof specific for the DC, the fusion protein further comprising a HCV peptide.

42. A method for generating a Hepatitis C virus (HCV) presenting dendritic cells (DCs) in a human subject comprising the steps of providing one or more DCs; incubating the dendritic cells with a fusion protein, wherein the fusion protein comprises an antibody or fragment thereof specific for a dendritic cell and a HCV antigen fused to the antibody or fragment thereof.

43. The method of claim 42, further comprising administering to the subject an effective amount of IFNA, Ribavirin, or a combination thereof.

44. A vaccine comprising one or more antibodies or fragments thereof specific for a dendritic cell (DC) and one or more HCV antigens or antigenic domains attached to the one or more antibodies or fragments thereof, wherein the vaccine has a general structure given by: H-w, H-w-x, H-w-x-y, or H-w-x-y-z, wherein H represents a heavy chain of an antibody or a fragment thereof specific for a DC, w, x, y, and z represent one or more HCV antigens or domains selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, or any combinations thereof.

45. The vaccine of claim 44, wherein w comprises the HCV antigenic domains selected from the group consisting of ProtA, ProtB, HelB, Palm, E1b, and E2.

46. The vaccine of claim 44, wherein x comprises the HCV antigenic domains selected from the group consisting of HelC, HelA, Palm, ProtA, ProtB, and E1b.

47. The vaccine of claim 44, wherein y comprises the HCV antigenic domains selected from the group consisting of Palm, ProtB, and Protb.

48. The vaccine of claim 44, wherein z comprises HCV antigenic domains selected from E2, ProtA, and HelB.

49. The vaccine of claim 44, wherein the one or more HCV antigens or antigenic domains are linked or attached to one another by one or more flexible linkers.

50. The vaccine of claim 44, wherein the vaccine comprises H-ProtA, H-ProtB, H-HelB, H-Palm, H-E1b, H-E2, H-HelB-HelC, H-HelB-HelA, H-HelB-Palm, H-Palm-HelB, H-HelB-ProtB, H-ProtB-HelB, H-ProtA-ProtB, H-ProtB-ProtA, H-ProtB-Palm, H-Palm-ProtB, H-ProtA-HelB, H-HelB-ProtA, H-E2-E1b, H-HelB-ProtB-Palm, H-HelB-Palm-ProtB, H-ProtB-HelB-Palm, H-ProtB-Palm-HelB, H-Palm-HelB-ProtB, H-Palm-ProtB-HelB, H-HelB-ProtB-Palm-E2, or any combinations thereof.

51. A vaccine comprising one or more antibodies or fragments thereof specific for a dendritic cell (DC) and one or more HCV antigens or antigenic domains attached to the one or more antibodies or fragments thereof, wherein the vaccine has a general structure given by L-w-x-y-z, wherein L represents a light chain of an antibody or a fragment thereof specific for a DC, w, x, y, and z represent one or more HCV antigens or domains selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, or any combinations thereof.

52. The composition of claim 51, wherein w, x, y, and z comprise HCV antigenic domains selected from the group consisting of ProtA, ProtB, HelB, HelA, HelC, Palm, E1a, E1b, and E2.

53. The composition of claim 51, wherein the vaccine comprises L-ProtA-HelA-E1b-HelB.

54. A vaccine comprising one or more antibodies or fragments thereof specific for a dendritic cell (DC) and one or more HCV antigens or antigenic domains attached to the one or more antibodies or fragments thereof, wherein the vaccine has a general structure given by: ##STR00002## wherein H represents a heavy chain of an antibody or a fragment thereof specific for a DC, L represents a light chain of an antibody or a fragment thereof specific for the DC, w, x, y, and z represent one or more HCV antigens or domains selected from the group consisting of protein E1, envelope protein E2, non-structural protein NS3, non-structural protein NS4b, non-structural protein NS5b, or any combinations thereof.

55. The composition of claim 54, wherein w, x, y, and z comprise HCV antigenic domains selected from the group consisting of ProtA, ProtB, HelB, HelA, HelC, Palm, E1a, E1b, and E2.

56. The composition of claim 54, wherein the vaccine comprises ##STR00003##

57. The composition of claim 54, wherein the vaccine comprises ##STR00004##